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Abstract 
Congenital cardiovascular malformation (CVM) affects 7/1000 live births.  
Approximately 20% of cases are caused by chromosomal and syndromic conditions.  
Rare Mendelian families segregating particular forms of CVM have also been described.  
Among the remaining 80% of non-syndromic cases, there is a familial predisposition 
implicating as yet unidentified genetic factors. Since the reproductive consequences to 
an individual of CVM are usually severe, evolutionary considerations suggest 
predisposing variants are likely to be rare.  The overall aim of my PhD was to use next 
generation sequencing (NGS) methods to identify such rare, potentially disease causing 
variants in CVM.  
First, I developed a novel approach to calculate the sensitivity and specificity of NGS 
data in detecting variants using publicly available population frequency data. My aim 
was to provide a method that would yield sound estimates of the quality of a sequencing 
experiment without the need for additional genotyping in the sequenced samples.  I 
developed such a method and demonstrated that it provided comparable results to 
methods using microarray data as a reference. Furthermore, I evaluated different variant 
calling pipelines and showed that they have a large effect on sensitivity and specificity.        
Following this, the NovoAlign-Samtools and BWA-Dindel pipelines were used to 
identify single base substitution and indel variants in three pedigrees, where 
predisposition to a different disease appears to segregate following an autosomal 
dominant mode of inheritance. I identified potentially causative variants segregating 
with disease in all three of the pedigrees. In the pedigrees with Dilated Cardiomyopathy 
and Hereditary Sclerosing Poikiloderma these variants were in plausible candidate 
genes.  
Finally, NGS was used to identify rare, potentially disease causing indel variants in 
patients with sporadic, non-syndromic forms of CVM characterised by chamber 
hypoplasia. Two indel calling pipelines were used as a means to increase confidence in 
the identified indels. These two pipelines achieved the highest sensitivity calls using the 
method described above. In the 133 cases, evaluated for 403 candidate genes, indels 
were identified in 4 known causative genes for human cardiovascular disease, namely 
MYL1, NOTCH1, TNNT2, and DSC2. 
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1.1 Summary 
The overall aim of my PhD was to use next generation sequencing (NGS) methods to 
identify rare, potentially disease causing variants involved in various diseases, 
particularly in Congenital Cardiovascular Malformations (CVM). I explored different 
aspects and uses of NGS for variant identification in three linked sub-projects which all 
progressed concurrently. First, I developed a novel approach to calculate the sensitivity 
and specificity of variant calls in NGS data using publically available SNP frequency 
data. I developed a simple and fast method to calculate the sensitivity and specificity of 
variant calls for an entire NGS data analysis pipeline. The new method generated results 
which were comparable to current methods requiring microarray data, without requiring 
such data as a reference technique.  This work is reported in Chapter 3. 
The knowledge gained regarding the performance of different analysis pipelines was 
used in the second sub-project, in which I analysed whole exome sequence data for 
individuals from three pedigrees using the pipelines optimised in chapter 3, namely 
NovoAlign-Samtools. In each of these pedigrees predisposition to a different disease 
appears to segregate following an autosomal dominant mode of inheritance. I identified 
potentially disease causing variants segregating with disease in all three of the pedigrees. 
In the pedigrees where cases presented with Dilated Cardiomyopathy and Hereditary 
Sclerosing Poikiloderma I identified potentially disease causing variants in plausible 
candidate genes for disease. Genes were considered as plausible candidates based on 
current literature and knowledge on their possible influence on the same, or similar, 
phenotypes. Results of these experiments, including discussion of the genes and variants 
identified, are presented in chapter 4.   
In the third linked sub-project, I used NGS to identify rare, potentially disease causing 
insertion/deletion (indel) variants in patients with various congenital cardiovascular 
malformations. Targeted sequence data for genes believed to be involved in cardiac 
development was generated in 133 cases with particular subtypes of cardiovascular 
malformation clinically considered to represent hypoplasia of one or other of the main 
cardiac chambers. As indels are difficult to identify using NGS methods, I decided early 
on to use two indel calling pipelines as a means to increase confidence in the indels that 
I identified, namely BWA-Dindel and BWA-GATK. The selection of these two analysis 
pipelines was based on current knowledge available in the literature at the time. 
However, during the process, I used my assessment method, when it was fully 
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developed, to calculate the sensitivity and specificity values for a range of different 
indel calling pipelines, and found that the BWA-Dindel and BWA-GATK pipelines did 
indeed achieve the highest sensitivity calls.  In the 133 cases, evaluated for 403 
candidate genes, I discovered previously undescribed frameshifting indels that, given 
the strong evolutionary constraints on such indels, have a high a priori likelihood of 
being related to disease.  Results of these experiments, together with discussion of the 
genes harbouring potentially causative indels, are presented in chapter 5 
As all three of the sub-projects described in chapters 3, 4, and 5 were running 
concurrently from the beginning of my PhD, I considered they would be most cogently 
presented as standalone chapters. As such, they have all been written and developed to 
contain individual introduction and discussion sections. Therefore, in this general 
introduction I will provide a background to CVM, in particular I focus on the current 
knowledge of the genetic factors in such disorders. I then discuss current methods used 
to identify the genetic causes of disease, and why I chose to use NGS over other 
possible techniques. Finally, I provide a background to the different NGS platforms 
presently available, outline the rationale for choosing the methods used throughout the 
thesis, and highlight the different methods for analysing the data produced by these 
sequencers. In the final summary discussion of the thesis (Chapter 6), I highlight and 
describe what I think are the main points and conclusions of each of my data chapters, 
together with the limitations of the work and the prospects for further study. 
    
1.2 Cardiovascular Malformations 
1.2.1 Clinical Epidemiology 
Normal cardiac development is a complex process involving various transcription 
factors during early development (Cresci et al., 2012). The term Congenital 
Cardiovascular Malformation (CVM) refers to alterations in heart structure and function 
arising from abnormal heart development during embryogenesis (Bruneau, 2008; 
Rosamond et al., 2008). CVM’s represent the most common birth defect, with estimates 
of incidence ranging from 4 to 12 per 1000 births per year (Hoffman and Kaplan, 2002). 
However, the exact figure is difficult to determine as many CVMs may remain 
subclinical and may only be detected in later life (Pierpont et al., 2007; Rosamond et al., 
2008; Griffin et al., 2009). The value also depends on the types of defect that are 
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included in the estimation (Warnes et al., 2001; Hoffman and Kaplan, 2002; Pierpont et 
al., 2007; Bruneau, 2008; Ware and Jefferies, 2012). Figure 1.1 demonstrates the 
variation in incidence of cardiovascular malformations from 62 different cardiac centres 
from around the world (From Hoffman and Kaplan (2000)). The majority of centres 
report an incidence of ~7 per 1000 births per year. 
The prevalence of CVM is equally difficult to calculate. A study conducted in Taiwan 
using health care records from the National Health Insurance program, of patients born 
between 2000 and 2006, estimated an overall prevalence of 13.08 per 1000 people (Wu 
et al., 2010). Again, however, this value did depend on the types of CVM that were 
included. For example, if bicuspid aortic valve, which typically presents in middle age, 
is considered a CVM, prevalence figures will depend substantially on the age of the 
cohort enrolled.  Atrial septal defect (ASD) is also not uncommonly diagnosed after 
childhood, although in this case the diagnosis is usually made during young adult life 
rather than middle age.  In a study conducted in Yuma, Arizona, medical records from 
the University Medical Centre in Tucson were used to calculate the prevalence of CVM 
to be ~14 per 1000 people (Mayberry et al., 1990). Yet another study performed in 
England estimated the prevalence of CVM to be 5.6 per 1000 people (Wren et al., 2000). 
This value was calculated from records of cases born between 1985 and 1989 that were 
available from the diagnostic database in the regional cardiology unit at the Freeman 
Hospital, Newcastle upon Tyne. However, due to problems of classification and 
ascertainment, Pierpont et al. (2007) suggest that the true prevalence may in fact be 
much higher than what is calculated in these studies. Although they do not hazard a 
guess as to what this may be. 
The two most common forms of CVM are bicuspid aortic valve defects, occurring in 1% 
- 2% of the population, followed by septation defects, see figure 1.2 (Bruneau, 2008; 
Silversides et al., 2010), although bicuspid aortic valve defects are often removed from 
estimates of prevalence. As can be seen from figure 1.2, there are many different types 
of CVM and various morphological variations (Hoffman and Kaplan, 2002; Rosamond 
et al., 2008). Examples include ventricular septal defects, atrial septal defects, 
atrioventricular septal defects and pulmonary stenosis (Hoffman and Kaplan, 2002). All 
of these different variations and categories make accurate estimates of incidence and 
prevalence difficult to ascertain.  Since the focus of my work is chiefly on data analysis 
in NGS, I do not discuss the clinical aspects of the different types of CVM in detail here. 
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Mortality rates due to CVM vary depending on the defect and its severity (Bruneau, 
2008). For infants born between 1979 and 1997 in the USA, 24% of CVM associated 
deaths arose from patients suffering hypoplastic left heart syndrome, and 5.6% of deaths 
were from transposition of great artery sufferers (Boneva et al., 2001). However, despite 
this variation, up to 85% of CVM patients now survive to adulthood (Warnes et al., 
2001). This is due to dramatic improvements in surgery that have increased survival 
rates, and now the number of adults with the disease exceeds the number of children 
(Burn et al., 1998; Marelli et al., 2007; Pierpont et al., 2007; Bruneau, 2008; Rosamond 
et al., 2008). However, despite advancements in the field, patients can suffer from 
secondary complications later in life, in particular neurological disorders and 
arrhythmias (Bruneau, 2008).  
 
 
Figure 1.1. Incidence of congenital heart disease per 1000 live births. This table is 
from Hoffman and Kaplan (2002) who collated data from 62 cardiac centres.  
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Figure 1.2. Prevalence per million live births of different types of CVM. Values are 
on the log scale. The graph is based on original data from Hoffman and Kaplan 
2002. The “All CVM” column excludes cases of bicuspid aortic valve.  
 
1.2.2 Risk factors 
The known risk factors of CVM only account for ~20% cases (Jenkins et al., 2007; 
Pierpont et al., 2007; Griffin et al., 2009). Most of what is known is based largely on 
studies involving Mendelian syndromes and rare, familial, non-syndromic forms of 
CVM. The origin of most CVM (The remaining 80%) cases is unknown with various 
studies suggesting both environmental and genetic causes (Jenkins et al., 2007; Pierpont 
et al., 2007; Bruneau, 2008; Ware and Jefferies, 2012). Some of the known risk factors 
will be discussed in more detail below. 
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1.2.3 Environmental risk factors 
There is much evidence surrounding the possible influence of external risk factors on 
CVM and an understanding of these factors is important because it could lead to the 
possible prevention of a small number of cases (Jenkins et al., 2007). One example is 
exposure to angiotensin-converting-enzyme inhibitors early on in pregnancy, which has 
been demonstrated to result in an increased CVM risk. In one such study, 209 children 
that were exposed only to ACE inhibitors during the first trimester were identified, as 
well as 202 children exposed to other antihypertensive medications in the first trimester, 
and 29096 children which were not exposed to any antihypertensive drugs during any 
time of pregnancy (Cooper et al., 2006). Information from this study was obtained from 
the Tennessee Medicaid database of children born between 1985 and 2000. The study 
found an increased risk of major congenital malformations, which included CVM, in 
children exposed to ACE inhibitors, as compared to the group of children not exposed 
to any antihypertensive drugs.  
Another example of a risk factor for CVM is phenylketonuria in the mother. In one 
study, a group of 416 children from 412 maternal phenylketonuria pregnancies were 
compared to 100 children from 99 control pregnancies (Levy et al., 2001). Of these, 
CVM was identified in 34 (14%) of the children born from the phenylketonuric mothers, 
in comparison to only 1% from the 100 children of the control group. In addition, an 
article by Jenkins et al. (2007) reviewed the available literature on prenatal and parental 
conditions and exposures and associated risk of CVM up until 2006. This article 
highlighted many of the additional risk factors for CVM, such as maternal rubella, 
diabetes, and alcohol.  
Maternal rubella has been associated with various cardiac defects, such as pulmonary 
valve abnormalities, peripheral pulmonary stenosis, and ventricular septal defects 
(Jenkins et al., 2007). In particular, one such study reviewed literature describing 
congenital heart defects following maternal rubella between 1941 and 1961 (Way, 
1967). Congenital defects were found in 4 – 58% of the cases. Patent ductus arteriosuis 
was the most common (58% of cases) cardiovascular defect seen. 
Maternal pregestational diabetes has also been shown to increase the risk of CVM. 
Specific CVMs associated with maternal pregestational diabetes include laterality and 
looping defects, transposition of the great arteries, and ventricular septal defects 
(Becerra et al., 1990; Jenkins et al., 2007). It has been found that children born from 
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mothers with gestational diabetes mellitus and who required insulin during the third 
trimester of pregnancy, were 20 fold more likely to be born with a major cardiovascular 
malformation when compared to children of non-diabetic mothers (Becerra et al., 1990). 
The study used information on 4929 still born and live babies born between 1968 and 
1980, obtained from the Metropolitan Atlanta Congenital Defects Program. The study 
also included 3 029 healthy babies which were matched based on ethnicity, period of 
birth and hospital of birth. 
Alcohol has been shown to be responsible for a wide range of teratogenic affects during 
pregnancy, including cardiac defects (Jenkins et al., 2007). Although the risks do appear 
to be related to the amount of alcohol consumed during pregnancy. A case-control study 
examining 4705 case mothers and 4329 control mothers found that although sporadic, 
low doses of alcohol may increase the risk of congenital defects, these risks do increase 
with increasing alcohol exposure. Despite various environmental factors having been 
shown to influence CVM risk, the focus of my PhD is on the genetic risk factors. 
 
1.2.4 Genetic Epidemiology 
CVM can be caused by a range of genetic variants, including rare, highly deleterious 
variants resulting in Mendelian forms, and common variants with a weak affect that can 
modulate the risk of complex disease (Manning et al., 2005). Below I will provide a 
brief introduction to some of the Mendelian forms of CVM and their associated genetic 
risks, followed by an introduction to the sporadic, non-syndromic forms of CVM. As 
mentioned earlier, most knowledge on the genetic factors influencing CVM has been 
obtained from studies on Mendelian, syndromic and rare familial forms of non-
syndromic CVM.  
 
1.2.5 Mendelian forms 
The recurrence of some CVM in families provides evidence for a genetic influence on 
many of these defects (Bruneau, 2008; Faita et al., 2012). In fact, familial recurrence 
has been shown for both non-syndromic and syndromic forms of CVM (Wolf and 
Basson, 2010). With regards to inherited CVM, both monogenic (Single gene 
inheritance) and complex, polygenic (Multiple gene inheritance) forms occur (Faita et 
9 
 
al., 2012). Information on the frequency of recurrence within these inherited CVMs 
could help to improve understanding of the disease as well as provide the information 
necessary to help affected parents wanting to have children of their own (Burn et al., 
1998). Some of the inherited syndromes displaying CVM include Alagille syndrome, 
Noonan syndrome and Holt-Oram syndrome. These conditions as well as the genetic 
contributions to each will be discussed in more detail below. 
Alagille syndrome is an autosomal dominant disorder presenting with various 
abnormalities in the liver, heart, skeleton and eyes (Pierpont et al., 2007). In a study 
involving 222 cases, 94% displayed some form of cardiovascular abnormality 
(McElhinney et al., 2002). The most common cardiovascular abnormalities in patients 
with Alagille syndrome include peripheral pulmonary hypoplasia, tetralogy of Fallot, 
and pulmonary valve stenosis (Pierpont et al., 2007). Alagille syndrome can result from 
deletions of chromosome 20p12 or from mutations in the JAG1 gene (McElhinney et al., 
2002; Pierpont et al., 2007).  As an example, in one such study the JAG1 gene was 
analysed in four families where 10 members suffered from Alagille syndrome (Li et al., 
1997). In this study RT-PCR products were screened for mutations by heteroduplex 
mobility analysis. Four coding variants were identified in JAG1 which segregated with 
disease and were identified in all four families, but not in 100 controls. 
Another example is Noonan syndrome, in which 50 - 90% of patients are affected by 
cardiac disorders (Manning et al., 2005; Pierpont et al., 2007; Ware and Jefferies, 2012). 
This is an autosomal dominant disorder characterised by typical facies, pterygium colli, 
short stature and CVM (Marino and Digilio, 2000). Three disease genes in the RAS-
MAP Kinase signalling pathway have been shown to influence Noonan syndrome, 
namely PTPN11, SOS1, and KRAS (Pierpont et al., 2007). For example, a genome-wide 
linkage analysis in a large Dutch pedigree was able to identify the distal part of 
chromosome 12q as being linked to disease (Jamieson et al., 1994).  
Holt-Oram syndrome is an autosomal dominant disorder which is characterised by 
CVMs in patients with upper limb deformities (Pierpont et al., 2007). In a study 
involving 55 Holt-Oram cases, and their parents, 95% of the cases displayed some form 
of cardiac defect (Newbury-Ecob et al., 1996). The various cardiac disorders included 
atrial septal defects and ventricular septal defects. Studies have been able to link 
variants in the TBX5 gene to Holt-Oram syndrome (Pierpont et al., 2007). For example, 
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a genome wide linkage analysis was used to identify mutations in the TBX5 gene as 
responsible for Holt-Oram syndrome in two large families (Basson et al., 1994).   
As well as occurring as part of recognised syndromes, CVM’s can occur as isolated (or 
non-syndromic) inherited defects (Richards and Garg, 2010). For example, genetic 
variants within the NKX2-5 gene have been linked with non-syndromic CVM (Schott et 
al., 1998). In this study, four families displaying high incidences of CVM were analysed. 
In all four families the disease displayed a pattern of inheritance consistent with 
autosomal dominant transmission. A genome wide linkage analysis identified a region 
on chromosome 5, where the NKX2-5 gene is located. The exons of all genes in the 
linkage region were sequenced in all the affected individuals across all four families, 
with the NKX2-5 gene being identified as the only gene to have a shared variant in all 
affected family members. There are also many other cases describing genetic variants 
responsible for non-syndromic CVM. For instance, mutations in the GATA4 gene have 
been linked to cases of isolated CVM (Garg et al., 2003), and mutations in the MYH6 
gene have also been linked to dominantly inherited atrial septal defects (Ching et al., 
2005). 
 
1.2.6 Sporadic, non-syndromic forms 
The genetic causes of sporadic, non syndromic forms of CVM are far more difficult to 
identify (The reasons are discussed in more detail below). However there have been 
some successes. For example, de novo copy number variants (CNVs) have been 
associated with tetralogy of Fallot (Greenway et al., 2009; Soemedi et al., 2012). In the 
study by Soemedi et al. (2012), the frequency of CNVs in 2 256 CVM cases was 
compared with 841 controls. They were able to identify significant differences in the 
deletion burden between the cases and the controls. As well as CNVs, other 
deletion/duplication events have also been shown to share an association with CVM 
(Bruneau, 2008; Ware and Jefferies, 2012), and chromosomal aberrations appear to 
occur fairly frequently in some CVM cases (Pierpont et al., 2007). This has been 
demonstrated in a study examining infants born with CVM between 1981 and 1986, 
where ~13% of them displayed chromosomal abnormalities (Ferencz et al., 1989).  
 
 
11 
 
1.2.7 Genetic study approaches 
Linkage Analysis (LA) and Association Studies (AS) have commonly been used to try 
and identify the genetic causes of disease (Bailey-Wilson and Wilson, 2011). More 
recently, however, next generation sequencing approaches, sometimes in conjunction 
with linkage or association methods, have been employed to identify the genetic causes 
of various disorders. However, each of these methods have their own particular 
strengths and weaknesses and perform best depending on the disease. Faita et al. (2012) 
provide a diagram (Figure 1.3) describing the genetic contribution to monogenic and 
multigenic CVMs and the study approaches which can be adopted to identify these. In 
the case of complex diseases, many genetic variants occur at a higher population 
frequency and can be identified using a genome wide association approach. In the case 
of Mendelian, monogenic disorders the diseases are caused by rare mutations in specific 
genes, for which a linkage study can be used. NGS may provide a means of identifying 
the genetic causes of both monogenic and complex diseases. 
LA has been used highly successfully for identifying many thousands of disease causing 
variants in a range of Mendelian diseases, including various cardiac disorders (Bailey-
Wilson and Wilson, 2011; Parvez and Darbar, 2011). For example, LA allowed for the 
identification of variants in chromosomes 18q22, 13q34 and 5q21 which are linked to 
bicuspid aortic valve disease (Hinton et al., 2009), and LA was also used to identify a 
missense mutation in the JAG1 gene in families with Alagille syndrome (Eldadah et al., 
2001).   
LA often precedes approaches such as exome sequencing as it allows for all of the 
variants outside of linkage peaks to be excluded, hopefully reducing the number of 
candidate variants to a more manageable number (Bailey-Wilson and Wilson, 2011; 
Smith et al., 2011). These linkage peaks identify regions of identity-by-descent 
matching a particular genetic model (Smith et al., 2011). LA in combination with whole 
exome sequencing has been employed to identify many potentially causative variants in 
autosomal dominant and autosomal recessive disorders (Smith et al., 2011), for example 
in the case of the dominantly inherited Amyotrophic Lateral Sclerosis, ALS (Johnson et 
al., 2010a). That study describes a multigenerational family in which four members 
presented with ALS. Exome sequencing was performed on two of the affected family 
members in which 88 variants were identified. Of the 88 identified variants, 33 were 
validated using Sanger sequencing. Of these 33, only four were present in the VCP gene 
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with a LOD (Logarithm of the odds) score above zero. All four variants were predicted 
by SIFT to be disease causing, and none were present in a group of 200 healthy controls. 
LA and exome sequencing approaches have also been successfully employed to identify 
the causative variants in many recessive disorders, as in the case of autoimmune 
lymphoproliferative syndrome, ALPS (Bolze et al., 2010). That study describes a 
pedigree with multiple affected individuals and in which the disease appears to display 
an autosomal recessive inheritance pattern. Three patients were genotyped for use in the 
LA, and whole exome sequencing was performed on one of these individuals. LA 
identified three regions of homozygosity shared by the patients. All three sites were 
heterozygous in healthy members of the family.  Of the 23146 variants that were 
identified, only 81 were located in the candidate regions. After further filtering, only 1 
non-synonymous variant remained which was not seen in a group of 282 healthy 
controls. 
Despite the various successes, LA only has the power to detect alleles with large affect 
sizes, which are rare in populations, and which have high penetrance (Bailey-Wilson 
and Wilson, 2011). For complex diseases, an alternative approach would be to use a 
Genome Wide Association (GWA) study (Zhu and Xiong, 2012). Due to the availability, 
and decreased costs of genotyping using microarrays, GWA studies have recently 
become a commonly used method in complex disease research (Paynter et al., 2010; 
Bailey-Wilson and Wilson, 2011; Zhu and Xiong, 2012). 
GWA studies are used to identify associations between common alleles and disease 
phenotypes (Bailey-Wilson and Wilson, 2011) and  have proved useful in the search for 
the genetic causes of various different types of CVM (Arking and Chakravarti, 2009; 
Paynter et al., 2010). For example, in the study by Schott et al. (1998), a GWA 
identified NKX2-5 as a possible gene causing various CVM’s. Also, a GWA identified a 
region on chromosome 12q24 as being associated with tetralogy of Fallot (Cordell et al., 
2013 (In press)). Other successful studies include a study in which 7 SNPs were found 
to be associated with cardiovascular disease (Smith et al., 2010), and another study 
identified 3 genes associated with coronary artery disease (Feng and Zhu, 2010).  
However, GWA studies are based on the common disease-common variant model, 
assuming that common variants are likely to be important factors in common disease 
(Reich and Lander, 2001; Juran and Lazaridis, 2011). Supposing that individual rare 
variants only have a small affect on common disease, and also that they have very low 
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population frequencies, present methods for testing for associations have limited power 
(Zhu and Xiong, 2012). Therefore, GWA studies are better powered for common SNPs 
displaying a frequency of ~5% and higher (Hindorff et al., 2009; Manolio et al., 2009; 
Cirulli and Goldstein, 2010). However, some are now including variants with a 
frequency as low as ~1% (Manolio et al., 2009; Cirulli and Goldstein, 2010), but 
association testing using alleles with frequencies of <0.5% still has very low power, 
unless the effect size of the allele is very large (Manolio et al., 2009). Traditional GWA 
studies also assume a degree of sample independence and are therefore unable to assess 
correlated family data (Zhu and Xiong, 2012). Although more modern association 
methods may allow for case-control tests within pedigrees, they still require the allele 
frequencies to be high (Zhu and Xiong, 2012). Additionally, Manolio et al. (2009) 
highlight the importance of sample size in GWA studies, stating that much larger 
sample sizes are required to detect associations using very rare alleles.  
Despite the many success stories using GWA and LA methods, the identified variants 
only appear to explain a very small proportion of the heritability of disease (Zuk et al., 
2012). Here I define heritability as the proportion of phenotypic differences in a 
population that are explained by genetic factors (Manolio et al., 2009). For example, in 
atrial fibrillation, both GWA and LA have been used to successfully identify causative 
genetic variants, but these genes only explain less than 10% of the genetic heritability of 
the disease (Parvez and Darbar, 2011). This phenomenon has been termed “missing” 
heritability, and the current understanding is that this missing heritability lies in 
additional variants which have not been discovered yet (Maher, 2008; Makowsky et al., 
2011; Zuk et al., 2012).  
Manolio et al. (2009) provides a diagrammatic representation of the possible 
relationship between allele frequency and effect size, figure 1.4. The diagram describes 
the difficulty of identifying very rare variants (allele frequency <0.001) with low effect 
sizes. Other explanations include the difficulty in identifying and genotyping certain 
types of variants such as CNVs, a low power to detect gene-gene interactions, and the 
inadequate identification of possible, shared environmental factors (Maher, 2008; 
Manolio et al., 2009).  
Both LA and GWA studies have demonstrated that the “missing heritability” cannot be 
explained by rare, large effect alleles, or by common moderate effect alleles (Manolio et 
al., 2009). However, it is important to be able to correctly identify risk alleles, and the 
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source of this missing heritability (Paynter et al., 2010), as it may lead to a better 
understanding and treatment of the disease (Manolio et al., 2009). Some authors have 
claimed that sequencing could be used to investigate the presence of causative rare 
variants further, and as a means of identifying the sources of this missing heritability 
(Manolio et al., 2009).   
 
 
Figure 1.3. Genetic contribution to monogenic and complex CVM (From Faita et 
al. (2012)). 
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Figure 1.4. Identifying genetic variants based on risk allele frequency and strength 
of genetic effect. The figure is from Manolio et al. (2009). 
 
1.3 NGS in Mendelian Diseases 
NGS approaches have been particularly successful in identifying the causes of various 
Mendelian diseases displaying a recessive mode of inheritance (Lalonde et al., 2010; 
Ng et al., 2010b; Bamshad et al., 2011; De Keulenaer et al., 2012; Pyle et al., 2012). 
This is largely because homozygous, disease causing variants in populations occur 
rarely (Ng et al., 2010b; Ng et al., 2010c; Stitziel et al., 2011). For example, in the case 
of spastic ataxia of Charlevoix-Saguenay (Pyle et al., 2012). In this study, the authors 
were able to identify the SACS gene as the likely cause of disease by using the exomes 
of only two cases. Many of the other studies quoted here are described in more detail in 
chapter 4. 
In chapter 4 I used NGS methods to identify rare variants in diseases appearing to show 
a dominant mode of inheritance. Although, more difficult than causal variant discovery 
in recessive conditions (See chapter 4), various studies have shown a degree of success 
in identifying the causative variants responsible for dominant disease (Johnson et al., 
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2010a; Ng et al., 2010a; Dickinson et al., 2011; Pfeffer et al., 2012). As with the 
recessive studies listed above, these studies are discussed in more detail in chapter 4. 
 
1.4 NGS in Complex Diseases 
As well as identifying potentially disease causing variants in Mendelian conditions, I 
also used NGS methods to identify potentially disease causing variants in sporadic 
forms of CVM (Chapter 5). Of particular interest in this regard was an empirical study 
of exome sequence data from 438 individuals, comprising 184 individuals from the 
International HIV Controllers Study and 254 control individuals (Kiezun et al., 2012). 
In this study several of the important aspects of exome sequencing for disease 
identification in non-Mendelian diseases were discussed, in particular the problem of 
obtaining adequate sample sizes. Using simulated data, the authors expect that over 
10000 exomes would be required to achieve sufficient statistical power to detect 
associations of rare variations with complex traits. Also, the many GWA studies which 
have been carried out to date, demonstrate that common variants underlying complex 
traits are not necessarily located in exonic gene regions, but spread across many more 
regions of the genome (Day-Williams and Zeggini, 2011). However, protein coding 
genes do provide well defined and easily interpretable targets (Kiezun et al., 2012), 
particularly in genes known to be involved in disease, such as the targeted approach I 
used in chapter 5.  
Despite these difficulties, there have been some successes, such as in Type I diabetes 
(Nejentsev et al., 2009). In this study exons and splice sites of 10 candidate genes in 
480 cases and 480 controls were re-sequenced using a 454 GS-FLX sequencer 
(Described below). A total of 212 point mutations were identified using the Staden 
package (http://staden.sourceforge.net/). Of these, 179 were categorised as rare (Minor 
allele frequency <3%), of which 156 had been previously unreported. The authors tested 
for association using all 212 variants by comparing cases and controls, and were able to 
confirm the previously known associations of common SNPs with type 1 diabetes. 
However, they also identified associations with two rarer SNPs, rs35667974 and 
rs35337543, in the IFIH1 gene. Both variants were predicted to alter the expression and 
structure of the gene.    
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1.5 NGS platforms 
1.5.1 Sanger sequencing 
Since its inception, the Sanger sequencing method has been used in thousands of ground 
breaking studies, such as in the sequencing of the first human consensus sequence 
(Lander et al., 2001; Harismendy et al., 2009). Sometimes called first generation 
sequencing, this method employs dideoxy and arabinonucleoside analogues which act 
as chain terminating inhibitors of DNA polymerase (Sanger et al., 1977). This process 
can generate reads of up to 900 base pairs in length (Zhang et al., 2011; Liu et al., 2012) 
and is frequently used in validation studies. 
Although still considered by many as the “gold standard”  sequencing approach, in 
comparison to more modern approaches it is expensive and has a considerably lower 
output, see table 1.1 (Harismendy et al., 2009; Audo et al., 2012). The recent 
advancements in NGS technologies have made it possible to sequence entire genomes 
and exomes in a relatively short space of time. It is now possible to examine variation in 
multiple genomic segments of several samples (Choi et al., 2009), which could greatly 
improve understanding of the genetics behind complex diseases (Choi et al., 2009; Ng 
et al., 2009), especially in the identification of rare variants (Choi et al., 2009; Cirulli 
and Goldstein, 2010; Parvez and Darbar, 2011). These methods are able to rapidly 
generate millions of sequence reads per patient and provide a fast, cost effective means 
to identify potentially disease causing variants in CVM cases (Mardis, 2008; Arking and 
Chakravarti, 2009).  
 
1.5.2 Roche 454 GS-FLX system 
The 454 GS-FLX system was the first commercially available NGS platform. It utilised 
an emulsion PCR amplification stage followed by a sequencing-by-synthesis technique 
whereby reagents flowing across a slide allow for simultaneous nucleotide extension 
reactions, with each base incorporation emitting a light signal captured by a camera 
(Margulies et al., 2005; Mardis, 2008; Pareek et al., 2011; Zhang et al., 2011).  
Initially the genome is sheared to produce random libraries of DNA fragments. 
Adaptors are added to each fragment, and the fragments are then captured on beads. 
These are then clonally amplified in an emulsion PCR step, and the resultant DNA 
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strands are denatured and deposited into wells of a fibre-optic slide. The slide is 
deposited in a flow chamber where sequencing-by-synthesis occurs. Reagents 
simultaneously flow across the flow chamber allowing for extension reactions where 
nucleotide incorporation results in the release of a light signal which is detected by a 
camera. The intensity of the light signal depicts the number of nucleotides which were 
added at each reaction (Margulies et al., 2005). The most recent 454 GS-FLX system is 
able to generate reads of up to 700bp long (Liu et al., 2012). Although its throughput is 
lower than for the other NGS systems, it is much faster than both the SOLiD and HiSeq 
sequencers and able to generate much longer reads (Liu et al., 2012). The 454 GS-FLX 
system is often used for de novo sequence assembly, cancer and mutation detection 
applications (Liu et al., 2012).    
Roche has also released a bench top sequencer called the GS Junior, in which the library 
preparation and data processing has been simplified and the system can now generate up 
to 14Gb per run (Liu et al., 2012). This sequencer is able to generate up to 100 000 
reads with an average read length of ~400bp’s (http://www.gsjunior.com/instrument-
workflow.php).  
  
1.5.3 Applied Biosystems SOLiD 
The Applied Biosystems SOLiD Sequencer employs an emulsion PCR amplification 
step, before DNA sequencing using fluorescently labelled dinucleotides that are added 
by ligation (Mardis, 2008). This system has many applications, including whole genome 
resequencing, targeted resequencing, transcriptome research (including gene expression 
profiling and small RNA analysis), and epigenomic research (Liu et al., 2012).  
Initially, the genomic DNA is fragmented and oligo adaptors ligated to the ends of the 
DNA fragments. The adaptor sequences are then hybridised to magnetic beads 
containing complementary oligos and the sequences are amplified via emulsion PCR. 
The beads are then attached to the surface of a glass slide and placed in the sequencer. 
During sequencing, a universal primer, complementary to the adapters, is annealed to 
the library fragments. A set of 8mer oligonucleotides and DNA ligase is then added. If 
an oligonucleotide hybridises to the DNA fragment sequence next to the 3’ end of the 
primer, the DNA ligase seals the phosphate backbone. After ligation, the 8mer 
oligonucleotide is identified by a fluorescent label on the fifth or second base position. 
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Finally the 6
th
 through 8
th
 bases of the oligonucleotide sequence are removed by 
cleavage, allowing for another round of ligation. The DNA fragment sequence is 
therefore identified in steps of five nucleotide intervals (Mardis, 2008). The ABI SOLiD 
5500xl system can now generate reads of up to 85bp in length and has a total output of 
30Gb per run (Liu et al., 2012). 
 
1.5.4 Illumina Genome Analyser 
The Illumina Genome Analyser (Illumina GA) was the second commercially available 
NGS platform and utilised cluster amplification and a sequencing-by-synthesis 
technique using reversible fluorescently labelled chain terminators (Mardis, 2008; 
Zhang et al., 2011). 
Initially the single stranded genomic DNA is fragmented and adaptor oligonucleotides 
ligated to the individual fragments. The fragments are then added to the surface of a 
glass flowcell comprising 8 lanes with complementary, covalently attached oligos. The 
fragments can then hybridise to the flow cell oligos and then undergo PCR 
amplification in a cluster. The flowcell is transferred to the sequencer and supplied with 
polymerase and fluorescently labelled nucleotides. The fluorescent label identifies the 
base. The 3’ end of each base is inactivated insuring the addition of only one base per 
cycle. Each cycle is followed by an imaging step to identify the particular base that was 
incorporated and the fluorescent group and the 3’ block are removed (Mardis, 2008). 
The original Illumina GA was able to output up to 95Gb of sequence data, comprising 
reads of up to 150bp long (http://www.illumina.com/).  
Then in early 2010, Illumina launched the HiSeq2000 which due to various 
improvements in polymerase, buffer, flowcell, and software, is now able to output up to 
600Gb per run (Liu et al., 2012). Like its predecessor, the HiSeq2000 employs a 
sequencing-by-synthesis approach, but at a 2 – 5 fold higher rate of data acquisition by 
using a four camera system able to detect the intensities of all four bases simultaneously 
(Minoche et al., 2011).  Additionally, in comparison to the Roche 454 GS-FLX system 
and the Applied Biosystems SOLiD systems, the HiSeq2000 is also the cheapest on the 
market, with a sequencing cost of only $0.02/million bases (Liu et al., 2012). The 
HiSeq2000 can be used for a range of different applications; in particular it is frequently 
used in targeted reqequencing and mutation discovery studies.  
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Illumina has also released its own compact, bench top sequencer called the MiSeq. This 
sequencer still makes use of Illumina’s reversible terminator-based sequencing by 
synthesis technique and is able to generate reads of up to 150bp in length and output up 
to 1.5Gb of data (Liu et al., 2012). This lower throughput, fast turnaround sequencer has 
been largely aimed at small laboratories and for use in clinical diagnostics (Quail et al., 
2012). 
 
1.5.5 Life technologies Ion Torrent PGM 
Clonal amplification of the DNA fragments is achieved via an emulsion PCR step on 
the surface of 3-micron diameter beads, called Ion Sphere Particles (Quail et al., 2012). 
These beads are then loaded into proton-sensing wells on a silicone wafer, after which 
each of the four bases is introduced sequentially (Zhang et al., 2011; Quail et al., 2012). 
During the sequencing process, when a nucleotide is incorporated onto the growing 
DNA strand, a hydrogen ion is released which is detected by an ion sensor and 
converted into a digital output (Zhang et al., 2011). The direct connection between 
chemical and digital information improves speed, simplicity and output (Pareek et al., 
2011). 
However, the system does carry with it some disadvantages, as listed by Niedringhaus 
et al. (2011). The author’s state that the need for the reaction wells to be cleared 
between each reaction step can lead to an accumulation of errors, and that the system 
has difficulties sequencing highly repetitive or homopolymer regions.  
 
1.5.6 Third generation sequencing 
As well as the next generation platforms described above, methods utilising single DNA 
molecule sequencing are currently being made available (Zhang et al., 2011). These 
methods do not require amplification and simply read through DNA templates in real 
time, making them potentially more accurate than the NGS platforms (Pareek et al., 
2011; Zhang et al., 2011; Liu et al., 2012).  
For example, the Pacific Biosciences RS which relies on a process termed single 
molecule real time sequencing that employs a sequencing-by-synthesis method which 
uses fluorescently labelled nucleotides and DNA templates attached to the bottom of 
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zero-mode waveguide wells (Pareek et al., 2011; Quail et al., 2012). During this process 
the DNA templates are attached to the bottom of the 50nm wide zero-mode waveguide 
wells (Quail et al., 2012). DNA synthesis is carried out by DNA polymerase in the 
presence of y-phosphate fluorescently labelled nucleotides (Pareek et al., 2011; Quail et 
al., 2012). With each new base incorporation, the flourophores attached to the 
nucleotides are excited, generating a pulse of fluorescence which is detected in real time 
(Quail et al., 2012).   
Some of the advantages of this method of sequencing are listed by Liu et al. (2012). 
These advantages include a decreased sample preparation time of only 4 - 6 hours, a 
PCR step is not required which reduces errors caused by PCR, the turnover rate is very 
fast (An entire run can be completed in a day) and finally, the average read length is 
~1300bp. Despite these apparent advantages, the system suffers from inefficient loading 
of the DNA polymerase into the zero-mode waveguide wells and subsequent 
degradation of the polymerase in these wells, a low accuracy of between 81 – 83%, and 
a high cost per base (Niedringhaus et al., 2011). 
 
1.5.7 Comparison of different sequencing platforms 
Harismendy et al. (2009) compared the base calls generated using Sanger sequencing to 
those generated using the 454 GS-FLX, Illumina GA and the ABI SOLiD platforms. 
They identified heterozygous and homozygous variants in 258 879 base pairs using all 
four methods and found 20 loci that the three NGS technologies were concordant with, 
but discordant with the Sanger calls. Eight of these 20 calls were base calling errors in 
the original samples, while 9 of the remaining 12 discrepancies were found to be 
incorrect in the Sanger sequences.  Sanger sequencing had a 0.9% false positive call rate 
and a 3.1% false negative call rate, whereas the 454 GS-FLX, Illumina Genome 
Analyser and ABI SOLiD displayed false positive rates of 2.5%, 6.3% and 7.8% 
respectively, and false negative rates of 3.1%, 0%, and 0.9% respectively.  
Liu et al. (2012) also provided a comparison between the Sanger sequencing platform 
and three NGS platforms, namely the 454 GS-FLX system, the Illumina HiSeq2000 
system, and the SOLiD 5500xl system (Table 1.1). This table and its information was 
extracted from Liu et al. (2012). As can be seen, the most significant differences 
between the systems are in terms of read length, data output and cost. By far, the most 
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expensive, with the lowest throughput, is Sanger sequencing. However, it does generate 
very long reads and displays a very high accuracy. 
A further study by Niedringhaus et al. (2011) compared the Sanger, 454 GS-FLX, 
HiSeq2000, and SOLiD sequencing platforms. They too found that although the Sanger 
sequencing method was more expensive and had a lower throughput than the next 
generation platforms, it could generate longer, high quality reads that also displayed 
good quality in repeat and hompolymer regions. They found that the sample preparation 
step was complicated for the 454 GS-FLX system and that it generated low quality 
reads in repetitive and homopolymer regions. However, the 454 GS-FLX sequencer was 
able to generate longer reads than any of the other next generation platforms.  In 
comparison, the SOLiD sequencer produced relatively short reads amongst, but had a 
very high throughput and very low reagent costs. 
Quail et al. (2012) provides a comparison of three next generation bench-top sequencers, 
namely the Illumina Miseq, the Ion Torrent, and the PacBio RS (Table 1.2). Although 
the Illumina MiSeq has the lowest costs and highest output, it also has the shortest read 
length and longest run time. However, the MiSeq also has the lowest error rate at 0.8%, 
with the PacBio RS sequencer having a much higher error rate at 12.86%. 
Due to its very high output, very low per base cost, and its versatility I chose to use the 
Illumina Genome Analyser and Illumina HiSeq2000 as the sequencers of choice in 
chapters 4 and 5 of my thesis. 
 
 
 
 
 
 
 
 
 
23 
 
Sequencer 454 GS FLX HiSeq2000 SOLiD 5500xl Sanger 3730xl 
Read length 700 bp 50SE, 50PE, 100PE 85bp 900 bp 
Accuracy 99.90% 98%, (100PE) 99.99% 100.00% 
Output 
data/run 
0.7 Gb 600 Gb 30 Gb 84 Kb 
Time/run 24 Hours ~8 Days 7 Days for SE or 14 Days for PE 20 Mins - 3 Hours 
Cost/million 
bases 
$10 $0.02 $0.13 $2400 
Advantage Read length, fast High throughput Accuracy 
High quality, long 
read length 
Disadvantage 
Error rate with 
polybase more 
than 6, high cost, 
low throughput 
Short read assembly Short read assembly 
High cost low 
throughput 
 
Table 1.1. Comparison of the 454 GS FLX, HiSeq2000, SOLiD 5500xl and Sanger 
3730xl sequencing systems. Table and information has been extracted from Liu et 
al. (2012). SE=Single-end and PE=Paired-end. 
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Platform Illumina MiSeq Ion Torrent PGM PacBio RS 
Instrument Cost $128K $80K $695K 
Sequence yield per run 1.5-2Gb 
20-50Mb on 314 chip, 
100-200Mb on 316 chip, 
1Gb on 318 chip 100Mb 
Sequencing cost per Gb $502 $1000 (318 chip) $2000 
Run Time 27 hours 2 hours 2 hours 
Observed Raw Error 
Rate (%) 0.8 1.71 12.86 
Read length up to 150 bases ~200 bases Average 1500 bases 
 
Table 1.2. Comparison of three next generation, bench-top sequencing platforms. 
The table and information has been adapted from Quail et al. (2005). 
 
1.6 NGS Data Analysis 
Following sequencing, a series of programmes are employed to convert the sequencer 
output into a nucleotide sequence, and ultimately to identify variants, from the 
sequencer output files. A base caller must first be used to convert the output into 
sequence reads and to assign the correct base identity to each sequence (Nielsen et al., 
2011). A sequence aligner is then used to align the sequence reads  to a reference 
sequence, and remove miscellaneous sequences not matching the reference sequence 
(Day-Williams and Zeggini, 2011). Finally a variant caller can be used in order to 
identify variants (Which I define as deviations from the reference sequence) from these 
aligned reads (McKenna et al., 2010; Koboldt et al., 2012). 
There are a whole host of programmes available to perform sequence alignment (Li and 
Durbin, 2009; Wu and Nacu, 2010; Langmead and Salzberg, 2012) and variant calling 
(Li et al., 2009; McKenna et al., 2010; Albers et al., 2011; Koboldt et al., 2012). 
However not all programmes perform equally well, and all have their own potential 
shortfalls (Shen et al., 2010; Albers et al., 2011; Nielsen et al., 2011; Wang et al., 2011). 
There is much variation between these different analysis pipelines, which I explore in 
chapter 3. Therefore, the selection of the appropriate pipeline will have a large effect on 
the potential of a study to identify causative variants. 
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Furthermore, variant callers often identify many thousands of variants (See chapter 4) 
per patient. Therefore one of the challenges in NGS studies is how to decide which of 
these variants are responsible for disease (Ng et al., 2009; Ng et al., 2010c; Zhi and 
Chen, 2012). This presents a major challenge, and as such many “variant filtering” 
procedures have been developed (Ng et al., 2010b; Erlich et al., 2011). Filtering 
methods include the selection of variants present only in cases (Bamshad et al., 2011), 
removing variants identified outside of the target regions (Dickinson et al., 2011), and 
incorporating a prediction programme to assess the potential impact of the variant on 
protein function (Bamshad et al., 2011). However, many of these filtering methods 
imply a choice of genetic/biological model, which may not always be known. A detailed 
discussion of the approaches to variant filtering that I adopted is presented in the 
relevant chapters of this thesis. 
NGS methods have been successfully applied to a range of monogenic, Mendelian 
diseases (Ng et al., 2009; Ng et al., 2010b; Bamshad et al., 2011; Gilissen et al., 2011). 
Due to the large capacity and cost requirements of whole genome sequencing (Teer and 
Mullikin, 2010; Gilissen et al., 2011),  whole exome sequencing is currently the more 
popular approach (Gilissen et al., 2011; Smith et al., 2011). The advantages and 
disadvantages of targeted capture approaches are discussed in chapters 3, 4, and 6. 
 
1.7. Specific aims 
The aim of my PhD was to use NGS methods to identify rare and potentially disease 
causing variants in various diseases, in particular CVMs. First, I implemented analysis 
pipelines, in the process becoming the first researcher in Newcastle University’s 
Institute of Genetic Medicine to analyse NGS whole exome data.  Realising the constant 
questions regarding the adequacy of sequencing quality, coverage, and analysis 
methodology that arise during NGS studies - particularly when nothing is found in a 
promising family and some estimate of the merit of investing further effort is required - 
I developed and tested a method to assess the performance of different NGS variant 
calling pipelines and the adequacy of a given set of sequencing output.  I then applied 
the methods I had developed in two clinical contexts, attempting to identify rare 
variants that were disease-causing. The first used NGS methods to identify variants 
responsible for three Mendelian diseases (Atroventricular Septal Defects, Dilated 
Cardiomyopathy, and Hereditary Sclerosing Poikiloderma), and the second used NGS 
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methods to identify potentially disease causing variants in a group of patients suffering 
from sporadic, non-Mendelian CVMs. In the second project, recognising the 
bioinformatics challenges that remain regarding the accurate calling of indels, I tested 
different analysis pipelines and evaluated their performance using the methods I 
developed earlier in my work.   
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Chapter 2. Methods 
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2.1 Methods overview 
With regard to the bioinformatics analyses that were my principal focus, methods were 
specific to each sub-project and are described in the respective chapter.  In this section, I 
provide an overview of those methods (chiefly laboratory methods) which were 
employed throughout my thesis to generate the data I was responsible for analysing.  
Experimental strategy for the laboratory work was decided by my supervisory team and 
as work progressed, was informed by the results I generated.  Unless specified 
otherwise, the information in this chapter, which is chiefly provided for reference, was 
provided by Dr. Thahira Rahman and Mr. Rafiqul Hussain (University of Newcastle), 
who were the individuals responsible for carrying out the “wet lab” work. However, all 
data analysis and bioinformatics analysis was performed by myself. 
 
2.2 Samples, target enrichment and sequencing 
In chapter 4, I analysed data from cases in three pedigrees suffering from Mendelian 
diseases. In chapter 5 I analysed cases from the HeartRepair project, which consisted of 
133 unrelated individuals suffering from various sporadic CVMs characterised by 
hypoplasia of one or other of the ventricles of the heart. The library preparation, target 
enrichment and sequencing varied between these two studies and will be discussed in 
more detail in this methods chapter.  
 
2.2.1 Whole exome sequencing of Mendelian family samples (studied in chapter 4) 
Blood and saliva samples were collected from members of three pedigrees. In each 
pedigree predisposition to a different disease appeared to segregate following an 
autosomal dominant mode of inheritance. Family trees and discussion of the phenotypes 
are provided in chapter 4. 
Five micrograms of genomic DNA was extracted from pre-existing samples. A Covaris 
instrument (http://covarisinc.com/; University of Newcastle) was used to shear the 
genomic DNA into fragments ranging in size from 150 to 200bp. Fragmented samples 
were then assessed on a DNA1000 lab chip (Agilent) on an Agilent Bioanlyser to 
determine whether they were in the correct size range. The next step involved the end 
repair and adenylation of the fragments, after which Illumina adapters were added. The 
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ligated products were then cleaned up to select only those DNA fragments which have 
adapters on both ends. Then in the following PCR stage, additional sequences were 
added to the ends of the adapters so that the final amplified templates contained 
sequences to enable hybridisation with primers bound to the flow cell surface for cluster 
generation (http://www.genomics.agilent.com).  
Enrichment then proceeded using either the 38Mb or 50Mb SureSelect Human All Exon 
Capture Kit from Agilent Technologies (http://www.agilent.co.uk). Each enrichment kit 
consisted of custom biotinylated SureSelect oligonucleotides (also known as baits; 
http://www.genomics.agilent.com). The RNA bait-DNA hybrids were captured on 
streptavidin-coated magnetic beads. Amplification by PCR followed, after which the 
target samples were loaded onto the Illumina Genome Analyser IIx for paired end 
sequencing. 
 
2.2.2 Targeted sequencing of unrelated cases of CVM (studied in Chapter 5) 
Peripheral blood or saliva samples were collected from patients of European ancestry. 
Unrelated patients were recruited from four sources: (1) CONCOR (National Registry 
and DNA bank of congenital heart defects), The Netherlands, n=59 (2) National 
Registry for Congenital Heart Defects (NR-CHD), Berlin, Germany, n=13, (3) The 
Institute of Human Genetics, Newcastle University, United Kingdom, n=48, and (4) the 
University Hospital Zürich, Zürich, Switzerland, n=13. Informed consent was obtained 
from all participants according to institutional guidelines after approval of local ethics 
committees. Probands were evaluated by history taking, review of medical records, 
physical examination, 12-lead electrocardiography and transthoracic echocardiography. 
Family members, preferably the parents of the proband (trios), were included wherever 
possible but were only evaluated by history taking and review of medical records. 
Newcastle patients and their parents (when available) were recruited in the Freeman 
Hospital, Newcastle upon Tyne, UK after ethics approval by the Northern and 
Yorkshire Multi-centre Research Ethics committee.  
Genomic DNA was extracted from blood and saliva samples by either the Phenol-
chloroform method or the Oragene kit (DNA Genotek, Canada) respectively. For the 
NR-CHD patients genomic DNA was extracted by the Gentra Autopure LS automated 
DNA purifier (Gentra Systems, Minneapolis, USA) Genomic DNA samples were 
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quantified by Qubit® Fluorometer (Invitrogen, Life Technologies) and their quality 
assessed on a Nanodrop (California, USA). 5 µg of gDNA was suspended in 1X TE 
buffer and made up to 100 µl. This was sonically sheared to fragments with average size 
of 200bp on the Covaris S2 system (Covaris, Massachusetts, USA). After 
fragmentation, samples were purified using QIAquick columns from a QIAquick PCR 
Purification Kit (Qiagen, Hilden, Germany) and eluted in Qiagen buffer EB. The size of 
fragments was assessed on the 2100 Bioanalyzer using DNA1000 chip.  
The indexed paired-end libraries were prepared using reagents from the Illumina 
Genomic DNA Sample preparation kit and Multiplexing sample preparation 
oligonucleotide kit. Nucleotide overhangs produced as a result of the shearing process 
were converted to blunt ends using Klenow enzyme, T4 DNA polymerase, Klenow 
enzyme and T4 PNK. After incubation, samples were purified using QIAquick columns 
from a QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) and eluted in Qiagen 
buffer EB. 
Double stranded, blunt, phosphorylated DNA fragments were adenylated at their 3’ends 
in a reaction mix containing Klenow buffer, dATP and Klenow fragment (3' to 5' exo 
minus).  After incubation, samples were purified using QIAquick MinElute columns 
from a MinElute PCR Purification Kit (Qiagen, Hilden, Germany) and eluted in Qiagen 
buffer EB. 
Illumina multiplex paired-end adapters (Multiplexing Sample Preparation 
Oligonucleotide Kit, PE-400-1001, Illumina, San Diego, USA) were ligated to the 
adenylated DNA fragments in a reaction mix containing DNA sample, ligase buffer and 
Illumina multiplex paired-end adapter oligo mix and DNA ligase. After incubation, 
samples were purified using SPRI beads (Qiagen, Hilden, Germany) and eluted in 
Nuclease-free water. Quality and concentration of adapter ligated DNA fragments were 
checked on the 2100 Bioanalyzer using DNA1000 chip.  
Four hundred and three (Appendix table 2.1) genes that were linked to cardiovascular 
malformations in humans or animal models were selected for capture and sequencing 
(further details on gene selection strategy are presented in Chapter 4). DNA sequences 
were downloaded from the UCSC Genome Browser and the coordinates of genomic 
sequences were based on NCBI genome build 36. The target regions encompassed 5152 
exons and 1.68 Mbp. In these regions, 50406 unique capture probes were designed 
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using the eArray algorithm following the manufacturer’s instructions and with 5× tiling 
frequency. The biotinylated 120-mer cRNA probes were synthesised by Agilent 
Technologies (SureSelect target Enrichment System).  
Target enrichment was performed using a SureSelect Custom Target Enrichment Kit 
(Agilent, California, USA). Libraries were made up to147 ng/µL ready for in-solution 
hybridisation with the custom SureSelect biotinylated cRNA oligonucleotides. To reduce 
non-specific hybridization, human Cot-1 DNA (2.5 µL) and 0.6 µL of a custom-made 
oligonucleotide block 3 pool containing equimolar concentrations (100 µM each) of four 
oligonucleotides. 
 
The biotinylated cRNA-DNA hybrids were separated from the hybridisation mixture 
using Dynabead M-280 Streptavidin (Invitrogen, California, USA), washed and cRNA 
baits were digested following recommended protocol. Enriched fragments were purified 
using QIAquick MinElute PCR purification columns from the MinElute PCR 
Purification Kit (Qiagen, Hilden, Germany). 
A post-hybridisation PCR was performed to barcode adapter ligated fragments and to 
selectively amplify enriched samples. The amplification reaction mix was prepared 
using Captured DNS fragments, Phusion High Fidelity DNA Polymerase master mix 
(Finnzymes, Finland), PCR primer InPE 1.0, PCR primer and PCR primer Index 
(Illumina Multiplex PCR kit) and incubated in a thermocycler. Quality and 
concentration of enriched DNA fragments were accessed on 2100 Bioanalyzer using the 
High-Sensitivity DNA kit.  
Five samples were pooled at equimolar concentration and sequenced in a single lane of 
the Illumina GAIIx or Illumina HiSeq2000 sequencer with separate priming for reading 
the 6 nucleotide index sequences. For clustering on the GAIIx version 2 cluster kits 
were used on the GAIIx cluster station and for clustering on the cBot cluster station (for 
HiSeq 2000) version 3 HS cluster kits were used. Version 4 sequencing reagents were 
used for GAIIx and SBSv2 sequencing reagents were used for Hiseq2000. Base calling 
was performed with BclConverter-1.7.1 and subsequent use of Illumina’s GAPipeline-
1.5.1 (GAIIx) or CASAVA-1.7 pipeline (HiSeq2000). Demultiplexing was performed 
with a custom perl script allowing for one mismatch with the expected index sequence. 
For an initial assessment of coverage in targeted regions, sequences were aligned to the 
hg18 genome with bowtie v0.12.7, and only samples with at least 20x coverage in at 
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least 80% of the targeted regions were used. In case of insufficient coverage, 
sequencing was repeated once or twice and resulting fastq files were merged. This was 
done at the AMC, Amsterdam. 
 
2.3 Data analysis 
2.3.1 Computers  
Originally, the work was begun using a Dell PowerEdge 2970 system including 2 AMD 
Opteron HE 212 (2.0GHz) processors. This system had 12 cores, 32GB ram and 8TB 
storage. 
The institute then acquired a cluster including a Dell PowerEdge R510 headnode, and 
16 nodes housed in 4 Dell C6100 chassis. The headnode consisted of 2 Intel Xeon 
E5503 (2.0GHz) processors 8 cores and 12GB ram. The 16 additional nodes comprised 
2 Intel Xeon E5640 (2.67GHz) processors, 8 cores, 48GB ram, and 150GB scratch 
space.  
The cluster was later upgraded to a cluster including the original headnode, the original 
16 nodes mentioned above, 4 new nodes, and a login node. The new login node 
comprised a Dell PowerEdge C1100 system with 2 Intel Xeon E5640 (2.4GHz) 
processors, 8 cores, and 24GB ram. The 4 new nodes are housed in a Dell C6100 
chassis and each node consists of 2 Intel Xeon E5640 (2.66GHz) processors, 8 cores, 
96GB ram and 1TB scratch space. 
In total the cluster provided 20 nodes, 37TB lustre storage (via 2 Dell PowerEdge R510 
processors), 20TB direct cluster NFS storage and 27TB attached NFS storage (via 2 
Dell PowerEdge R715 processors). It runs a Scientific Linux release 6.3 operating 
system, and the OGS/GE 2011.11p1 batch-queuing system. 
 
2.3.2 Scripting  
In all chapters, I constructed analysis scripts using the Perl programming language 
(http://www.perl.org/), versions 5.10.1, 5.12.4, and 5.16.1. Perl scripts were used 
throughout my PhD to perform a range of tasks, and some of the more relevant tasks 
will be highlighted below. 
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I combined many of the alignment and variant calling programmes into single pipelines 
throughout my PhD. These created single analysis pipelines which, on specification of 
input fastq files and the desired criteria, would perform the alignment, variant calling, 
and the variant prediction stages of the pipeline. Appendix script 2.1 is an example of a 
script that I used to run MutationTaster. 
In chapter 3 I developed a novel method to assess the performance of an entire next 
generation sequencing experiment. Due to the sheer volume of data contained in both 
the HapMap and 1000 Genomes databases, I developed scripts which could be used to 
extract only the on-target SNPs which were required for my method to assess the 
performance of the analysis pipelines (Method described in more detail in chapter 3). 
More importantly though, a script had to be developed which given a list of reference 
SNPs and a VCF file, would calculate the sensitivity and specificity of the variant calls 
(See chapter 3 for more details on the method). Due to the length and complexity of the 
script it will not be made available here, but in the publication of the method. 
Many aspects of chapter 4 involved the development and use of complex scripts for data 
analysis. In addition to the scripts which were used to run the analysis pipelines, this 
chapter also required the use of various scripts to perform all of the downstream data 
analysis steps. For example, given a list of identified variants I developed and used 
scripts that would remove all of the off-target variants and select those not found in the 
dbSNP database as well as removing those variants found in a control list.  
Many of the scripts in chapter 5 performed similar functions to those in chapter 4. For 
instance, removing the off-target variants and those present within the control list (See 
methods in chapter 5). However, this chapter did require some additional scripts that 
were designed and implemented by myself. For example, I had to design a script to 
calculate the length of all the identified insertions and deletions (Appendix script 2.2). I 
also designed a script to identify the overlaps of indels identified by both the BWA-
Dindel and BWA-GATK analysis pipelines (Appendix script 2.3). 
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2.3.3 Sequence analysis 
Base calling was done using GERALD (cassava 1.6.0). 
Alignment was performed using a series of programmes, specified in the relevant 
chapters. These included: 
1) Bowtie v0.12.8 (Langmead et al., 2009) 
2) Bowtie2 v2.0.0beta6 (Langmead and Salzberg, 2012) 
3) BWA v0.5.10 and v0.5.8 (Li and Durbin, 2009) 
4) GMAP (GSNAP) v20120720 (Wu and Watanabe, 2005) 
5) NovoAlign v2.07.13 (www.novocraft.com) 
6) SSAHA2 v2.5.5 (Ning et al., 2001) 
 
Variant calls were also performed using a variety of programmes, which again are 
specified in the relevant chapters. These included: 
1) Dindel v1.01(Albers et al., 2011) 
2) GATK v2.2.9 (McKenna et al., 2010)  
3) Samtools v0.1.8 and v0.1.18 (Li et al., 2009) 
4) Varscan v2.3.1 (Koboldt et al., 2012) 
 
All statistical analyses was performed using the R package (http://www.r-project.org/), 
versions 2.15.0 and 2.15.1.   
 
2.3.4 Accessory programmes 
Both a local version of Annovar (v506 and v510) and the online wAnnovar 
(http://wannovar.usc.edu/) version were used for variant annotations in chapter 4 and 5. 
Given a list of input variants, these two programmes annotate their functional affects 
and match them to public SNP databases using information form databases such as 
Ensembl (http://www.ensembl.org/index.html), 1000 genomes 
(www.1000genomes.org/) and the Exome Variant Server (EVS; 
http://evs.gs.washington.edu/EVS/) project. 
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MutationTaster (http://www.mutationtaster.org/) was used to predict the pathogenicity 
of variant calls. 
Where applicable, BAM files were converted to fastq files using Bam2fastq v1.1.0 
(http://www.hudsonalpha.org/gsl/information/software/bam2fastq). 
The ngsqctoolkit v2.2.3 (Patel and Jain, 2012) was used to generate the graphs 
displaying average base coverage across the sequence reads in chapter 4. 
The Picard v1.75 set of programmes was used in chapters 4 and 5 to remove duplicate 
reads from the sequence files. 
In addition graphs were generated using the R package and SigmaPlot v11. 
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Chapter 3. Using population data for assessing next-generation 
sequencing performance 
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3.1 Aim 
In the work outlined in this chapter, I describe the design of a simple, fast and effective 
method to calculate sensitivity and specificity of variant calls from NGS data. This is 
often done by comparing identified variants with those obtained using a reference 
technique such as a genotyping microarray. I designed a novel technique to calculate 
sensitivity and specificity using publically available population frequency data obtained 
from databases such as the HapMap and 1000 genomes databases.  
I demonstrate that my method provides comparable results to those requiring microarray 
data. I compare different analysis pipelines used to identify single base substitutions and 
indels. As my method relies on allele frequencies obtained from public databases I also 
investigate the impact of using “incorrect” frequency data on sensitivity and specificity, 
and also explored the influence of sequence coverage.  
 
3.2 Introduction 
NGS technologies are often used for the identification of sequence variants predisposing 
to diseases that follow Mendelian inheritance patterns (Ng et al., 2010a; Ng et al., 
2010b; Wang et al., 2010a; Bamshad et al., 2011; Gilissen et al., 2011). Here I will 
define a variant as a deviation from a reference sequence. In particular, the sequencing 
of material enriched for exonic sequences has been successful in many cases but failed 
to identify the causative variants in others (Ng et al., 2009; Bamshad et al., 2011; 
Gilissen et al., 2011). These successes and failures are described in more detail in 
chapter 4. In fact less than 50% of such studies are able to successfully identify the 
disease causing variant (Gilissen et al., 2011). Such apparent failures may have many 
causes but also focus attention on the desirability of simple measures to assess the 
performance of different sequencing and analysis pipelines. The ideal analysis pipeline 
would have a high probability of identifying a variant, while maintaining a low number 
of falsely identified variants reducing the amount of work needed for validation.  
Therefore, I developed a simple and flexible approach for assessing the performance of 
a whole exome or genome sequencing experiment. The method allows for the 
assessment of an entire sequencing study, from sample preparation through to variant 
calling. Here, the focus was on the detection of single base sequence variants as 
opposed to changes in copy number or large rearrangements.  A common approach is to 
compare the identified variants with variants known to be present or absent, by using, 
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for example, genotyping microarrays (Ng et al., 2009). This allows for the probability 
of a specific variant at a given position in an individual to be considered as either 0 or 1. 
However, this obviously requires both sequence data and microarray data to be 
available which will increase the cost of an experiment, and is therefore not always a 
feasible approach.  
An alternative approach, as is proposed here, is to use changes where the probability of 
occurrence in a specific sample can be ascertained. This allows the probability of a 
variant present at a specific position to assume values other than 0 or 1. My approach 
formalises this method by using sites known to be polymorphic in the human population. 
This can also be seen as an extension of methods that rely on quality criteria such as the 
number of variants found in sites known to be polymorphic (Marth et al., 2011; Challis 
et al., 2012). 
The results of such comparisons can be summarised in many ways, such as assessing 
the number or proportion of variants that have previously been reported in databases 
such as HapMap (www.hapmap.org) or the 1000 genomes (www.1000genomes.org).  
Since the focus is on a dichotomous outcome I use here the probabilities of identifying 
the variant given that the variant is really present and of finding no variant at a site 
where none is present. I refer to these probabilities as sensitivity and specificity 
respectively.  
I describe the method in detail below. In the results section I have compared my method 
to the method of calculating sensitivity and specificity using microarray data and 
explored possible applications of the proposed method in NGS studies.  
 
3.3 Method 
I designate with M the presence of a variant allele and with  D  the detection of a 
variant allele. Correspondingly  M  and D  represent the absence of a variant allele and 
the not detecting a variant allele. For an autosomal locus we have: 
             iiiiiiiiiiiiiiii MMpMMDpMMpMMDpMMpMMDpDp ||| 
             iiiiiiiiiiiiiiii MMpMMDpMMpMMDpMMpMMDpDp |||   
Assuming Hardy-Weinberg equilibrium we obtain for the genotype frequencies 
  2iii fMMp  ,    iiii ffMMp  12  and    
2
1 iii fMMp  , where if  designates 
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the frequency of the variant allele. We further designate with s the sensitivity 
 MDps |  and with u the specificity,   MDpu |  and obtain for the remaining 
terms:     ssMMDp iii  2| ,     ussMMDp iii  11| ,   21| uMMDp iii  , 
   21| sMMDp iii  ,    usMMDp iii  1|  and   2| uMMDp iii  . 
We treat all sites as independent and assume that detection probability for one site is 
independent from that for another, thus for an individual the likelihood is  
     


DD
Sj
j
Si
i DpDpusl ,  
Where the index DS  represents the set of sites where a variant was detected and DS  the 
sites were only the reference was observed. 
When several individuals are analysed and we assume that their genotypes are 
independent the likelihood of the whole group of individuals can be described as 
 


K
k
k usll
1
,   
 
3.4 Materials 
3.4.1 Sequence and genotype data  
Targeted whole exome sequencing was carried out for 31 (12+19) samples using an 
Illumina Genome Analyser IIx.  Agilent 38Mb target positions were obtained from 
Agilent, and the human genome (Build36.1) was used as reference sequence 
(http://genome.ucsc.edu/).  
Genotype chip data were available for 19 of the 31 samples, comprising a total of 
557124 SNPs on the Illumina 660 genotype chip (https://my.illumina.com/). 10762 of 
these SNPs were located within the target regions.  
 
3.4.2 Comparison of array and sequencing data 
As described in the introduction, my analysis focuses on the ability of detecting variants, 
therefore I assessed at any position whether a variant was detected or not.  The 
sensitivity is defined as the number of sites in which both sequencing and microarrays 
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detected a deviation from the reference sequence divided by the number of sites where a 
variant was detected by using the microarrays. Correspondingly the number of sites 
where both methods detected no deviation from the reference sequence divided by the 
number of sites where the microarray detected only the reference residue was used as an 
estimate of the specificity.  
   
3.4.3 Selection of polymorphisms 
The HapMap database was used to obtain allele frequencies in the calculation of 
sensitivity and specificity for the single base substitution variant calls. The HapMap 
database consists of 4083713 SNPs in total (CEU population, build 36, downloaded 28 
October 2010). 10165 overlap with the on target (Agilent 38Mb whole exome targets) 
genotype chip SNPs. Allele frequency data was obtained for each of these SNPs from 
the HapMap database. 
For the calculation of sensitivity and specificity of indel calls, allele frequencies were 
obtained from the 1000 genomes database. As indel positions were not typed on the 
microarray, I used all the indel positions from the 1000 genomes database which were 
located in the target regions (Agilent 38Mb whole exome targets). This provided 8365 
on target indels from the 1000 genomes database for which frequency information was 
also available. 
 
3.4.4 Sequence analysis 
For the identification of single base substitutions, reads were aligned to the reference 
using the following aligners: Bowtie (Langmead et al., 2009), BWA (Li and Durbin, 
2009), GSNAP (Wu and Nacu, 2010), NovoAlign (http://www.novocraft.com/), SOAP2 
(Li et al., 2008b), SSAHA2 (Ning et al., 2001). Variants were identified using either 
Varscan (Koboldt et al., 2009) or Samtools (Li et al., 2009). Unless specified otherwise, 
the default parameters were used for each program. Coverage was assessed from the 
Pileup files.  Coverage depth was varied by sampling with replacement from the SAM 
files. 
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Twelve of the samples were used for indel analysis. Reads were aligned to the human 
genome reference (Build 37, hg19) sequence using Bowtie2 (Langmead and Salzberg, 
2012), BWA and NovoAlign. Indels were identified using Samtools, Dindel (Albers et 
al., 2011) and GATK (McKenna et al., 2010; DePristo et al., 2011). Due to the large 
number of windows produced by Dindel, a minimum threshold of 7 reads covering each 
indel variant was applied. For all other indel callers, the default parameters were used. 
 
3.5 Results 
In this section I first explore some applications of the proposed method, then compare 
its results with estimates generated using the genotypes obtained through the microarray 
as the true genotypes. The method I propose here assumes that the allele frequencies in 
the population from which the samples were drawn are known. At the end of this 
section I explore the effects of using incorrect allele frequencies.  
 
3.5.1 Pipeline comparisons 
Figure 3.1 compares the sensitivity and specificity estimates achieved using the 
different alignment and variant calling programmes for the detection of single 
nucleotide substitutions. The values are based on 31 samples and represent the median 
and the upper and lower quartiles. For 8 samples SSAHA2 failed to produce results and 
generated the messages “error: memory allocation failed cannot allocate memory” or 
“error: memory allocation for array of fasta structures failed cannot allocate memory”.  
Interestingly, the alignment programmes appear to have a stronger effect on sensitivity, 
while the variant calling programmes appeared to effect specificity more strongly. All 
aligners yield similar specificities when used in combination with Samtools and the 
NovoAlign-Samtools and BWA-Samtools pipelines provided the highest sensitivity 
values. Therefore I used the NovoAlign aligner and the Samtools variant caller as the 
standard pipeline for all of the subsequent analyses. The estimates for the specificity 
using Samtools with any aligner were over 0.998. Conversely, the specificity fell below 
0.996 when using Varscan. 
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Figure 3.2 shows the results for different indel calling pipelines. The number of 
positions considered makes estimation of specificity problematic. Sensitivity was poor 
compared to the value for single base substitutions across all pipelines and it was shown 
that Samtools had the lowest sensitivity, while GATK performed best.  The best 
performing pipeline was BWA-GATK. The average estimates for sensitivity using the 
Bowtie2-GATK and Novoalign-GATK pipelines are 0.354 and 0.337 respectively. 
 
  
Figure 3.1. Specificity and sensitivity of different analysis pipelines used to call 
single base substitutions. 
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Figure 3.2 Specificity and sensitivity for indel calling pipelines. 
 
3.5.2 Parameter selection 
Each alignment and variant calling programme has a range of parameters which can be 
set by the user. In general default values are provided but these may not always be 
appropriate and altering these parameters can have a marked effect on sensitivity and 
specificity. Therefore, I used my method to explore the effects of choosing different 
variant calling parameters. To test this I used the NovoAlign-Samtools pipeline but used 
a range of base quality thresholds for variant calling (Figure 3.3A and 3.3B). This is the 
minimum base quality at the position, for a read, required for that read to be included in 
the variant call for that position.   
Figure 3A shows that altering the base quality threshold used in variant calling has a 
dramatic effect on sensitivity, with a rapid drop when the values are set above 20. The 
effect on specificity (Figure 3B) is more modest and increasing the base quality 
threshold beyond 30 has only a limited effect. 
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3.3A 
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3.3B 
 
Figure 3.3 (A, B). The effect of parameter choice. Each point on the graph 
represents the value obtained for one sample using a particular base quality 
threshold. Figure 3.3A represents the influence of parameter choice on sensitivity, 
and Figure 3.3B represents the influence of parameter choice on specificity. 
   
3.5.3 Coverage 
Figure 3.4 explores the effects of average coverage on sensitivity. As expected, 
sensitivity increases as the coverage increases. This reflects the fact that at low coverage 
finding evidence for a variant generally becomes more difficult, thus leading to a low 
sensitivity. With the parameters used such a loss began to be evident when the average 
coverage was below 40 fold.   
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Figure 3.4. Influence of average coverage on sensitivity. Each point on the graph 
represents the sensitivity value calculated for a particular sample at a particular 
target coverage. 
 
3.5.4 Microarray comparison 
As stated above, both sequence data and microarray data were available for 19 of the 
samples. Table 3.1 compares the parameter estimates using the genotyping microarray 
data (Fourth column) and two different sets of allele frequencies (Second and third 
column).  The values in the third column are derived from the genotyping results. 
Compared to microarrays both specificity and sensitivity estimates are slightly lower by 
the frequency method using the CEU population frequencies (Second column).  
One possible reason for this is that the estimates are distorted because the HapMap CEU 
allele frequencies do not match the allele frequencies in my sample. Indeed the 
difference is smaller when the allele frequencies used are derived from the genotyping 
results of the 19 samples (Third column), and the sensitivity is even slightly higher than 
when calculated by comparing to the microarray data (Fourth column). This suggests 
that the sensitivity estimates are influenced by the choice of frequency data and should 
therefore be considered with care.  
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It should also be mentioned that specificity estimates are in the order of 0.999. These 
estimates however are based only on a limited number of polymorphic sites (10165 
sites), suggesting that the ability to adequately assess changes in specificity will be 
limited. This is reflected in the correlation between the estimates obtained from 
microarrays and from population frequencies. While there is a good correlation between 
the estimates for the sensitivity (see Figure 3.5, R
2
=0.71, P=4x10
-50
), the correlation for 
specificity is rather poor although still significant (R
2
=0.39,P=7x10
-21
). 
 
 Estimated from 
 CEU frequencies
a
 Sample frequencies
b
 Microarray
c
 
Sensitivity 
(95% CI
d
) 
0.962 
(0.945-0.970) 
0.979 
(0.962-0.986) 
0.984 
(0.982-0.986) 
Specificity 
(95% CI) 
0.998 
(0.997-0.998) 
0.999 
(0.999-0.999) 
0.999 
(0.999-1.00) 
a
  Allele frequencies for the Hapmap CEU population  
b
  Allele frequencies determined from the all the samples using the microarray genotyping results. 
c
  Genotypes determined using the Illumina 660W chip 
d
: 95% confidence interval for the mean, determined by resampling. 
Table 3.1. Mean sensitivity and specificity estimates. Represented are the estimates 
for the specificity and sensitivity of the NovoAlign-Samtools pipeline.  
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Figure 3.5. Correlation between sensitivity estimates from microarray data and 
using CEU population frequencies. The points represent the values for different 
individuals and analysis pipelines. 
 
3.5.5 Influence of using different allele frequencies  
The method proposed here uses allele frequencies in the calculation of sensitivity and 
specificity. However, allele frequencies vary between populations and the ethnicity of 
the individuals who provided a sample may not always be known. Therefore, I explored 
the influence of using different frequencies on sensitivity and specificity by using allele 
frequencies from all 11 HapMap populations (Figure 3.6A and 3.6B).   
Figure 3.6 suggests that misspecification of population frequencies tends to lead to 
lower estimates of both sensitivity and specificity. However the lines connecting the 
values for the different pipelines calculated using different allele frequencies tend to be 
parallel. This indicates that the results are correlated (p<0.01 for all comparisons) 
suggesting that although the absolute values may vary, the order of the different 
pipelines will remain the same. 
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Figure 3.6 (A, B). Effect of reference population misspecification on specificity 
(3.6A) and sensitivity (3.6B). The x-axis represents the different HapMAp 
populations for which allele frequency data were available. CEU: Utah residents 
with Northern and Western European ancestry from the CEPH collection; TSI: 
Tuscan in Italy; MEX: Mexican ancestry in Los Angeles, California; GIH: 
Gujarati Indians in Houston, Texas; ASW: African ancestry in Southwest USA; 
MKK: Maasai in Kinyawa, Kenya; CHB: Han Chinese in Beijing, China; JPT: 
Japanese in Tokyo, Japan; CHD: Chinese in Metropolitan Denver, Colorado; 
LWK: Luhya in Webuye, Kenya; YRI: Yoruban in Ibadan, Nigeria. 
 
3.6 Discussion: 
The approach presented here estimates two parameters, sensitivity and specificity, from 
NGS variant calls. I illustrated some of its potential applications by comparing analysis 
pipelines, variant calling parameters and exploring the effects of differences in coverage. 
Since both sensitivity and specificity are influenced by various steps including sample 
preparation, the sequencing itself and the bioinformatic pipelines, the procedure could 
be used to assess the performance of a sequencing experiment globally and could 
complement other commonly used approaches such as the assessment of base call 
quality or of coverage metrics. The main advantage of the method presented here is that 
it does not require a reference technique, such as genotyping using microarrays.  
However, it does rely on the availability of appropriate allele frequencies.  
The use of allele frequencies has two consequences. The first is that compared to the 
situation where the presence or absence of variants is known, using a probability 
introduces a degree uncertainty that is reflected in a larger scatter of the estimates (see 
Table 3.1).  The second is that it forces one to decide which set of allele frequencies to 
use. The choice of the allele frequencies from a specific population or, if available, from 
a particular subpopulation, disregards the possibility that individuals may represent a 
mixture from different populations. This problem could be avoided using a more 
complicated approach that considers, for example, the probability of belonging to a 
certain population, or of carrying certain haplotypes and perhaps allowing these 
probabilities to differ for different regions of the genome. I demonstrated that the 
misspecification of the population frequencies will influence the specificity and 
sensitivity values. However, figure 3.6 suggests that if two procedures have 
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substantially different specificity or sensitivity values, the use of different allele 
frequencies will still tend to preserve the order of the different analysis pipelines. 
One very important issue is the location of the polymorphisms used. Here I chose those 
included in the regions targeted by the enrichment procedure. However, since the 
practical interest here is to detect variants likely to cause disease, it would perhaps be a 
better choice to use all the polymorphisms in coding or non-coding regions. Another 
issue surrounds the type of polymorphism included in the analysis. Here I chose the 
polymorphisms represented in the microarray. These polymorphisms represent a 
selection based on criteria that probably includes the likelihood of being efficiently 
typed using microarray technology. This will probably result in avoiding certain types 
of polymorphisms, such as indels, and polymorphisms in certain locations such as gene 
regions with extreme base compositions. It is possible that sequencing experiments are 
accurate, or inaccurate, in exactly the same regions and this would lead to a bias in the 
sensitivity and specificity values. However, the proposed method allows for a 
comparison of different types of polymorphisms and I showed its application to the 
identification of indels. As expected both specificity and sensitivity appear to be lower 
than the values for single nucleotide substitutions. Although allele frequencies for 
polymorphisms not included in microarrays may not be accurate, my results are 
consistent with published studies that show that indel detection is still a challenging 
issue (Albers et al., 2011; Bansal and Libiger, 2011). Albers et al. (2011) compared the 
false discovery rate of indel calls using Dindel, Varscan and SAMtools. Dindel 
achieved the lowest false discovery rate of 1.56%, while Varscan achieved the highest 
rate of false discoveries, 16.67%.  
Since the interest here was on the detection of rare variants, I was able to dichotomise 
the outcome by scoring at each position whether a variant was present or absent. This 
leads effortlessly into the determination of specificity and sensitivity. However more 
complicated scenarios are possible, such as assessing the calling of each of the three 
possible genotypes defined by a variant/reference allele combination at each position. 
Here, however, I chose the more simple approach.  
Studies frequently focus on sensitivity as oppose to specificity (Pattnaik et al., 2012), 
however specificity is also very important as it may help to assess the amount of 
validation work that is required, which is closely related to false positive rate. A 
specificity of 0.99 and a frequency of deviations from the reference sequence in the 
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order of 1 per 1000 sites would be expected to lead, on average, to approximately ten 
false to one true positive. Therefore, practically useful methods of variant detection 
should have specificities that are much higher than 0.99. Estimating such a parameter 
accurately will require examining a large number of sites. For example, simply counting 
false and true negatives, relying for example on microarray data would require at least 
10 650 variant positions to establish the difference between a method that has 
specificity of 0.999 compared to one with a specificity 0.9999 with 80% power. In the 
present study I relied on sites that are known to be polymorphic, however I could also 
include sites for which there are no reported variants and assume a low minor allele 
frequency for all of these sites. This would increase the number of sites used and 
improve the ability to estimate the specificity.     
Since this procedure is quite simple it would be possible to use it to optimise analysis 
parameters, by integrating it into, for example, a variant caller so that it maximises the 
sensitivity while not allowing specificity to drop below a certain threshold. Such a 
procedure would benefit from the fact that the order appears to be insensitive to the 
choice of population. This would allow for an estimation of the amount of validation 
work required and the likelihood that a change of interest can really be identified, and 
can guide the design of future experiments.  
In summary, I have developed a method to assess the performance of an entire exome 
NGS experiment. The major advantage of my method is that it does not require the use 
of a reference technique, but calculates sensitivity and specificity values using freely 
available frequency data from databases such as HapMap or the 1000 genomes. The 
proposed method is simple, and fast to implement but still produces sensitivity and 
specificity values comparable to those calculated using microarray data. Therefore, such 
a method could be simply used to inform the choice of analysis pipeline, analysis 
parameters or even of experimental protocol.   
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Chapter 4. Exome sequencing to identify the causative variants in 
three diseases showing transmission consistent with Mendelian 
inheritance 
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4.1 Aim 
In the work outlined in this chapter, next-generation sequencing was used to identify 
potentially causative variants in three pedigrees where disease segregates in a 
Mendelian fashion consistent with a monogenic cause. Whole exome sequencing was 
carried out using an Illumina Genome Analyser IIx for both affected and unaffected 
individuals. The NovoAlign aligner and Samtools variant caller were originally used to 
identify both single base substitutions and indels, however on completion of chapter 3 I 
identified the BWA-Dindel pipeline as being a better pipeline for identifying indels. 
Therefore this was used as an additional pipeline for indel identification in the three 
families.   
Various filtering steps were used to identify the most likely variant resulting in disease 
from amongst the many thousands of variants which were identified. I identified 
potentially disease causing variants in plausible candidate genes for disease in the 
pedigrees where cases presented with Dilated Cardiomyopathy and Hereditary 
Sclerosing Poikiloderma. There are various reasons why I was not able to identify any 
potentially disease causing variants in plausible candidate genes in the pedigree where 
cases presented with Atrioventricular Septal Defects, which will be discussed in this 
chapter. 
 
4.2 Introduction 
NGS methods have proved very successful in the search for the genetic causes of 
disease, particularly where disease follows a Mendelian inheritance pattern and appears 
to be monogenic (Ng et al., 2009; Ng et al., 2010b; Bamshad et al., 2011; Gilissen et al., 
2011). Although sequencing the entire genome is a feasible option (Gilissen et al., 
2011),  its uses are limited by the large capacity and cost requirements (Teer and 
Mullikin, 2010; Gilissen et al., 2011). Instead, exome sequencing is a more popular 
approach (Gilissen et al., 2011), because it is cheaper but still allows for the 
identification of variants within the coding portions of genes (Ng et al., 2009; Bamshad 
et al., 2011). 
Although exome sequencing does not assess the potential impact of non-coding variants 
(Bamshad et al., 2011), less than 1% of the identified variants in Mendelian disease 
have been found in non-coding regions (Ng et al., 2008). Furthermore, many of the non-
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synonymous variants which have been identified in coding regions have been shown to 
be deleterious (Kryukov et al., 2007; Stenson et al., 2009; Ng et al., 2010b; Bamshad et 
al., 2011; Kiezun et al., 2012), and the large effect of causal mutations in Mendelian 
diseases suggests that the variants are largely coding (Ng et al., 2010c).  
On the other hand, it is possible for the genetic variants causing some of these diseases 
to be present in the non-coding regions of the genome (Hirschhorn and Daly, 2005). For 
example, deep intronic substitutions in the CDKN2A have been shown to cause some 
types of melanoma (Harland et al., 2001), and in other cases, intronic substitution 
events in the SLC12A3 gene have been proposed to cause Gitelman’s Syndrome (Nozu 
et al., 2009). 
Despite its popularity, the majority of exome sequencing projects have proved 
unsuccessful in identifying the causative variants responsible for disease (Gilissen et al., 
2011; Zhi and Chen, 2012). Gillisen et al. (2011) suggest that only 50% of studies 
involving rare, well defined Mendelian conditions are able to identify the genetic causes. 
One of the major challenges of exome sequencing is how to distinguish the disease 
causing variants from the non damaging, rare or even unique variants also present 
within an individual (Ng et al., 2009; Ng et al., 2010c; Erlich et al., 2011; Stitziel et al., 
2011; Zhi and Chen, 2012). To this end various filtering methods have been developed 
to reduce the number of identified variants to encompass only those most likely to cause 
disease. The advantages and disadvantages of these methods will be discussed in more 
detail in the discussion section of this chapter. 
In this chapter I aimed to employ exome sequencing to identify the causative variants 
for three different diseases segregating in a Mendelian fashion consistent with a 
monogenic cause.  Sequence data was available for individuals from three pedigrees 
(Figures 4.2, 4.4, and 4.5). The affected individuals suffer from Dilated 
Cardiomyopathy (DCM), Atrioventricular Septal Defect (AVSD), and Hereditary 
Sclerosing Poikiloderma (HSP). Single base substitutions and indels were initially 
identified using the NovoAlign aligner and Samtools variant caller. However, the results 
obtained in chapter 3 indicated that the BWA aligner and Dindel variant caller would be 
more appropriate methods for indel identification. Therefore, the BWA-Dindel pipeline 
was employed as an additional indel calling pipeline. I include indel calls from both 
pipelines. 
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The identified variants were then filtered using methods commonly employed in the 
literature. After filtering I hoped to be able to identify potentially disease causing 
variants in plausible candidate genes of interest. Here I defined plausible candidate 
genes of interest as genes which appear interesting at first, based on current 
understanding of gene function and related diseases from databases such as OMIM. For 
example, potentially disease causing variants in genes that result in phenotypes similar 
to the ones in the present study. I will use this term throughout this chapter. For clarity 
the three different diseases will be introduced under their own subheadings below. 
 
4.2.1 Dilated cardiomyopathy 
Cardiomyopathies comprise a range of cardiac disorders affecting the heart muscle 
(Schonberger and Seidman, 2001; Towbin et al., 2006). They are categorised based on 
their anatomic and haemodynamic attributes (Schonberger and Seidman, 2001). The 
two major forms of cardiomyopathy are dilated cardiomyopathy (DCM) and 
hypertrophic cardiomyopathy (Parvari and Levitas, 2012). The affected individuals in 
this study suffer from DCM.  
DCM is the most common form of cardiomyopathy, making up more than 80% of all 
cases (Schonberger and Seidman, 2001; Luk et al., 2009). It results in the myocardial 
walls stretching and thinning which negatively affects ventricular function (Luk et al., 
2009). This diminished contractile function is one of the more serious haemodynamic 
features of the disease, and can lead to various complex, compensatory neurohumoral 
responses which later result in heart failure (Schonberger and Seidman, 2001). The 
clinical symptom of DCM is eventual heart failure often associated with arrhythmia and 
sudden death (Parvari and Levitas, 2012). 
The severity of symptoms and survival varies considerably between patients and 
diagnosis is often made using non-invasive cardiac imaging (Schonberger and Seidman, 
2001). Although the disease can manifest in early childhood, it is usually only identified 
later in life at which point it has often progressed to end-stage myocardial fibrosis 
(Schonberger and Seidman, 2001; Luk et al., 2009).   
Estimating the incidence and prevalence of individual conditions is difficult as the effect 
of disease may remain subclinical (Raju et al., 2011). A ten year study conducted in the 
USA estimated the incidence of DCM to be ~6 per 100000 people per year, with a 
57 
 
prevalence of ~36.5 per 100 000 people (Codd et al., 1989). Whereas the Paediatric 
Cardiomypathy Registry estimates the annual incidence of DCM to be 1.13 cases per 
100 000 people aged 18 years or younger (Parvari and Levitas, 2012). 
The underlying causes of DCM are varied, and include both environmental and genetic 
factors (Tsubata et al., 2000; Miyamoto et al., 2001; Schonberger and Seidman, 2001; 
Luk et al., 2009; Hazebroek et al., 2012). Some of the principal causes include viral 
myocarditis (usually occult and unable to be proven at the time of presentation with 
DCM), thyroid disease (reversible with therapy), immunological processes, toxins (such 
as alcohol and heavy metals), drugs (notably anticancer chemotherapy) and infiltrative 
processes (Schonberger and Seidman, 2001; Hazebroek et al., 2012). Nevertheless, the 
causes of up to 65% of cases remains unknown, a condition termed “idiopathic” DCM 
(Parvari and Levitas, 2012). 
Among these idiopathic cases, genetic causation is prominent. Familial forms of DCM, 
which are mostly monogenic, account for 25-35% of idiopathic DCM cases (Miyamoto 
et al., 2001; Towbin et al., 2006; Luk et al., 2009; McDermott et al., 2012). Although 
autosomal dominant transmission accounts for about 70% of inherited DCM cases 
(Tesson et al., 2000; Mahon et al., 2005; Hazebroek et al., 2012), three other modes of 
inheritance have also been identified, namely autosomal recessive, X-linked and 
mitochondrial inheritance (Luk et al., 2009; Hazebroek et al., 2012).  
The discovery of the genes responsible for DCM has proven difficult, largely due to the 
presence of both substantial aetiological and genetic heterogeneity (Mahon et al., 2005). 
Multiple genetic regions and genes have been shown to be involved (Tsubata et al., 
2000). Various methods have been used to identify these causative genes. These include 
using direct candidate gene sequencing in affected individuals (van der Zwaag et al., 
2012), association (Zarrouk Mahjoub et al., 2012) and linkage studies (Yoskovitz et al., 
2012), or through a combination of approaches such as sequencing and association 
methods (Herman et al., 2012).  
Dellefave & McNally (2010) provide an electron micrograph of a cardiomyocyte which 
describes specific intracellular regions and the genes in these regions which have been 
shown to cause DCM (Figure 4.1). In addition, Hershberger et al. (2010) and Parvari & 
Levitas (2012) both provide detailed lists of known genes responsible for DCM. Table 
4.1 is taken from Parvari & Levitas (2012), and describes all of the genes known to 
cause cardiomyopathies, in particular DCM. Most causative genes seem to encode for 
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cytoskeletal and sarcomeric proteins, thus affecting the structure of the muscle 
(Dellefave and McNally, 2010; Hershberger et al., 2010; Hazebroek et al., 2012; 
Parvari and Levitas, 2012).  
 
 
 
Figure 4.1. Intracellular regions and the genes from these regions that cause DCM. 
From Dellefave & McNally (2010).  
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Clinical type Inheritance Gene name (symbol) 
HDCM/DCM/RDCM AD Myosin heavy chain 7, (MYH7) 
HDCM/DCM/atrial septal defect type 
3 AD Myosin heavy chain 6, (MYH6) 
HDCM/DCM/RDCM/LVNC AD Troponin T2, cardiac (TNNT2) 
HDCM/DCM/LVNC AD Tropomyosin 1 (TPM1) 
HDCM/DCM AD Myosin binding protein 3, cardiac (MYBPC3) 
HDCM/DCM/RDCM AD, AR Troponin I3, cardiac (TNNI3) 
HDCM/DCM AD Actin alpha cardiac (ACTC1) 
HDCM/DCM AD/AR Titin (TTN) 
HDCM/DCM AD Troponin C1, cardiac (TNNC1) 
HDCM/DCM AD Cystein- and glycine-rich protein 3 (CSRP3) 
HDCM/DCM AD Titin cap (TCAP) 
HDCM/DCM AD Vinculin (VCL) 
HDCM/DCM AD Ankyrin repeat domain containing protein (ANKRD1) 
DCM/RDCM AD Desmin (DES) 
DCM AD Lamin A/C (LMNA) 
DCM AD Sarcoglycan-delta (SGCD) 
DCM AD Actinin alpha 2 (ACTN2) 
DCM/LVNC AD Lim domain binding 3 (LDB3) 
DCM AD Phospholamban (PLB) 
DCM AD Presenilin 1 (PSEN1) 
DCM AD Presenilin 2 (PSEN2) 
DCM AD ATP binding cassette C9 (ABCC9) 
DCM AD Sodium channel voltage-gated 5A (SCN5A) 
DCM/HDCM AD Muscle-restricted coiled-coil (MURC) 
DCM/HDCM AD Crystallin-alpha B (CRYAB) 
DCM AD Four and a half Lim domains 2 (FHL2) 
DCM AD Laminin alpha 4 (LAMA4) 
DCM AD Nebulette (NEBL) 
DCM/HDCM/RDCM AD Myopalladin (MYPN) 
DCM AD RNA-binding motif protein 20 (RBM20) 
HDCM/DCM AD Nexilin (NEXN) 
DCM AD Bcl2-associated athanogene 3 (BAG3) 
DCM XR Dystrophin (DMD) 
DCM XR Emerin (EMD) 
DCM/LVNC XR Tafazzin (TAZ) 
DCM XR Fukutin (FKTN) 
DCM/ARVC AR Desmoplakin (DSP) 
DCM AR Dolichol kinase (DOLK) 
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Continuation of table 4.1 
DCM AR GATA zinc finger domain-containing protein 1 (GATAD1) 
DCM/ARVC AR/AD Plakoglobin (JUP) 
DCM AR Flavoprotein (SDHA) 
 
Table 4.1. DCM causative genes. The table is from Parvari et al. (2012). AD: 
autosomal dominant; AR: autosomal recessive; ARVC: arrhythmogenic right 
ventricular cardiomyopathy; DCM: dilated cardiomyopathy; HDCM: 
hypertrophic cardiomyopathy; RDCM: restrictive cardiomyopathy; LVNC: left 
ventricular noncompaction; XR-X-linked recessive. 
 
Familial DCM risk is usually attributed to coding nucleotide variants that alter the 
amino acid sequence. For example, Tsubata et al. (2000) were able to identify a T451G 
change in the delta-sarcoglycan gene which was shared between affected individuals of 
a family suffering from DCM. This variant was not present in any of the unaffected 
individuals of the family, nor in a group of 200 controls. Mutations in sarcoglycans 
result in cytoskeletal abnormalities, and animal models with mutations in these genes 
frequently develop DCM (Towbin et al., 1999). In another study, the exons of 10 genes, 
half of which comprised sarcomere genes, were sequenced in a group of 264 patients 
suffering from DCM (Lakdawala et al., 2012). Forty clinically relevant variants were 
identified, none of which were present in a set of 200 healthy controls. This, together 
with the variants being found in genes known to cause DCM provides strong support for 
these variants influencing disease in these patients. 
The family I analysed is depicted in figure 4.2. The pedigree shows that cases of DCM 
occur throughout the family, and both male and female individuals are affected. The 
pattern of DCM in this pedigree is consistent with an autosomal dominant mode of 
inheritance with incomplete penetrance. Sequence data was available for three cousins 
(v-5, v-13, v-15) and an uncle (iv-6), all four of whom suffer from DCM.  
With regard to clinical presentation of the affected individuals, family member IV-6 had 
a heart transplant for DCM at the age of 54. Patient V-5 was diagnosed with DCM at 
~40 years of age, and later died (although the age and cause of death are unknown). 
Patient V-15 was diagnosed with DCM at ~28 years of age, and with diabetes at ~37 
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years of age. Patient V-15 also displayed renal problems, however these were secondary 
to an renal tract outflow obstruction in infancy and thought to be unrelated to DCM. 
Family screening was triggered by the occurrence of multiple DCM cases in the 
pedigree and during the course of this process patient V-13, who was asymptomatic, 
was shown on echocardiography to have an established global dilated cardiomyopathy. 
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Figure 4.2. DCM pedigree. Sequence data was available for individual samples v-5, v-13, v-15, IV-6 (Indicated by a red squares).
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4.2.2 Atrioventricular septal defects 
AVSD is a complex disorder, covering a range of congenital heart conditions of varying 
severities (Hartman et al., 2011). They involve incomplete septation of the 
atrioventricular valves and septa (Marino and Digilio, 2000; Craig, 2006; Miller et al., 
2010). The most severe form of AVSD, complete AVSD, occurs when both the atrial 
and ventricular septa do not develop properly, and when a single, common 
atrioventricular valve remains after development, as seen in figure 4.3A (Marino and 
Digilio, 2000; Robinson et al., 2003). In the less severe form, partial AVSD, there is a 
deficiency of the atrial septum where there are separate right and left atrioventricular 
openings that do not close, figure 4.3B (Omeri et al., 1965; Robinson et al., 2003; Craig, 
2006). Although complete AVSDs are detected at birth, children with the less severe 
forms may be asymptomatic so that detection occurs only at an older age (Robinson et 
al., 2003; Minich et al., 2010).  
 
 
 
Figure 4.3 (A,B). Diagrammatic representation of AVSD.  4.3A = Complete AVSD. 
4.3B = Partial AVSD. 
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AVSD’s account for ~5-7% of all congenital heart defects with an incidence of ~0.24-
0.31 per 1000 births per year, and a prevalence of ~3.5-4.1 per 10 000 people (Craig, 
2006; Reller et al., 2008; Hartman et al., 2011). They can occur as part of other 
recognised syndromes or as a single identifiable condition (Marino and Digilio, 2000; 
Robinson et al., 2003; Hartman et al., 2011). However, about 85% of cases are 
associated with other syndromes (Marino and Digilio, 2000). For example, AVSD is 
common in children with Down’s syndrome, with the complete form affecting between 
17 - 50% of them (Marino and Digilio, 2000; Craig, 2006). Additionally, AVSD has 
been shown to be associated with the 3p-syndrome, a rare disease resulting from a 
deletion in chromosome 3, where it affects about a third of all cases (Green et al., 2000).  
As well as occurring as part of other identifiable syndromes (Sheffield et al., 1997; 
Robinson et al., 2003), there are some reported families in which multiple affected 
individuals occur with no other syndromic features (Wilson et al., 1993; Kumar et al., 
1994; Sheffield et al., 1997). This indicates a pattern consistent with autosomal 
dominant inheritance and incomplete penetrance (Marino and Digilio, 2000; Robinson 
et al., 2003; Craig, 2006) in those families.  
Various studies have been conducted in an attempt to identify the genes responsible for 
this disease. For example, a linkage study was performed on a large family containing 
14 affected individuals (Sheffield et al., 1997). Although the study failed to identify the 
particular genes responsible, a linkage region on chromosome 1 was identified. A 
further study by Robinson et al. (2003) analysed 50 unrelated individuals displaying full 
or partial AVSD to test for an association between CRELD1 mutations and disease. Ten 
coding exons of CRELD1 were sequenced in all the cases and they were able to identify 
three single base variants which were not identified in at least 100 controls and 
concluded that these represent disease associated variants. Also, the strong association 
of AVSD with Down Syndrome indicates causative genes on chromosome 21 (Locke et 
al., 2010), and Trisomy 18 has also been implicated in some AVSD cases (Digilio et al., 
1999).  
The pedigree I analysed is shown in figure 4.4 and contains 31 individuals, 10 of whom 
have AVSD. Sequence data was available for four of the family members (samples ii-5, 
iii-22, iv-30, iv-36). The occurrence of AVSD in the pedigree is consistent with an 
autosomal dominant mode of inheritance with incomplete penetrance (Wilson et al., 
1993). As AVSD’s occur predominantly as part of other syndromes, non-syndromic 
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Mendelian families such as these provide a very useful means of identifying possible 
causative genes and in understanding the disease further. The clinical findings for each 
member of the family are described in detail in the original paper by Wilson et al. 
(1993). Below, I will provide a brief description of the individuals analysed in the 
present study (As in Wilson et al. 1993).    
Individual iv-30 was born with a complete AVSD with an aortic shelf coarctation.  The 
aortic defect was treated using balloon dilation, and the AVSD surgically repaired. 
Facial features suggested the patient did not suffer from Down syndrome, and no other 
chromosomal abnormalities could be identified using high-resolution chromosome 
analysis. Although displaying no clinical evidence of AVSD, due to family history, 
individual ii-5 was described as an obligate carrier. This individual had three sons, none 
of which displayed any clinical symptoms of AVSD, one of which (iii-18), however, 
had a further two fully affected children. Individual iii-22, the son of obligate carrier ii-8, 
was affected and had to undergo surgery to repair the AVSD. Finally, individual iv-36, 
the son of obligate carrier ii-18, was born with AVSD, which was also repaired. This 
individual also had two brothers, one affected and one unaffected. 
Wilson et al. (1993) performed a linkage study on this pedigree using a series of 
microsatellite polymorphisms along chromosome 21. Due to AVSDs being the 
predominant heart defect in children with Down Syndrome, they focused on the region 
of trisomy 21, and were able to exclude loci from this region as the cause of AVSD in 
this family.  
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Figure 4.4. AVSD pedigree. Sequence data was available for individuals samples ii-5, iii-22, iv-30, iv-36 (Indicated by red squares). 
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4.2.3 Hereditary sclerosing poikiloderma 
Hereditary sclerosing poikiloderma (HSP) is a very rare disease, and to my knowledge 
only 12 other cases have been described in the literature, (Lee et al., 2012). In addition, 
I am aware of one other case from collaborators in Nantes, France, under Dr. Sébastien 
Küry, DVM at the Institut de Biologie (Service de Génétique Médicale, Laboratoire de 
génétique moléculaire). Although this case has not yet been published, Dr. Küry did 
provide sequence data for the unaffected parents and the affected offspring, which I 
analysed in addition to the sequence data generated in-house on the South African 
family described below.  
HSP was first described in seven individuals from two unrelated families as a hereditary 
disorder displaying distinct features (Weary et al., 1969) including widespread 
poikiloderma (A skin condition which can present with hyper/hypo-pigmentation and 
sclerosis), sclerosis of the palms and soles, linear or reticular hyperkeratotic and 
sclerotic bands in various regions, clubbing of the fingers, and calcinosis of tissues 
(Weary et al., 1969; Lee et al., 2012). Lee et al. (2012) describe the widespread 
poikiloderma and sclerotic bands as being the most important features in diagnosing the 
disease. As symptoms are not present at birth, detection only occurs in early childhood 
with the onset of progressive poikiloderma (Grau Salvat et al., 1999). 
Studies have noted that individuals affected with HSP and related family members 
sometimes also display cardiovascular abnormalities, such as heart valve defects and 
ventricular hypertrophy, thus also implicating cardiovascular disease as part of the 
phenotypic spectrum in HSP (Weary et al., 1969; Grau Salvat et al., 1999; Lee et al., 
2012). Most affected families indicate that HSP is consistent with an autosomal 
dominant form of inheritance with incomplete penetrance (Weary et al., 1969; Khumalo 
et al., 2006; Lee et al., 2012). This appears to be the case in the pedigree I analysed, 
figure 4.5. The causative genetic defect for HSP has not yet been identified. 
Five members of the pedigree I analysed suffer from HSP. A full clinical report on each 
patient is given in Khumalo et al. (2006). A description for the three family members 
for which sequence data were available follows. The family members included two 
affected siblings (ii-4 and ii-5) and an unaffected mother (i-3). During childhood 
individual ii-5 displayed heat intolerance and skin lesions including hyper- and hypo-
pigmentation and epidermal atrophy, and by age 9 had developed Achilles tendon 
contractures. The tendon contractures were surgically treated at age 14. By adulthood 
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she had also developed telangiectasias, a mottled skin, epidermal atrophy around the 
face, fine to no body hair, and tendon abnormalities. Her arms and legs had virtually no 
hair and mottled skin pigmentation. She had atrophy of both thenar and hypothenar 
eminences and was unable to fully extend her fingers. She also suffered from 
hypohidrosis, which together with the sparse hair, suggested ectodermal dysplasia. Her 
brother, individual ii-4, displayed similar skin and limb characteristics, as well as heat 
intolerance, but suffers from no tendon abnormalities (Khumalo et al., 2006). He 
suffered a slight cardiomegaly and left ventricular hypertrophy.  
Two other affected patients, the father (i-2) and an a half brother (ii-3), were said to 
have suffered from similar conditions. However, both had died as a result of pulmonary 
fibrosis prior to the present study commencing and no sequence data were available for 
them (Khumalo et al., 2006).  However, collaborators in South Africa were able to 
extract DNA from the deceased brother using a paraffin embedded liver sample.  
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Figure 4.5. HSP pedigree. Sequence data was available for individuals samples ii-4, ii-5, and i-3 (Indicated by red squares). 
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 4.3 Materials and Methods 
4.3.1 Samples and sequencing 
DNA was extracted from blood using standard methods. This was done in the 
laboratory at The University of Newcastle by Thahira Rahman and Rafiqul Hussain, and 
described in chapter 2. Targeted NGS sequencing was performed as described in 
chapter 2. In the current study, target enrichment was carried out using the SureSelect 
Agilent 38Mb Human All Exon targeting kit (http://www.genomics.agilent.com).   
  
4.3.2 Sequence analysis  
GERALD (CASAVA-1.6.0) was used as base caller and to generate the Fastq files. 
Read quality was assessed using average base quality, calculated using the NGS QC 
Toolkit v2.2.3 (Patel and Jain, 2012). 
The NovoAlign aligner v2.07.13 (http://www.novocraft.com) was used to map the 
sequences to the Human Genome (Build 37) and the Samtools/bcftools v0.1.17 (Li et al., 
2009) package was originally used to identify both single base substitution and indel 
variants. However, it was later decided that the BWA-Dindel pipeline would be a better 
pipeline for identifying indels (see chapter 3). Therefore, BWA-Dindel was also used as 
a method to identify indels. I will present indel results from both pipelines. Aside from 
the selection of only unique alignments in NovoAlign, default alignment and variant 
calling criteria were used in all programmes. 
Variants were filtered and annotated using custom written perl scripts. MutationTaster 
v20100416 (Schwarz et al., 2010) and wAnnovar v2011-11-20 (Wang et al., 2010b), 
were used to annotate variants and to assess potential variant pathogenicity.  
 
4.3.3 Variant filtering 
There is a risk that variant filtering methods could inadvertently remove the disease 
causing variant. Therefore, in cases where a potentially disease causing variant in a 
plausible candidate gene of interest was not identified I implemented an additional, less 
stringent set of filtering criteria, filtering set B (Figure 4.6). Both sets are described in 
detail below.  
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The first step of filtering set A (Stringent filtering) involved the selection of only the on-
target variants using the Agilent Exome target positions. Indel variants were allowed to 
lie within 500 base pairs of the target positions, while single base substitutions had to be 
completely located within the target regions. All homozygous variants were then 
removed and only those variants present in all of the affected individuals were selected. 
Variants occurring within the Exome Variant Server (EVS) and 1000 Genomes 
databases at a frequency exceeding 1% were then also removed. A control list of 
variants was also used as a filter to remove possible errors. The control list contains 
single base substitutions from 119 unrelated exomes, and indel variants from 114 
unrelated exomes. All exome data comprising the control lists had been sequenced in-
house using the Agilent 50Mb Whole Exome Targeting kit and the Illumina Genome 
Analyser IIx. The list was compiled by Dr. Helen Griffin (2012, pers. comm). All 
variants present in the control list at a frequency of more than 1% were removed. Only 
coding, non-synonymous and splice variants were then selected for analysis with 
MutationTaster. 
The first step of filtering set B (Less stringent) involved the selection of only the on-
target variants from the Agilent Exome target positions. Indel variants were allowed to 
lie within 500 base pairs of the target positions, while single base substitutions had to be 
completely located within the bait regions. The second filtering step involved selecting 
only heterozygous variants present in all of the affected individuals. All variants 
occurring in the EVS and 1000 Genomes databases were then removed, as well as those 
occurring within the control list, at a frequency exceeding 1%. As well as coding, non-
synonymous and splice variants, filtering set B also included non-coding and 
synonymous variants for assessment using MutationTaster, making it less stringent than 
filtering set A (See figure 4.7). 
 
4.3.4 Variant validations 
Variants were validated using Sanger sequencing, in labs at The University of 
Newcastle by Dr. Elise Glen. 
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Figure 4.6. Filtering steps adopted in both filtering set A and filtering Set B. 
 
4.4 Results 
The results section is divided into two parts. The first provides an overview of the 
sequencing and variant call results, including details on the amount of sequence data 
that was generated, the sequence and alignment quality, sensitivity and specificity 
estimates, and the effect of the filtering criteria. The second part provides more detailed 
results on the potentially disease causing variants that were identified in each family. 
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4.4.1 Sequence and variant call overview 
Between ~107x10
6
 and ~160x10
6
 paired end reads were generated across all of the 
samples. A mean target base coverage of between 102 and 191 was achieved across all 
samples and over 97% of the target bases were covered at least 1 fold, and over 85% 
were covered at least 20 fold (Table 4.2). Where I looked, the base quality was above 35 
for at least the first 40 bases of each read, only dropping down to ~30 towards the ends 
of the reads. 
 
 Samples 
Mean target 
coverage 
%bases > 
20fold 
%bases > 
10fold 
%bases > 
5fold 
%bases > 
1fold 
DCM Patient 1 - Affected 177.63 90.03 94.3 96.46 98.37 
DCM Patient 2 - Affected 177.63  86.73 91.84  94.83  97.99  
DCM Patient 3 - Affected 177.63 86.41  91.48  94.52  97.91  
DCM Patient 4 - Affected 177.63 87.07 92.8 95.74 98.28 
            
AVSD Patient 1 - Affected 121.47 85.29 91.37 94.61 97.3 
AVSD Patient 2 - Affected 116.83 86.54 92.63 95.65 98.17 
AVSD Patient 3 - Affected 144.07 86.19 92.19 95.41 98.18 
AVSD Patient 4 - Affected 150.89 90.37 94.61 96.64 98.29 
            
HSP Patient 1 - Affected 191.62 86.95 91.98 94.89 97.73 
HSP Patient 2 - Affected 177.63 90.04 94.3 96.46 98.37 
HSP Patient 3 - Unaffected 179.88 88.66 93.44 95.9 98.15 
 
Table 4.2. Sample summary statistics. The table describes the mean target base 
coverage and percentage target bases covered 20 fold and above, 10 fold and above, 
5 fold and above, and 1 fold and above. Values for each patient of each pedigree 
are given.  
 
More than 93% of the variants could be removed by selecting only the on-target 
variants, those variants shared amongst affected individuals, and by removing the 
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homozygous changes (Appendix figures 4.1 – 4.3). Therefore, a very large proportion 
of the variants could be removed by using only the first three filtering steps. 
 
4.4.2 Dilated cardiomyopathy family 
In excess of 200000 variants were identified across all the samples from this family, of 
which at least 88% comprised single base substitutions (Figures 4.7). After applying 
filtering set A, 4 variants remained (Table 4.3). Only the HYDIN variant was predicted 
as disease causing by MutationTaster. However, this variant was also observed in all 
samples from the AVSD and the HSP pedigrees, and is therefore not a good candidate 
for disease in this family. 
The filtering criteria were then relaxed (Filtering set B), after which 11 variants 
remained (Table 4.3). Three were predicted as disease causing by MutationTaster, the 
HYDIN mutation, the SLC38A10 mutation, and a splice site mutation in the 
ANKRD20A1 (chr9, 67927076). Out of these three only the ANKRD20A1 variant is not 
a recognised SNP, and ANKRD20A1 is related to ANKRD1 which can cause DCM. 
 
 
Figure 4.7. Number of unfiltered single base substitutions and indels identified 
using NovoAlign-Samtools for all patients in the DCM pedigree. 
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Chrom.  Position Reference Indel Gene EVS 1000G dbSNP135 
Control 
list 
Filter 
set 
chr1 87045902 ACCTAC - CLCA4 0 0 rs77067122 0 B 
chr9 38397083 G A ALDH1B1 0.005856 0.0023 rs41278335 0 B 
chr9 67927076 G A ANKRD20A1 0 0   0 B 
chr9 67968476 C T 
ANKRD20A1, 
ANKRD20A3 0 0 rs4055530 0 
A,B 
chr10 46999607 - 
AGGTG 
GGGG GPRIN2 0 0 rs58801928 0 
B 
chr10 126463282 T C METTL10 0.000197 0 rs139315006 0 A,B 
chr11 17352482 CAA - NUCB2 0 0 rs72423941 0 B 
chr11 56467881 T C 
OR9G1, 
OR9G9 0 0 rs73474900 0 
B 
chr11 56468212 G A 
OR9G1, 
OR9G9 0 0 rs591369 0 
A,B 
chr16 70896017 A - HYDIN 0 0 rs57797337 0 A, B 
chr17 79219505 TGA - SLC38A10 0 0 rs3833102 0 B 
 
Table 4.3. Variants shared between all affecteds which passed the filtering steps in 
the DCM pedigree. Columns titled EVS, 1000G, Control list give the variant allele 
frequency as listed in the exome server project (5400), 1000 genomes, and the 
control list respectively. All positions based on HG19 reference. 
Using the BWA-Dindel pipeline for indel identification, I was unable to identify any 
indels which passed either filtering set A (Stringent) or filtering set B (Less stringent). 
 
4.4.3 Atrioventricular septal defect family 
In excess of 170000 variants were identified across all the samples of this family, of 
which at least 88% were single base substitutions (Figure 4.8). After stringent filtering 
(Filtering set A), only the HYDIN variant was described by MutationTaster as 
potentially disease causing (Table 4.4). However, this variant was also identified in all 
the samples from both the DCM and HSP pedigree. 
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Therefore, the relaxed set of filtering criteria was applied to the data (Filtering set B), 
however this resulted in only one additional variant being identified in the OR9G1 gene 
(Table 4.4), which is a synonymous change and not predicted as disease causing by 
MutationTaster.  
 
Figure 4.8. Number of unfiltered single base substitutions and indels identified 
using NovoAlign-Samtools for all patients in the AVSD pedigree. 
Chr. Position Reference Indel Gene EVS 1000G dbSNP135 
Control 
list 
Filter 
set 
chr6 30558478 - A ABCF1 0 0 rs4148252 0 A,B 
chr11 56467881 T C OR9G1,OR9G9 0 0 rs73474900 0 B 
chr11 56468212 G A OR9G1,OR9G9 0 0 rs591369 0 A,B 
chr16 70896017 A - HYDIN 0 0 rs57797337 0 A,B 
 
Table 4.4. Variants shared between all affecteds which passed the less stringent 
filtering steps in the AVSD pedigree. Columns titled EVS, 1000G, Control list give 
the variant allele frequency as listed in the exome server project (5400), 1000 
genomes, and the control list respectively. All positions based on HG19 reference. 
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Using the BWA-Dindel pipeline, 5 indels were predicted as disease causing (Table 4.5). 
The same 5 were identified and predicted as disease causing using both filtering set A 
(Stringent), and filtering set B (Less stringent). None were in plausible candidate genes. 
Chromosome Position Reference Indel Gene EVS 1000G dbSNP135 
Control 
list 
chr6 29912029 G - HLA-A 0 0 rs149455102 0 
chr16 70896016 A - HYDIN 0 0 rs11337008 0 
chr16 81242149 TT - PKD1L2 0 0 rs150289691 0 
chr17 21319651 GAG - KCNJ12 0 0 rs112163749 0 
chr22 38120176 CCT - TRIOBP 0 0 rs146565844 0 
 
Table 4.5. Variants shared between all affecteds identified using the BWA-Dindel 
pipeline and which passed both filtering sets. All were predicted as disease causing 
by MutationTaster. Columns titled EVS, 1000G, Control list give the variant allele 
frequency as listed in the exome server project (5400), 1000 genomes, and the 
control list respectively. All positions based on HG19 reference. 
 
4.4.4 Hereditary Sclerosing Poikioderma family 
In excess of 88000 variants were identified for all of the samples from this family, 
comprising at least 88% single base substitutions (Figure 4.9). Using the stringent set of 
filtering criteria (Filtering set A) I was able to identify 56 variants (Table 4.6), of these 
30 were predicted as potentially disease causing by MutationTaster (Table 4.7). Of 
particular interest are the variants in the BLK and ALOXE3 genes, as previous studies 
indicate that changes to these two genes result in skin disorders presenting with 
keratosis and icthyosis (Starfield et al., 1997; Appel et al., 2002; Jobard et al., 2002).  
However, both have been observed in the EVS and 1000 Genomes data, substantially 
reducing their candidacy for causing HSP.   
Collaborators in Nantes provided exome sequencing data on a trio family consisting of 
one affected offspring with HSP with a phenotype very similar to that described by 
Khumalo et al. 2006 (the family sequenced in-house).  In this family, which was 
simplex, a strategy involving searching for de novo variants in the affected offspring 
was followed.  This process identified a novel, non-synonymous variant in the 
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FAM111B gene (c.1789A>G) which is unreported in the dbSNP, 1000 Genomes or 
EVS databases. I also identified a non-synonymous variant in this gene (c.1771T>G; 
Table 4.6), which was present in both affected siblings, but not in the unaffected mother. 
The variant I identified within the FAM111B gene has been validated, alters the amino 
acid, and is not located in either the dbSNP135 or 1000 genomes databases. Also 
FAM111B was validated in the affected, deceased brother using DNA extracted from a 
paraffin embedded liver sample. 
I reanalysed their sequencing data using my pipeline and after stringent filtering were 
able to identify 101 de novo variants, including the FAM111B variant (Table 4.8). In 
addition to the FAM111B, two additional genes were shared between the two pedigrees 
(Table 4.9). Of these, the variants in the CNTNAP3B present in my sample and my 
collaborators’ patient are known SNPs, rs62558062 and rs3739621 respectively. 
However, these are possibly very rare SNPs as they are not present in the EVS, or 1000 
genomes databases, or in the control list. 
FAM111B is a gene of unknown function which to date has not been implicated in any 
human disease. Expression analysis, performed by Dr. Elise Glen, showed that the gene 
is expressed in skin fibroblasts. 
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Figure 4.9. Unfiltered single base substitutions and indels identified using 
NovoAlign-Samtools for all patients in the HSP pedigree. 
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Chr. Position Reference Indel Gene EVS 1000G dbSNP135 Control list 
chr2 1457549 G C TPO 0 0   0 
chr2 17692189 C T RAD51AP2 0.001258 0.0009 rs183882477 0 
chr2 24929631 A G NCOA1 0 0   0 
chr2 242169660 C T HDLBP 0 0   0 
chr3 19479731 G A KCNH8 0.001208 0.0014 rs138531032 0 
chr3 45942584 C T CCR9 0.001301 0.0009 rs139107036 0.003521127 
chr4 8416586 T G ACOX3 0.007436 0.01 rs73211315 0.007042254 
chr5 56778305 A G ACTBL2 0.003346 0.0005 rs148214432 0.003521127 
chr5 169446042 G A DOCK2 0.000186 0 rs149008494 0 
chr6 90422360 C T MDN1 0.003718 0.0009 rs62417304 0.003521127 
chr6 126210797 G A NCOA7 0.004467 0.0018 rs35223550 0 
chr7 26224760 G A NFE2L3 0.003811 0.0037 rs148159120 0.007042254 
chr7 120965470 - CCCA WNT16 0 0 rs55710688 0 
chr8 11412934 G A BLK 0.003625 0.0009 rs141865425 0.007042254 
chr8 20036702 C T SLC18A1 0.001115 0 rs17215808 0 
chr8 30916058 A G WRN 0.00316 0.0014 rs34477820 0.003521127 
chr8 33361016 C T TTI2 0.001208 0 rs150984360 0 
chr9 20995555 C T FOCAD 0.001859 0.0014 rs145021526 0 
chr9 33953294 G A UBAP2 0.001022 0.0009 rs150275904 0.003521127 
chr9 43685298 G T CNTNAP3B 0 0 rs62558062 0 
chr9 125391777 - A OR1B1 0 0 rs11421222 0 
chr10 50732139 C T ERCC6 0.009481 0.01 rs4253047 0.003521127 
chr10 51768664 G T AGAP6 0 0   0 
chr11 4389407 G - OR52B4 0 0 rs11310407 0 
chr11 58893431 T G FAM111B 0 0   0 
chr11 62381864 G A ROM1 0 0   0 
chr11 63487475 G C RTN3 0.0066 0.0023 rs7936660 0.003521127 
chr11 66360021 C T CCDC87 0.007157 0.0046 rs1110707 0.003521127 
chr11 66468736 C T SPTBN2 0.000093 0   0 
chr12 4737404 C T AKAP3 0.005298 0.0018 rs71579261 0 
chr13 75887003 T C TBC1D4 0.00197 0.01 rs149821147 0 
chr13 96511850 A G UGGT2 0.007639 0.01 rs9525072 0.007042254 
chr16 14028081 C T ERCC4 0.004276 0.0032 rs1799802 0 
chr16 20335264 C T GP2 0.003253 0.0032 rs145297751 0 
chr16 55844871 T C CES1 0.001394 0 rs140704082 0.003521127 
chr16 56871605 G A NUP93 0 0   0 
chr16 67000764 C T CES3 0 0   0 
chr16 71318184 C G FTSJD1 0 0   0 
chr16 85697023 G A KIAA0182 0.000651 0 rs146762745 0 
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Table 4.6 Continued 
chr17 3594281 G - P2RX5 0 0 rs3215407 0 
chr17 7224519 T A NEURL4 0.005058 0.0037 rs145900596 0 
chr17 8006708 G A ALOXE3 0.000558 0.0009 rs147149459 0 
chr17 8195873 C T SLC25A35 0.000279 0 rs146737646 0 
chr17 10322333 C G MYH8 0.003067 0 rs146732664 0 
chr17 10409243 G A MYH1 0.003067 0.0005 rs142560385 0 
chr17 11572991 T G DNAH9 0.000093 0 rs142009409 0 
chr17 46620525 G C HOXB2 0.000372 0   0 
chr18 12329644 G A AFG3L2 0.001208 0.0018 rs117182113 0 
chr18 23619302 A T SS18 0 0   0 
chr19 6754659 A T SH2D3A 0 0   0 
chr19 21132126 G A ZNF85 0.00084 0.0014 rs140775014 0 
chr19 21477325 A T ZNF708 0.002231 0.0014 rs77583547 0 
chr19 52004794 - C SIGLEC12 0 0 rs67024588 0 
chr19 52004795 - T SIGLEC12 0 0   0 
chr22 41616779 G A L3MBTL2 0 0   0 
chr22 45198034 C T 
ARHGAP8, 
0.006507 0.01 rs41278883 0 PRR5-
ARHGAP8 
 
Table 4.6. Variants which passed the stringent filtering steps in the HSP pedigree. 
Columns titled EVS, 1000G, Control list give the variant allele frequency as listed 
in the exome server project (5400), 1000 genomes, and the control list respectively. 
All positions based on HG19 reference. 
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Chr. Position Reference Indel Gene 
chr1 150199051 TTCCTC - ANP32E 
chr2 242169660 C T HDLBP 
chr3 19479731 G A KCNH8 
chr3 45942584 C T CCR9 
chr5 56778305 A G ACTBL2 
chr6 126210797 G A NCOA7 
chr7 26224760 G A NFE2L3 
chr8 11412934 G A BLK 
chr8 20036702 C T SLC18A1 
chr9 20995555 C T KIAA1797 
chr9 33953294 G A UBAP2 
chr9 125391777 - A OR1B1 
chr10 51768664 G T AGAP6 
chr11 4389407 G - OR52B4 
chr13 75887003 T C TBC1D4 
chr13 96511850 A G UGGT2 
chr15 71276488 AAC - LRRC49 
chr16 10524660 GAC - ATF7IP2 
chr16 14028081 C T ERCC4 
chr16 56871605 G A NUP93 
chr16 71318184 C G FTSJD1 
chr17 3594281 G - P2RX5 
chr17 8006708 G A ALOXE3 
chr17 10409243 G A MYH1 
chr17 46620525 G C HOXB2 
chr18 12329644 G A AFG3L2 
chr18 23619302 A T SS18 
chr19 30500143 TGA - URI1 
chr22 41616779 G A L3MBTL2 
chr22 45198034 C T 
PRR5-
ARHGAP8 
 
Table 4.7. Variants which passed the strict filtering set and were identified as 
potentially disease causing by MutationTaster in the HSP pedigree. All positions 
based on HG19 reference. 
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Chr. Position Reference Indel Gene EVS 1000G dbSNP135 
Control 
list 
chr1 2126139 C G C1orf86 0 0 rs6662296 0 
chr1 2433578 C A PLCH2 0 0   0 
chr1 108152557 G T VAV3 0.001766 0.0014 rs138334746 0.002092 
chr1 117158857 C T IGSF3 0 0   0.002092 
chr1 12907408 T A 
HNRNPCL1, 
0.000651 0 rs146075045 0.008368 
LOC649330 
chr1 149902766 G A MTMR11 0 0   0 
chr1 156438602 T C MEF2D 0 0   0 
chr1 161514691 A T FCGR3A 0 0   0 
chr1 230561391 C A PGBD5 0 0   0 
chr1 247615264 G - OR2B11 0 0   0 
chr2 74466662 A G SLC4A5 0 0   0 
chr2 109098822 T C GCC2 0 0   0 
chr2 236761415 - GGGC AGAP1 0 0   0 
chr2 240029799 T G HDAC4 0 0   0 
chr3 49329992 G T USP4 0 0   0 
chr3 73673586 GC - PDZRN3 0 0   0 
chr4 159590833 C T C4orf46 0 0   0 
chr5 7820771 T C ADCY2 0 0   0 
chr5 139422562 C G NRG2 0 0   0 
chr5 140604659 G A PCDHB14 0 0   0 
chr6 26444248 T A BTN3A3 0 0   0 
chr6 29911119 G C HLA-A 0 0 rs3173419 0.006276 
chr7 2353998 G T SNX8 0 0   0 
chr7 2552898 - GTGG LFNG 0 0   0 
chr7 48349604 C G ABCA13 0 0   0 
chr7 51098567 GTCT - COBL 0 0   0 
chr7 73249193 - 
TTCCA 
WBSCR27 0 0 
  
0 
CAGGCG 
chr7 73249197 - 
TCAGG 
WBSCR27 0 0 
  
0 
CGGTCC 
chr7 95926236 C T SLC25A13 0 0   0 
chr7 149506211 - G SSPO 0 0   0 
chr7 151684361 C A GALNTL5 0 0   0 
chr7 153750014 G A DPP6 0 0 rs2240820 0 
chr8 22436870 C A PDLIM2 0 0   0 
chr8 25279148 G A GNRH1 0 0   0 
 
 
 
84 
 
Table 4.8 continued 
chr8 52732981 C G PDCMTD1 0 0   0 
chr9 21228151 G C IFNA17 0 0   0 
chr9 33558121 G T ANKRD18B 0 0   0 
chr9 33796703 C G PRSS3 0 0   0 
chr9 43822704 G A CNTNAP3B 0 0 rs3739621 0 
chr9 139964853 G C SAPCD2 0 0   0 
chr10 51748530 - C AGAP6 0 0   0 
chr10 51827896 C T FAM21A 0 0 rs11552619 0 
chr10 74790045 G A P4HA1 0 0   0 
chr10 81272467 A T EIF5AL1 0 0   0 
chr10 121196274 G T GRK5 0 0   0 
chr10 125780764 GT GGGT CHST15 0 0   0 
chr10 126312137 C T FAM53B 0.000093 0   0 
chr11 1078654 G T MUC2 0 0   0 
chr11 32119977 C A RCN1 0 0   0 
chr11 46342260 - T CREB3L1 0 0   0 
chr11 49974777 C T OR4C13 0 0   0 
chr11 58893449 A G FAM111B 0 0   0 
chr11 64669850 C G ATG2A 0.000469 0 rs149707582 0 
chr12 10167883 C T CLEC12B 0 0   0 
chr12 52629122 C T KRT7 0 0   0 
chr12 56094151 G A ITGA7 0 0   0 
chr12 117977558 C - KSR2 0 0   0 
chr12 132633381 T C NOC4L 0 0   0 
chr13 28942761 G C FLT1 0 0   0 
chr13 52650273 C T NEK5 0.000558 0 rs139136964 0.002092 
chr13 78272278 - C SLAIN1 0 0 rs71102772 0 
chr14 93176029 C A LGMN 0 0   0 
chr15 31521516 T - LOC283710 0 0   0 
chr15 35086927 G A ACTC1 0 0   0 
chr15 40545052 G A C15orf56 0 0   0 
chr15 75131978 C T ULK3 0.000207 0   0 
chr15 75981901 C T CSPG4 0 0   0 
chr16 2159179 G A PKD1 0 0   0 
chr16 15112733 G C PDXDC1 0 0   0 
chr16 15489840 C A MPV17L 0 0   0 
chr16 88677735 G T ZC3H18 0 0   0 
chr16 88772985 C A CTU2 0 0   0 
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Table 4.8 continued 
chr17 7734052 C T DNAH2 0 0   0 
chr17 34499245 G C TBC1D3B 0.0051 0   0.004184 
chr17 39296135 G A KRTAP4-6 0 0.0037 rs28405099 0 
chr17 40336172 TC - HCRT 0 0   0 
chr17 44626083 C A LRRC37A2 0 0   0 
chr17 61660896 T - DCAF7 0 0   0 
chr18 72997837 A C TSHZ1 0 0   0 
chr19 5610086 C A SAFB2 0 0   0 
chr19 16582756 T C EPS15L1 0 0   0 
chr19 33355209 T C SLC7A9 0 0   0 
chr19 35504178 C A GRAMD1A 0 0   0 
chr19 40421674 G T FCGBP 0 0   0 
chr19 41060188 G T SPTBN4 0 0   0 
chr19 43411160 G C PSG6 0.000093 0 rs140788501 0 
chr19 50040423 C A RCN3 0.000279 0.0005 rs142564622 0 
chr20 126310 AC - DEFB126 0 0   0 
chr20 2083466 A T STK35 0 0   0 
chr20 19261648 T C SLC24A3 0 0   0 
chr20 23965998 T G GGTLC1 0 0 rs62195276 0 
chr20 62065186 C A KCNQ2 0 0   0 
chr21 36042747 G T CLIC6 0 0   0 
chr22 41252508 C T ST13 0 0   0 
chrX 8699935 C T KAL1 0 0   0 
chrX 48895943 T C TFE3 0 0   0 
chrX 54780125 T A ITIH6 0 0   0 
chrX 100749038 C T ARMCX4 0 0 rs34379067 0 
chrX 100749041 A G ARMCX4 0 0   0 
chrX 111000833 C G ALG13 0 0   0 
chrX 153690631 G A PLXNA3 0.008909 0.0036 rs141197316 0.006276 
 
Table 4.8. De novo variants which passed the stringent filtering steps in the second 
HSP pedigree identified by my collaborators. Columns titled EVS, 1000G, Control 
list give the variant allele frequency as listed in the exome server project (5400), 
1000 genomes, and the control list respectively. All positions based on HG19 
reference. 
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Gene 
Chr,position,reference,variant 
(Patient sample) 
Chr,position,reference,variant 
(Collaborators patient) 
AGAP6 chr10, 51768664,G,T chr10,51748530, -,C 
CNTNAP3B chr9,43685298,G,T chr9,43822704,G,A        
FAM111B chr11,58893431,T,G chr11,58893449,A,G 
 
Table 4.9. Genes in which variants were identified in both HSP pedigrees. All 
positions based on HG19 reference. 
 
Using the BWA-Dindel pipeline as an additional indel calling pipeline, 4 indels passed 
filtering set A and were predicted as potentially disease causing, and 5 passed filtering 
set B and were predicted as potentially disease causing (Table 4.10). None of the 
variants were identified in plausible candidate genes of interest. 
 
Chromosome Position Reference Variant Gene EVS 1000G dbSNP135 
Control 
list 
Filtering 
set 
chr10 55582230 AGG - PCDH15 0 0 - 0 A,B 
chr10 127668864 GAA - FANK1 0 0.01 rs146106149 0 A,B 
chr19 30500119 TGA - URI1 0 0 rs3840928 0 A,B 
chr19 49657711 CAT - HRC 0 0 rs66501117 0 A,B 
chr21 47707039 - AAAAAA YBE 0 0 rs71318058 0 B 
 
Table 4.10. Variants shared between all affecteds, that were identified using the 
BWA-Dindel pipeline. All were predicted as disease causing by MutationTaster. 
Columns titled EVS, 1000G, Control list give the variant allele frequency as listed 
in the exome server project (5400), 1000 genomes, and the control list respectively. 
All positions based on HG19 reference. 
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4.5 Discussion 
I identified potentially damaging variants, segregating with disease in all three families. 
In particular, I was able to identify potentially disease causing variants in the HSP and 
DCM pedigrees. Variants in all three pedigrees were identified using whole exome 
enrichment and NGS, in combination with widely used sequence analysis and variant 
filtering methods. I was unable to identify any potentially disease causing variants in 
plausible candidate genes in the AVSD pedigree. There are various possible reasons for 
this (Discussed below). A detailed discussion of the results obtained for the DCM and 
HSP families will be given below, followed by a discussion on reasons why I think 
potentially disease causing variants may not have been recognised in the other two 
pedigrees.  
 
DCM variants 
The ANKRD20A1 is a little known gene which is part of the ankyrin repeat domain 20 
family (http://www.genecards.org). However, it is related to the ANKRD1 gene which 
has been shown as a candidate gene for DCM (Moulik et al., 2009). For example, the 
study by Moulik et al. (2009) screened 208 DCM patients for variants in the ANKRD1 
gene. The study identified three missense mutations. Functional studies indicated that 
these variants result in differential stretch-induced gene expression. 
I identified a splice site variant in the ANKRD20A1 gene (Figure 4.10), which due to 
previous reports of the influence of ANKRD1 genes on DCM, may be of importance.  
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Figure 4.10. Splice site variant identified in the ANKRD20A1 gene in the DCM pedigree.
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HSP variants 
I identified five variants of potential interest in members of the HSP family. All the 
variants represent single base substitutions and are located in the affected siblings, but 
not in the unaffected mother. Although not predicted as potentially disease causing by 
MutationTaster, the FAM111B, AGAP6, and CNTNAP3B genes are of interest as variants 
were identified in these genes in both my cases and in the cases of my collaborators. 
Due to the rarity of HSP, identifying shared genes containing non-synonymous variants 
in both unrelated pedigrees greatly increases their candidacy as possible candidates for 
disease. These three genes will be discussed in more detail below. 
Firstly, I identified a non-synonymous variant in the FAM111B gene. This missense 
variant results in a p.Tyr591Asp change and is conserved across different species 
(Figure 4.11). The missense variant identified by my collaborators results in a 
p.Arg597Gly change. In both families the variant was present in only the affected 
individuals and had not been previously listed in public SNP databases. The FAM111B 
gene is also known as a Cancer-associated Nucleoprotein and belongs to the FAM111 
family (http://genome.cse.ucsc.edu; 23 December 2012). Very little is known of the 
gene, but it is likely to be an enzyme with peptidase cysteine/serine trypsin-like 
functions (Dr. Sébastien Kury; perscomm). The functional consequences of aberrations 
in this gene have not been previously identified, and Dr. Elise Glen (perscomm; 
University of Newcastle) has shown that it is expressed in the skin, and not in the liver.  
Secondly I identified a non-synonymous single base substitution in the AGAP6 gene. 
This missense variant is in a conserved region of the gene and results in a p.S260I 
change (Figure 4.12). As with FAM111B, a non-synonymous variant was also observed 
in the AGAP6 gene in the HSP case provided by my collaborators. This gene is 
officially known as “ArfGAP with GTPase domain” 
(http://www.ncbi.nlm.nih.gov/gene/414189) and is a putative GTPase activating protein 
(http://www.uniprot.org/uniprot/Q5SRD3). The gene is of unknown function and no 
human genetic condition is known to result from mutations in the gene.  
 
Finally, I identified a non-synonymous, missense variant within the CNTNAP3B in both 
my cases and the case from my collaborators. The variant is in a conserved region and 
results in a p.A2S change (Figure 4.13). Unfortunately, as with the last two genes, very 
little appears to be known about the function of CNTNAP3B besides that it may be 
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involved in cell adhesion processes (http://www.uniprot.org/uniprot/Q96NU0). As 
mentioned previously, although very little is known about the functions of these three 
genes, given that this is a very rare disease, and affected individuals in both families 
have non-synonymous variants in the same genes, indicate that these genes could be 
related to HSP in these two families. 
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Figure 4.11. p.Tyr591Asp variant identified in the FAM111B gene in the HSP pedigree. 
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Figure 4.12. p.S260I  variant identified in the AGAP6 gene in the HSP pedigree.  
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Figure 4.13. p.A2S variant identified in the CNTNAP3B gene in the HSP pedigree.
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Aside from these three genes, I was also able to identify variants in two additional genes 
of possible interest in the two affected cases. However, these genes were not shared with 
the case of my collaborators but due to the possible functions of these two genes, they 
still warrant further discussion.  
The first  is a known (rs141865425) missense variant resulting in a c.G713A SNP 
change, with a population frequency <1% (1000 genomes database). It is located in a 
conserved region of the BLK gene. BLK belongs to the Src family kinases, which are 
thought to function in the cell proliferation and differentiation pathways (Islam et al., 
1995; Zwollo et al., 1998). In particular, BLK is expressed in B lymphoid cell lines 
(Dymecki et al., 1990), and in immature T cell lines (Islam et al., 1995). More recently, 
the gene has also been found to be expressed in the spleen, liver, leukocytes, ovary, 
muscle and testis (Appel et al., 2002). 
Interestingly, the BLK gene is located in the 8p22-q23 chromosomal region thought to 
contain a gene responsible for Keratolytic Winter Erythema, KWE (Starfield et al., 1997; 
Appel et al., 2002). KWE is an autosomal dominant skin disorder resulting in erythema, 
keratosis and peeling of the palms and soles (Appel et al., 2002). Many of the features 
of KWE are shared amongst the family suffering from HSP, in particular the keratosis 
and sclerosis of the palms of the hands and soles of the feet (Weary et al., 1969; Lee et 
al., 2012).  
 A study performed by Starfield et al. (1997) identified a region on chromosome 8 
which was linked to KWE. The study involved a German family with 20 affected and 
14 unaffected individuals. A panel of 230 genome wide, evenly spaced microsatellite 
markers was used to identify regions of linkage. Appel et al. (2002) designed and 
sequenced 7 BAC clones spanning the linkage region for KWE that was identified by 
Starfield et al. (1997). The BAC clones were used to identify a total of 12 transcripts 
covering the linkage region, one of which corresponded to the BLK gene. Direct 
sequencing of the gene was carried out using the individuals from the German pedigree 
in Starfield et al. (1997), and variants were subsequently identified. However, they were 
unable to identify any potentially pathogenic mutations in the KWE patients. The 
functional implications of the BLK gene, in particular its presence in the linkage region 
for KWE, make it a good candidate for HSP in this family. Although it is a SNP, it has a 
very low population frequency (<1%), so it may still be of interest with regard to HSP 
in this pedigree.  
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Finally I identified a missense c.C1889T change in the ALOXE3 gene, which was 
predicted as disease causing by MutationTaster. ALOXE3 is one of the five active LOX 
genes that are expressed predominantly in keratinised epithelia and functions in 
keratinocyte differentiation (Yu et al., 2003). Variants within the ALOXE3 gene have 
previously been reported to cause Non-bullous Ichthyosiform Erythroderma, NIE 
(Jobard et al., 2002). Icthyoses comprise a heterogenous group of disorders 
characterised largely by scaly skin, with NIE in particular being characterised by 
hyperkeratosis and displaying an autosomal recessive pattern of inheritance (Oji and 
Traupe, 2006). By analysing 8 NIE patients from 6 families, Jobard et al. (2002) 
identified 3 nonsense mutations and a frameshift deletion shared by all the patients, and 
not found in 120 control individuals. 
As with the BLK variant, the variant I identified in ALOXE3 is a SNP, but it does have a 
very low population frequency. The possibility of mutations within the ALOXE3 gene 
causing NIE, and the overlapping features of NIE with HSP, I think make this a 
potentially interesting variant.  
 
Reasons for not identifying potentially disease causing variants 
As mentioned previously, there are various reasons why I may not have identified any 
potentially disease causing variants in plausible candidate genes in the pedigree where 
cases presented with AVSD. Many of these reasons involve challenges of using exome 
capture in the detection of causative variants, and include, for example, sample choice, 
various technical limitations of target capture and sequencing, and in obtaining 
sufficient coverage. All these issues will be discussed in detail below. 
 
Sample selection 
Deciding which individuals, and of course how many, are to be sequenced in a pedigree 
is a very important consideration in exome sequence studies. When searching for very 
rare alleles, it may not be necessary to sequence all the affected individuals within a 
pedigree. In these cases Bamshad et al. (2011) suggest that because of the high 
probability of identity-by-descent, sequencing only two distantly related individuals 
within a pedigree could provide enough information to identify the disease causing 
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variants. As an example, the exomes of two siblings were sequenced in an attempt to 
identify the causative variants for an inherited lipid metabolism disorder called 
hypobetalipoproteinemia (Musunuru et al., 2010). As the disease is inherited in an 
autosomal recessive fashion, the investigators restricted their search to homozygous, 
novel variants present in both individuals and not present in the dbSNP database. Ng et 
al. (2010) also used NGS methods to discover the gene responsible for Miller syndrome 
by sequencing the exomes of only four unrelated individuals. The study identified two 
variants within the ANGPTL3 gene, which were either not present in, or heterozygous in, 
38 control exomes. However, both of these examples represent studies on recessive 
disorders which have proved more successful (Bamshad et al., 2011). 
Nevertheless, NGS studies on dominant disorders have proved successful, in particular 
when searching for causative de novo variants in dominant Mendelian disorders by 
sequencing of parent-offspring trios (Bamshad et al., 2011). For example, this study 
design was successfully implemented to identify the causative variants in ten patients 
suffering from unexplained mental retardation (Vissers et al., 2010). The study used the 
sequenced exomes of parent-offspring trios and identified an average of 21 755 variants 
per individual. Variants were further prioritised by selecting only non-synonymous and 
splice site variants and removing all those present within dbSNP and an in-house variant 
database. Finally, all remaining inherited variants were removed, resulting in a final list 
of 51 variants. Thirteen of the remaining variants could be validated via Sanger 
sequencing, 9 of which were present in 7 of the affected individuals, and absent in 1 664 
controls. All 9 variants occurred in different genes, four of which displayed evidence for 
having a causal link to mental retardation in model organisms and protein interaction 
studies. 
 
Data analysis issues of exome sequencing 
Following sequencing, a base calling algorithm is used to determine the nucleotides 
from the intensity files produced by the sequencer (Nielsen et al., 2011). Some of the 
main difficulties involved in base calling, for which all base callers have to correct, are 
phasing, pre-phasing and decreased signal intensity with each cycle (Ledergerber and 
Dessimoz, 2011).  Phasing occurs when a sequence fails to add a base during a cycle, 
while pre-phasing is a term used to describe the situation where multiple bases are 
added during one cycle. An additional issue is that of cross-talk which refers to the 
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overlap in emission spectra of the four fluorescent labels, which can impede 
identification of the correct base (Coonrod et al., 2012). Reducing the error rate of base 
calls is important as it effects the downstream analyses and may result in a sequence not 
being aligned to the reference, being aligned to the incorrect position along the 
reference, or could result in false variant calls (Malhis et al., 2009; Nielsen et al., 2011). 
Many programmes are available to align reads to a reference, such as Bowtie-2 
(Langmead and Salzberg, 2012), NovoAlign (http://www.novocraft.com), BWA (Li and 
Durbin, 2009) and GSNAP (Wu and Nacu, 2010). Each of these programmes varies in 
its ability to correctly align reads to a reference (Li and Durbin, 2009; Wang et al., 2011; 
Pattnaik et al., 2012). For example Wang et al. (2011) compared the performance of 
various alignment algorithms by calculating the percentage of reads the program was 
able to map to the reference. The best performing program in their study was SHRiMP 
which aligned 81.23% of the reads to the reference, whereas the worst performing 
program was RMAP which only aligned 55.98% of the reads to the reference. Pattnaik 
et al. (2012) found that Bowtie was much faster than NovoAlign, but that it was only 
able to align 54.18% of the reads to the reference, whereas NovoAlign aligned 85.47% 
of the reads to the reference. 
The alignment step has obvious implications for the accurate identification of variants, 
and it is important for these programmes to produce accurate read alignment quality 
scores as these can later be used by the variant caller (Nielsen et al., 2011). However, 
accurate alignment does present with various difficulties, such as distinguishing true 
alignments from amongst multiple alignments (Wang et al., 2011), distinguishing 
sequencing errors from real genomic differences (Nielsen et al., 2011), and the fact that 
some areas of the genome are just difficult to align to, in particular those areas 
displaying a high level of inherent diversity within a population (Albers et al., 2011; 
Nielsen et al., 2011). For example, along homopolymer stretches where the indel 
polymorphism rate within a population is higher than in other genomic regions (Albers 
et al., 2011). Regions of the genome containing high numbers of indels are difficult to 
align to (Harismendy et al., 2009; Albers et al., 2011; Coonrod et al., 2012), where the 
presence of indel variants within the reads has been shown to increase both false 
positive and false negative calls (DePristo et al., 2011). 
Once reads have been aligned to the reference, variants can be identified as deviations 
in the reads from the reference sequence. The difficulty in this step involves accurately 
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distinguishing the true genetic variations from the errors produced in sequencing or 
alignment (Shen et al., 2010; Wang et al., 2011). There are many programmes available 
to call genetic variants from aligned reads, such as Varscan-2 (Koboldt et al., 2012), 
Dindel (Albers et al., 2011), Samtools/bcftools (Li et al., 2009) and GATK (McKenna 
et al., 2010). As with the different alignment programmes, the use of different variant 
callers can have a marked effect on sensitivity (Ji, 2012; Pattnaik et al., 2012). In 
conjunction with the bowtie aligner, using Samtools as a variant caller, Pattnaik et al. 
(2012) was able to match only ~40% of their identified variants to the dbSNP database, 
whereas by using GATK over 80% of the identified variants matched the dbSNP 
database. 
Many studies have used similar methods to those which I used to identify the genetic 
variants responsible for different diseases (Ng et al., 2009; Johnson et al., 2010b; 
Krawitz et al., 2010; Musunuru et al., 2010; Ng et al., 2010b; Wang et al., 2010a; 
Norton et al., 2011), including various in-house studies (Dickinson et al., 2011; Horvath 
et al., 2012; Pfeffer et al., 2012; Pyle et al., 2012). For example, in the study carried out 
by Pyle et al. (2012). However, there were some differences between the methods. The 
key difference between the methods employed by Pyle et al. (2012), and those 
employed here is in the use of different variant calling software. The study by Pyle et al. 
(2012) made use of the BWA aligner and Varscan variant caller to identify single 
nucleotide substitutions. Conversely, I made use of the NovoAlign aligner and 
Samtools/bcf tools variant caller to identify single nucleotide substitutions. However, in 
chapter 3 I demonstrated that, for the identification of single nucleotide substitutions, 
the NovoAlign-Samtools analysis pipeline is more sensitive than the BWA-Varscan 
analysis pipeline. 
 
Technical issues of exome sequencing 
The accuracy of variant calls is often seen to be strongly affected by the base quality 
score and sequencing depth (Nielsen et al., 2011; Pattnaik et al., 2012). In particular the 
depth of coverage has been shown to have a large effect on the false positive rate in 
Illumina sequence reads (Wang et al., 2008; Harismendy et al., 2009). A lack of 
sufficient coverage would also lead to increased numbers of false negatives and the 
disease causing variant not being identified (Zhi and Chen, 2012). Harismendy et al. 
(2009) demonstrated that at a sequence depth of ~10 fold, Illumina sequences have a 
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false positive rate of 0.7, while at a coverage of ~68 fold this drops to only 0.1. This is 
also true for indel variants where sensitivity has been shown to rise from less than 0.85 
to more than 0.95 at coverage depths of 10 and 20 respectively (Qi et al., 2010). 
However, as >95% of the target bases were covered more than 10 fold, I think that the 
targets were sufficiently covered in the present study. See also chapter 3 where I 
assessed the affect of coverage depth on sensitivity. 
A major flaw of exome sequencing is that not all of the coding regions are actually 
covered by commercial targeting kits (Asan et al., 2011; Parla et al., 2011; Sulonen et 
al., 2011). The problem arises in trying to define a set of targets that would encompass 
the exome, as not all of the protein coding sequences making up the human genome are 
known (Bamshad et al., 2011). Two widely used exome capture kits include the Agilent 
SureSelect kit and the NimbleGen kit. 
Parla et al. (2011) assessed the ability of both the Nimblegen (26.2Mb targets) and 
Agilent (37.6Mb targets) kits to capture known coding regions based on their intended 
targets of the CCDS. They found that the Agilent kit covered 97% of the CCDS targets, 
whereas the Nimblegen kit only covered 88% of the CCDS targets. However, Asan et al. 
(2011) found that a higher proportion of reads could be mapped to the reference 
sequence using the Nimblegen technology (>10% higher), rather than the Agilent 
technology. This superior target enrichment using the Nimblegen targeting kit has also 
been confirmed in other studies (Clark et al., 2011; Sulonen et al., 2011) 
The performance of both the Nimblegen and Agilent kits in variant identification 
studies was tested by Asan et al. (2011). They found that at a sequencing depth of 30 
fold, Nimblegen displayed a higher sensitivity, and they were able to identify 12 400 
variants in the targeted coding regions common to both kits, whereas when using the 
Agilent kit only 12 000 SNPs were identified in these regions. However, they also 
found that the Agilent kit detected 13 500 coding SNPs outside of these common coding 
regions, whereas the Nimblegen kit only detected 12 600 coding SNPs outside of these 
regions. They attribute this to the higher capture efficiency of the Nimblegen kit, and 
the larger area (~4Mb larger) captured by the Agilent kit. 
However, at 20 fold coverage Sulonen et al. (2011) found that both Nimblegen and 
Agilent kits could provide comparable, highly sensitive SNP calls (>97%) which they 
calculated by using the SNPs captured on the Illumina Human660W-Quad v1 SNP chip. 
This was further corroborated by Clark et al. (2011), who found a concordance of >99% 
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when SNP calls from both were compared to the Illumina 1M-Duo SNP chip. In chapter 
3, I used the NovoAlign aligner and Samtools variant caller to identify variants within 
19 exomes. On average, I was able to identify in excess of 98% of the on target markers 
on the Illumina 660W SNP chip.  
 
Issues of filtering in exome sequencing 
Exome sequencing studies often identify many thousands of variants. For example, I 
identified >88000 variants in the HSP pedigree and >222000 variants in the DCM 
pedigree. Due to these very large numbers of variants, various filtering steps are often 
used to reduce this number to a more manageable size. Often, one of the first steps used 
to reduce down the number of identified variants is the removal of all the variants 
occurring outside of the target regions (Dickinson et al., 2011; Horvath et al., 2012; 
Pfeffer et al., 2012; Pyle et al., 2012). The obvious danger with this technique is that the 
causative variant may lie outside of the target regions. 
By selecting only variants present within the targeted regions, I was assuming that the 
causative variant is exonic. However, Cooper et al. (2010) estimated that up to ~14% of 
the mutations within the Human Gene Mutation Database (A database containing 
known genes responsible for human inherited diseases) are located within the intronic 
and regulatory regions of genes (Cooper et al., 2010). There are also many examples 
where intronic variants and those found in 3’ and 5’-untranslated regions have been 
found to affect disease (Scheper et al., 2007; Chen et al., 2010). For example, in the 
case of a Retinitis Pigmentosa (RP) where linkage mapping suggested the involvement 
of the PRPF31 gene, extensive screening of the genes exons failed to identify the 
causative variant (Rio Frio et al., 2009), and sequencing the entire PRPF31 gene 
allowed Rio Frio et al. (2009)  to identify a deep intronic single base substitution 
causing RP in this family. Also, Scheper et al. (2007) provides examples of various 
inherited diseases caused by mutations within the 5` UTR’s of genes, such as in 
hereditary hyperferritinaemia. 
As well as selecting only on-target variants, I also removed variants recorded in public 
databases such as 1000 genomes. For a single European sample it is expected that 
between 74% - 95% of all identified variants will be present in a public database 
(Bentley et al., 2008; DePristo et al., 2011; Coonrod et al., 2012). This value has 
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obviously increased over time, and now in excess of ~95% of variants should be 
expected to be present in public databases. More than 96% of the variants I identified in 
all three families were already recorded in public databases. Of course, this method 
assumes that the variants present in these databases are common in the population and 
cannot therefore be the causative variant for a rare disorder, and often results in a 
considerable reduction in the numbers of variants from the candidate list (Ng et al., 
2009; Wang et al., 2010a; Bamshad et al., 2011; Norton et al., 2011; Coonrod et al., 
2012).  
However, there is a risk that the causative variant may be present in the population and 
therefore also in these databases, albeit at a low frequency. This is particularly relevant 
in the case of recessive disorders where carriers do not present with the disease 
phenotype (Bamshad et al., 2011). Therefore, it is becoming more popular to employ 
minor allele frequency thresholds when removing variants that are present in these 
databases (Bamshad et al., 2011; Stitziel et al., 2011).  
Applying a base coverage threshold to remove poorly supported variant calls is also 
often used as a filtering criterion. Coverage values falling outside of the normal range, 
i.e. excessively high or low coverage at a particular position, may result in false positive 
or negative calls (Bentley et al., 2008; Coonrod et al., 2012). As well as total coverage 
at a position, a minimum coverage of the variant allele has also been shown to be 
valuable in identifying false positive and negative calls (Mokry et al., 2010).  
A further filtering approach which can be implemented is to incorporate a prediction 
programme to estimate the potential impact of variants on protein function (Jordan et al., 
2010; Bamshad et al., 2011). In the current study, the MutationTaster prediction 
programme was used to assess the pathogenicity of variants. MutationTaster is a free 
programme which uses evolutionary conservation, annotation and structural information 
to assess the impact of a particular variant (Schwarz et al., 2010). Many other 
programmes also are available to predict potential variant pathogenicity, such as SIFT 
(Kumar et al., 2009) and PolyPhen-2 (Adzhubei et al., 2010). 
One of the major concerns regarding these prediction algorithms is the variations in 
sensitivity and specificity achieved between them (Chan et al., 2007; Hicks et al., 2011). 
Hicks et al. (2011) assessed the sensitivity and specificity of various prediction 
programmes, and highlighted a large variation in the results obtained using the different 
algorithms. For example, Polyphen2 and SIFT achieved sensitivity values of 0.9 and 
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0.85 respectively and specificity values of 0.40 and 0.52 respectively. In another study 
the accuracy of predictions between four different algorithms was assessed. The worst 
performing method was a program called A-GVGD (Tavtigian et al., 2006), which 
achieved a sensitivity of 72.9, whereas Polyphen was able to achieve a sensitivity of 
83.3 (Chan et al., 2007). Although prediction programmes may not correctly predict 
variant effects, they are still considered a useful means of prioritising variants in 
sequencing studies (Karchin, 2009; Jordan et al., 2010). 
Another common filtering approach is to focus only on those changes which alter the 
amino acid. By using the Human Gene Mutation Database, Kryokov et al. (2007) 
calculated that up to 20% of all missense mutations could result in a complete loss of 
protein function. They also estimated that up to 53% of all de novo missense mutations 
can be considered as mildly deleterious, which they defined as mutations which do 
effect, but not completely eliminate, protein function. Although removing all of the 
synonymous and common variants may provide an effective means of reducing the 
overall number of variants, there is a chance that these may include the disease causing 
variants (Ku et al., 2011).  
 
4.6 Conclusions/Future work 
In this chapter I identified variants potentially causing HSP and DCM. In the HSP 
pedigree, these include variants in the BLK, ALOXE3, FAM111B, AGAP6, and 
CNTNAP3B genes. Of particular interest are the variants in the FAM111B, AGAP6, and 
CNTNAP3B genes. Although, current literature and knowledge regarding the effect of 
variants in these genes suggest that they could potentially influence HSP in this family, 
functional analyses will be required to determine their role in disease. I also identified a 
variant in the ANKRD20A1 gene which could be responsible for disease in the DCM 
pedigree. There are various reasons why I was not able to identify any potentially 
disease causing variants in plausible candidate genes in the AVSD pedigree.  
In particular, the first three stages of variant filtering (i.e. the removal of off-target 
variants, selecting only those variants shared amongst affected individuals, and 
removing the homozygous changes) removed more than 90% of the identified variants. 
This suggests that these three steps are a very effective means of reducing variants down 
to a more manageable number, and should presumably make up the first three stages in 
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any filtering approach. However, care should be taken when removing variants 
occurring outside of the targets, as they may still be important. 
Therefore, any future work should alter the filtering criteria I used, or possibly more 
importantly, use a whole genome sequencing approach to capture more of the genome. 
However, this approach is currently limited by current cost and resource requirements. 
Furthermore, it may prove valuable to search for other kinds of variants, such as copy 
number variants. I only identified single nucleotide and indel variants, however, it is 
possible that disease in the DCM and AVSD families are caused by genomic variants 
such as CNV’s. See chapter 1 and 6 for a detailed discussion on these issues.  
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Chapter 5. Identifying disease causing indels using targeted next 
generation sequence data from patients with congenital 
cardiovascular disorders 
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5.1 Aim 
This study was conducted as part of an international collaborative project which aimed 
to identify rare variants potentially causing certain congenital heart malformations, in 
particular those characterised by ventricular hypoplasia. This was done by sequencing 
selected genes in a group of patients with various congenital malformations. My role 
within the project was to analyse targeted NGS data to identify potentially disease 
causing insertion/deletion (indel) events in these patients.    
 
5.2 Introduction 
5.2.1 Sample Origin 
One hundred and thirty three patient samples were provided by six centres located in 
The Netherlands (Academic Medical Center, Amsterdam and Leids Universitair 
Medisch Centrum, leiden), England (The University of Newcastle, Newcastle Upon 
Tyne), Belgium (Katholike Universiteit, Leuven, University of Leuven, Leuven), and 
Germany (Max Planck Institute for Molecular Genetics and the Max Delbrück Center 
for Molecular Medicine in Berlin). These patients suffer from a range of congenital 
cardiac disorders (Details on sample phenotyopes are provided in table 5.1) that are 
characterised by underdevelopment (hypoplasia) of either the left or the right ventricular 
chamber.  
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______________________________________________________________________ 
Right Ventricular hypoplasia/malformation: 
Double inlet left ventricle - 21 
Tricuspid atresia - 25 
Right ventricular hypoplasia - 6 
Pulmonary atresia with intact ventricular septum - 12 
Ebstein’s anomaly - 25 
Left Ventricular hypoplasia/malformation: 
Hypoplastic left heart syndrome - 8 
Mitral valve atresia - 4 
Left ventricular hypoplasia - 6 
Other: 
Noncompaction - 19 
Univentricular heart - 7 
______________________________________________________________________ 
Table 5.1. Categories, and subcategories, of congenital cardiac malformation that 
the 133 patients used in this study suffered from. The numbers represent the 
number of patients. 
 
5.2.2 Phenotypes 
All cases suffer from what are broadly termed “univentricular heart” defects, that 
comprise a range of malformations which are not easy to classify (Khairy et al., 2007). 
All these malformations have a poor prognosis and if left untreated, survival into late 
adulthood is rare (Hager et al., 2002). The cases in this study were categorised as 
suffering from right ventricular malformations and left ventricular malformations. In 
addition there is a group of 26 cases classified as “Other”, because they did not fit 
strictly into any of the subcategories. 
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Left ventricular hypoplasia comprises a range of congenital heart abnormalities 
characterised by the severe underdevelopment of the left side of the heart and which 
often prove to be lethal (Trivedi et al., 2011; Hickey et al., 2012). It is frequently 
associated with obstruction to left ventricular outflow, where the degree of hypoplasia is 
proportional to the degree of obstruction (Hickey et al., 2012). In severe cases, the left 
ventricle is unable to support systemic circulation, and the only options available for 
long term survival include neonatal heart transplant or a sequence of complex open-
heart operations during infancy (Fruitman, 2000; Trivedi et al., 2011; Hickey et al., 
2012).  It is generally accepted that lack of flow during embryonic development plays a 
critical role in the pathogenesis of left ventricular hypoplasia; in models where left sided 
flow can be readily modelled (eg the chick embryo), restriction of left sided flow 
reproducibly results in hypoplasia of left heart structures. Therefore, genes particularly 
involved in the development of critical left heart structures such as the mitral valve and 
aortic valve might be considered particularly good candidates for involvement in left 
heart hypoplasia. In addition, however, some studies have shown the presence of 
mutations in transcription factors critical to the specification of left ventricular 
myocardium in patients with left heart hypoplasia (Grossfeld, 2007; Hickey et al., 2012). 
Numbers, however, remain small due to the rarity and serious nature of this group of 
phenotypes, which remain the CVM phenotypes most likely to result in childhood death. 
Also, since the widespread availability of fetal cardiology services, the incidence of 
hypoplastic left heart syndrome, which is generally detectable using fetal 
echocardiography, has decreased due to termination of affected foetuses. As seen in 
table 5.1, even the pooled resources of a number of international congenital heart 
disease units resulted in the availability of relatively small numbers of patients with left 
ventricular hypoplasia. 
Right ventricular (RV) hypoplasia describes a group of cyanotic congenital heart 
disease conditions characterised by a small right ventricle, and which can lead to 
congestive heart failure and cyanosis during infancy (Goh et al., 1998). RV hypoplasia 
can be caused by the underdevelopment of one or more of a variety of structures on the 
right side of the heart, including the tricuspid valve, right ventricle (as a primary event), 
pulmonary valve, and the pulmonary artery (Van der Hauwaert and Michaelsson, 1971; 
Dib et al., 2012). The degree of underdevelopment is highly variable, with very severe 
forms presenting in early infancy, while in the less severe forms the patient can survive 
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to adulthood (Dib et al., 2012).  As is seen from Table 5.1, patients with RV hypoplasia 
from various causes were more readily collected from the collaborating centres.  It is 
however important to be aware that the right-sided conditions studied in Table 5.1 are 
far from common; for example pulmonary atresia with intact ventricular septum 
represents only 1-3% of all congenital heart disease, and Ebstein’s anomaly occurs in 
less than 1:20000 live births. Both right and left-sided phenotypes were therefore 
selected for rarity and severity; it was reasoned that selection of this group of patients 
would maximise the chances of finding rare variants of large phenotypic effect through 
NGS. 
 
5.2.3 Indels and disease 
Here I will define indels as deviations from the reference sequence where bases are 
either removed (deletions) or have been added (insertions). It is estimated that every 
individual harbours between 0.3 – 0.6 million indels, making these the second most 
common form of genetic variation, following SNPs (Levy et al., 2007; Bansal and 
Libiger, 2011; Lemos et al., 2012). Indels display very large variations in both 
distribution and size across the human genome, with sizes ranging from 1 to several 
1000 base pairs (bp) in length (Bhangale et al., 2005; Levy et al., 2007; Wheeler et al., 
2008; Lemos et al., 2012). For example, using 454 FLX sequence reads and a 
combination of the BLAT and cross_match 
(http://www.phrap.org/phredphrapconsed.html) programmes, Wheeler et al. (2008) were 
able to identify 222718 indels in a single individual, which ranged in size from 2 – 
38896bp long (Table 5.2).  
 
There is also a large amount of variation in indel frequency across different gene 
regions (MacArthur et al., 2012). Bhangale et al. (2005) identified 2393 indels in a set 
of 330 targeted genes, and found that indels occurred more frequently in the 3’-UTRs 
than in the 5’-UTRs of genes. This pattern is explained by the greater tolerance to 
truncation close to the end of the coding regions (MacArthur et al., 2012). However, 
despite this variation across different gene regions they identified very few indels in the 
coding regions of the genes, which they attributed to a strong negative selection on 
coding indels. The scarcity of coding indels in human genes is further corroborated by 
Wheeler et al. (2008), in which less than 1% of the 222718 indels they identified were 
located in coding regions.  
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Due largely to the difficulties involved in identifying indels using NGS methods (Bansal 
and Libiger, 2011), which are discussed in more detail below, far less is known about 
the effect of indels on genes than is known about SNPs (Cartwright, 2009; Mills et al., 
2011; Hu and Ng, 2012; Lemos et al., 2012). This, despite indels of less than 20 base 
pairs long accounting for nearly one quarter of known Mendelian disease mutations (Hu 
and Ng, 2012). Therefore, a detailed knowledge of indel variation and distribution in 
patient samples would be very useful to understand their potential influence on disease 
(Mills et al., 2011).  
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Length Deletions Insertions 
1 664 (41.76) 397 (57.87) 
2 309 (19.43) 68 (9.91) 
3 188 (11.82) 39 (5.69) 
4 185 (11.64) 79 (11.52) 
5 69 (4.34) 26 (3.79) 
6 29 (1.82) 17 (2.48) 
7 14 (0.88) 11 (1.6) 
8 20 (1.26) 6 (0.87) 
9 12 (0.75) 4 (0.58) 
10 9 (0.57) 7 (1.02) 
11 12 (0.75) 0 (0) 
12 17 (1.07) 0 (0) 
13 8 (0.5) 3 (0.44) 
>=14 54 (3.4) 29 (4.23) 
Table 5.2. Lengths of insertions and deletions identified in 330 targeted genes. 
Values represent insertion and deletion counts, while the values in brackets 
represents the proportion. From Bhangale et al. (2004). 
 
5.2.4 Indel identification using NGS data 
The development of tools to accurately identify indels is a very important step in the 
search for the genetic causes of disease (Bansal and Libiger, 2011). Various different 
programmes have been developed to try and identify indels from NGS reads, including 
MAQ (Li et al., 2008a), dindel (Albers et al., 2011), and GATK (McKenna et al., 2010). 
However, the performance and accuracy of these different programmes varies (Vallania 
et al., 2010; Albers et al., 2011). Using simulated data, Albers et al. (2011) compared 
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the false discovery rate of indel calls using Dindel, Varscan and SAMtools. Dindel 
achieved the lowest false discovery rate of 1.56%, while Varscan had the highest rate of 
false discoveries, 16.67%. In my analysis in chapter 3, I calculated the sensitivity values 
for different indel calling pipelines and found large differences between them. Across 12 
samples, the BWA-Dindel pipeline performed the best, achieving an average sensitivity 
of ~35%. Conversely, the NovoAlign-Samtools pipeline performed the worst, achieving 
an average sensitivity of <5%. This is considerably lower than the values achieved when 
identifying single nucleotide substitutions, highlighting the difficulties involved in 
identifying indels using NGS methods. 
 
Despite this, many studies have been able to identify disease causing indels using these 
approaches (Wei et al., 2011; Carmignac et al., 2012; Drielsma et al., 2012; Fuchs-
Telem et al., 2012; Pyle et al., 2012; Wang et al., 2012; Weterman et al., 2012). For 
example Wei et al. (2011) identified an exonic, frameshift deletion in the DMD gene 
causing Duchenne muscular dystrophy. Target capture was performed using a 
Nimblegen custom capture array, and sequencing performed using an Illumina 
HiSeq2000. Sequence reads were aligned to the human genome using BWA and indels 
were identified using GATK. They identified a large deletion of exon 1 in the DMD 
gene that was present in all affected samples, but not found in 100 controls. In a further 
study by Pyle et al. (2012), the BWA-Dindel analysis pipeline was used to identify one 
and two base pair deletions in the SACS gene causing prominent sensorimotor 
neuropathy. The mutations were identified in two affected siblings and not present in 
346 control samples, or in the 1000 genomes project.  
 
Despite various successes, identifying indels using short read sequence data does 
present with various problems (Albers et al., 2011). In particular, correctly mapping 
reads containing indels to the reference (Lunter and Goodson, 2011), particularly in 
cases where reads contain large insertions, is difficult (Albers et al., 2011). Still further 
problems may include, an increased rate of indel false positive calls in highly 
polymorphic gene regions, and the presence of technological artefacts such as 
polymerase slippage during PCR amplification (Albers et al., 2011; Bansal and Libiger, 
2011). 
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5.2.5 Indel prioritisation 
As with SNPs, programmes designed to locate indels will identify many thousands of 
variants per patient (Wei et al., 2011). Therefore, there is a need for methods which 
could be used to filter these indel variants down to a more manageable number (Zia and 
Moses, 2011; Hu and Ng, 2012). As well as reducing the total number of potential 
indels that need to be validated, applying variant filters could help improve the 
specificity of indel calls (Albers et al., 2011). As an example, Albers et al. (2011) 
suggest that, at the very least, indels should be required to be present on both the 
forward and reverse strands. Additionally, Mardis et al. (2009) suggest applying a 
coverage threshold to indel calls by, for example, only accepting those supported by at 
least 2 reads. Wei et al. (2011) prioritise indels by selecting only those which alter the 
protein and removing those present within the dbSNP, 1000 genomes and HapMap 
databases, as well as those present in an in-house list of controls. This is particularly 
relevant in the context of my study where I was expecting the variants to be rare and 
therefore not present, or present at a low frequency, in public databases. 
 
One of the simplest means to prioritise indels may include selecting coding, frameshift 
indels (Hu and Ng, 2012), as these are reported to occur very rarely (Wheeler et al., 
2008); see also the 1000 genomes (http://www.1000genomes.org/) and Exome Variant 
Server (http://evs.gs.washington.edu/EVS/) databases. However, not all indels occurring 
in coding regions lead to a loss of function, some are functionally neutral, and indels 
occurring outside of the coding regions could also have a considerable impact on genes 
by, for example, altering splicing (Pagani and Baralle, 2004; Zia and Moses, 2011; Hu 
and Ng, 2012). Alternatively, Wei et al. (2011) suggest employing a disease database, 
such as the HGMD (http://www.hgmd.cf.ac.uk/), as a means of selecting indels which 
may already be known to cause disease. Another more complex means to prioritise 
indels is by using a prediction programme (Lemos et al., 2012). However, as mentioned 
in chapter 4, Lemos et al. (2012) warn of discrepancies between the results produced by 
some of these programmes.  
 
5.2.6 Indel validations 
Even after prioritisation, validation rates for indels are lower than for single nucleotide 
substitutions (Weber et al., 2002; Mardis et al., 2009). For example, using PCR methods 
Weber et al. (2002) could only achieve a validation rate of 58% for indels of at least 
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2bp’s long. For single base indels this rate dropped down to ~14%, and as single base 
indels are the most common type of indel, their low validation rate is an important issue. 
In another study, Mardis et al. (2009) used the MAQ aligner and Samtools variant caller 
to identify possible disease causing indels in a patient suffering from Acute Myeloid 
Leukemia. They identified 142 indels, of which they were only able to validate 23 
(~16%). 
 
5.3 Materials and Methods 
5.3.1 Samples, gene selection, and sequencing 
Centres in The University of Newcastle, Newcastle Upon Tyne (Prof. B Keavney), the 
AMC, Amsterdam (Dr Alex Postma), and the Max Delbrück Center, Berlin (Prof Sabine 
Klaasen), provided 133 samples. Centres in Newcastle and Amsterdam provided 67 
samples each, while centres in Berlin provided 26 of the samples. Samples were 
obtained from individuals suffering from a range of congenital cardiovascular 
malformations.  
 
Targeted genes were prioritised in four stages by the lead authors of the study in all 
three centres. Firstly, genes containing mutations which have previously been reported 
to cause human CVM were selected. Secondly, genes shown to be involved in CVM in 
mice or other model organisms were selected. Thirdly, genes known to participate 
directly in known regulatory gene networks for heart development were selected. 
Finally, genes involved in known gene networks for CVM, not necessarily directly, 
were selected. The final gene list consisted of 403 genes (Supplementary table 2.1).  The 
number of genes represented on the array was limited by the size of the capture possible 
using the Agilent SureSelect system at the time the project began. Sequencing was 
performed in Amsterdam (LUMC, Leiden) using an Illumina Genome analyser IIx. 
More detail on the methods used here are provided in chapter 2. 
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5.3.2 Indel calling 
The BWA aligner was used to map the reads to the human genome reference sequence 
(Build 37, hg19). Given the known lack of specificity of indel calls in NGS data, I 
decided to use two variant callers, Dindel (Albers et al., 2011) and the Genome Analysis 
Toolkit (GATK) indel caller (McKenna et al., 2010; DePristo et al., 2011), focusing on 
the indels that were detected using both pipelines. It was hoped that this would increase 
the confidence of indel calls and decrease the amount of effort required in attempts at 
validation (using Sanger sequencing) of the many false positive variants that might be 
detected by one pipeline alone. Only reads that aligned uniquely to the reference and 
non-duplicate reads were selected using a combination of custom written Perl scripts 
and the Picard MarkDuplicates routine (http://picard.sourceforge.net/). Only the filtered 
indels called by both pipelines were validated using Sanger sequencing. 
 
5.3.3 Indel filtering and annotations 
As a first filtering step, all off-target variant calls were removed, and the filtered list 
submitted to wAnnovar (http://wannovar.usc.edu/) for indel annotations. Following 
annotations, only exonic, frameshifting and splice site indels were selected, and because 
I wanted to identify rare variants, all indels present in the EVS database, consisting of 
variant calls from 5400 human exomes, and 1000 genomes databases, comprising 
variant calls from multiple genomes, at a frequency exceeding 1% were removed 
(Figure 5.1). A control list of variants was also used as a filter. The control list contains 
indel variants from 114 unrelated exomes (Generated locally). All exome data 
comprising the control list had been sequenced in house using the Agilent 50Mb Whole 
Exome Targeting kit and the Illumina Genome Analyser IIx. The list was compiled by 
Dr. Helen Griffin (2012, pers. comm). All variants present within the control list at a 
frequency of more than 1% were removed. MutationTaster v20100416 (Schwarz et al., 
2010) was used to assess potential variant pathogenicity.  
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Figure 5.1. Filtering steps used to prioritise indel calls. 
 
 
5.4 Results 
5.4.1 Alignment results  
Average target base coverage ranged from 18 – 704x across all 133 samples. Between 
85 - 97% of the target bases were covered at least once, and between 25 - 93% of the 
target bases were covered to a minimum of 10 fold (Appendix table 5.1). 
  
5.4.2 BWA-Dindel pipeline 
Using the BWA-Dindel pipeline, an average of 696 non-unique indels were identified in 
each sample. This comprised 7223 unique indels, of which 3026 were insertions and 
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4197 were deletions. Insertions ranged in size from 1bp - 25bp’s long, with insertions of 
1bp long being the most frequent (Figure 5.2A). Deletions ranged in size from 1bp - 
40bp’s long, and as with the insertions, deletion lengths of 1bp were the most frequent 
(Figure 5.2B). 
After filtering 317 indels remained (Appendix table 5.2). 
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5.2A 
 
  
 
 
 
 
 
 
 
 
 
 
5.2B 
Figure 5.2 (A,B). Size distribution of insertions (5.2A) and deletions (5.2B) that I 
identified using the BWA-Dindel pipeline. 
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5.4.3 BWA-GATK pipeline 
Using the BWA-GATK pipeline, an average of 526 non-unique indels were identified in 
each sample. This comprised 2873 unique indels, of which 1272 were insertions and 1 
601 were deletions. Insertions ranged in size from 1bp - 24bp’s in length, with 1bp 
insertions being the most frequent (Figure 5.3A). Deletions ranged in length from 1bp 
long - 40bp’s long, with deletions of 1bp long being the most frequent (Figure 5.3B). 
 
After filtering 35 indels remained (Appendix table 5.3). 
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5.3A 
5.3B 
Figure 5.3 (A,B). Size distribution of insertions (A) and deletions (B) that I 
identified using the BWA-GATK pipeline. 
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5.4.4 Indels called by both pipelines 
Of the 317 filtered indels from the BWA-Dindel pipeline and the 35 filtered indels from 
the BWA-GATK pipeline, 25 were identified by both (Table 5.3). Two hundred and 
ninety two were unique to the BWA-Dindel pipeline, and 10 were unique to the BWA-
GATK pipeline (Table 5.4). 
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Chromosome Position Reference Variant Gene Alteration 
chr1 2235396 - G SKI frameshift insertion 
chr1 71418662 G - PTGER3 frameshift deletion 
chr1 92185675 - C TGFBR3 frameshift insertion 
chr1 120612003 GG - NOTCH2 frameshift deletion 
chr1 201334355 T - TNNT2 frameshift deletion 
chr1 202407190 T - PPP1R12B frameshift deletion 
chr2 66739381 - T MEIS1 frameshift insertion 
chr2 121747069 - A GLI2 frameshift insertion 
chr2 211179765 - T MYL1 frameshift insertion 
chr2 211179766 T - MYL1 frameshift deletion 
chr3 71090482 - C FOXP1 frameshift insertion 
chr4 123748299 - C FGF2 frameshift insertion 
chr9 139405664 C - NOTCH1 frameshift deletion 
chr10 88478558 - C LDB3 frameshift insertion 
chr10 92679010 - T ANKRD1 frameshift insertion 
chr10 99338053 G - ANKRD2 frameshift deletion 
chr11 2869086 - GG KCNQ1 frameshift insertion 
chr11 2869088 - GC KCNQ1 frameshift insertion 
chr12 115109685 - A TBX3 frameshift insertion 
chr12 124824739 - GCCG NCOR2 frameshift insertion 
chr12 124885147 - G NCOR2 frameshift insertion 
chr14 73664749 - GG PSEN1 frameshift insertion 
chr16 3778897 - C CREBBP frameshift insertion 
chr20 6750839 - G BMP2 frameshift insertion 
chr20 33334734 - A NCOA6 splice site 
 
Table 5.3. Indels which were identified by both the BWA-Dindel and the BWA-
GATK pipelines. All positions based on HG19 reference. 
 
 
 
Samples 
Unique indels 
(Total) 
Unique indels 
(Filtered) Found in both Unique to 
BWA-GATK 133 2873 35 25 10 
BWA-DINDEL 133 7223 317 25 292 
 
Table 5.4. Number of indels identified by both pipelines and the number of indels 
unique to each. 
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5.4.5 Indel validations 
Of the 25 indels identified by both pipelines 13 occurred in samples provided by the 
laboratory at Newcastle University and were therefore available for immediate 
validation. Of these, 6 were identified as true positives, 5 were found to be false 
positives, and 2 remain unconfirmed (Table 5.5). The remaining 12 indels occurred in 
samples that were not from Newcastle and I am still waiting for validation.  Therefore, 
of the 13 indels that occurred in available samples currently 6 have been proven to be 
true positives (Table 5.5). 
At the time of the writing of this thesis, the MYL1 deletion (Chromosome 2, position 
211179765) which is likely to be true because it is found within a variable T region and 
a single base deletion was validated one base pair position upstream from it, remains 
unconfirmed. There is also a recognised insertion of a “T”, rs71888939, which is one 
base position upstream from my validated insertion. I am also awaiting results for, the 
NOTCH2 variant (Table 5.5) that is located in a region where the primers were not 
specific enough (i.e. they aligned to two regions of the chromosome), and will have to 
be redesigned. Furthermore, I identified a 4 base pair long insertion (-/GCCG) in the 
NCOR2 gene. However, Sanger sequencing validated this variant as a reported 9bp (-
/GCCGCTGCT) insertion, rs77661573 (Table 5.6).  
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Chromosome Position Reference Variant Gene Validation notes 
chr1 2235396 - G SKI False 
chr1 71418662 G - PTGER3 True 
chr1 120612003 GG - NOTCH2 Unconfirmed 
chr1 201334355 T - TNNT2 True 
chr2 66739381 - T MEIS1 False 
chr2 121747069 - A GLI2 False 
chr2 211179765 - T MYL1 
Possibly true 
(Variable T 
region) 
chr2 211179766 T - MYL1 True 
chr4 123748299 - C FGF2 False 
chr9 139405664 C - NOTCH1 True 
chr10 99338053 G - ANKRD2 True 
chr11 2869088 - GC KCNQ1 False 
chr12 124824739 - GCCG NCOR2 
True, but 
validated as 9bp’s 
long 
 
Table 5.5. Number of indels identified by both analysis pipelines which were 
validated, or which were false positive calls. All positions based on HG19 
reference. 
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Gene Number of samples (%) EVS5400 1000genomes dbSNP Control list 
PTGER3 1(<1) 0 0.0041 0 0 
TNNT2 1 (<1) 0 0 0 0 
ANKRD2 1(<1) 0 0 0 0 
NCOR2 16 (12) 0 0 rs77661573 0 
MYL1 2 (1.5) 0 0 0 0 
NOTCH1 1 (1) 0 0 0 0 
 
Table 5.6. Variant frequency of the 6 validated indels which were identified using 
both pipelines. Sanger sequencing identified the NCOR2 variant as a 9 base pair 
SNP, rs7761573. 
 
 
5.5 Discussion 
Next-generation sequencing identified 25 potentially disease causing indels in 133 
patients suffering from congenital cardiovascular malformations. All of the identified 
indels were located in the coding regions of genes and resulted in frameshifts. As all of 
the targeted genes are suspected to be involved in cardiovascular malformations, these 
indels may be related to disease in these samples. However, further functional studies 
would still need to be conducted in order to identify the true consequences of these indel 
variants. 
 
Of the 25 indels called by both pipelines, 13 were identified in samples from Newcastle, 
and therefore available for immediate validation. Although a validation rate of only 46% 
was achieved, this is consistent with, or better than other studies reported in the 
literature. For example Weber et al. (2002), only achieved confirmation rates of 14% 
and 58% for indels of 1bp and 2bp’s long respectively. The 6 validated indels, all 
occurred in different genes, namely PTGER3, ANKRD2, NCOR2, MYL1, NOTCH1, and 
TNNT2. These genes will be discussed in more detail below. In addition, an indel was 
identified within the DSC2 gene in 7 of thesamples. This indel was not present in the 
final list as it had a frequency of 1.4% in the control list. However, it is a previously 
reported insertion and has been proposed to influence cardiovascular development 
(Beffagna et al., 2007; Syrris et al., 2007; De Bortoli et al., 2010; Gehmlich et al., 
2011). In addition, its population frequency has been estimated to be ~3% (Syrris et al., 
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2007; De Bortoli et al., 2010), and therefore its presence within the control list is not 
unexpected.  
 
5.5.1 Insertion and deletion, MYL1 
The Myosin Light Chain 1 (MYL1) gene is located at chromosomal position 2q33-q34, 
is 1052 base pairs long and comprises 7 exons (NCBI). I identified a single base 
insertion in one of the samples in MYL1 that resulted in a frameshift of the first exon. It 
is located within a variable T region and was therefore difficult to validate (See figure 
5.4). However, I also identified a single base deletion within the same variable T region 
in two additional samples. This deletion was only one base pair upstream from the 
previous insertion, and has been validated. It too results in a frameshift in exon 1 of the 
MYL1 gene. There is also a SNP located one base pair position upstream from my 
deletion, rs71888939. This highlights the variability of this gene region, and the 
possible difficulties in correctly identifying the positions of indels in this region. 
Despite this variability, MYL1 may still be of interest.  
The first stage in the development of the heart involves the formation of myofibrils in 
the cardiomyocytes, which allow for heart contraction (England and Loughna, 2012). 
Once fully developed, heart muscle contraction is accomplished by myosin containing 
filaments pulling on filaments composed largely of actin (Timson, 2003). Muscle 
myosin is a hexamer consisting of two myosin heavy chains (MHC) and four myosin 
light chains (MYL) (Barton et al., 1985; Timson, 2003; Rottbauer et al., 2006; England 
and Loughna, 2012). MYL chains are encoded for by eight genes, one of which is MYL1 
(England and Loughna, 2012). 
 
Genes encoding for MYL chains influence heart development, contraction and 
maintenance, and in model organisms, defects in these genes lead to hypertrophic 
cardiomyopathy (Shimada et al., 2009). More specifically, the myosin light chains are 
involved in the regulation of heart contraction (Timson, 2003), and disruption to these 
genes will severely affect cardiac function (Huang et al., 2003; Shimada et al., 2009). 
The study by Huang et al. (2003) suggests that myosin light chain 2 (MLC2a) is very 
important in the development of the atrial myofibrillar apparatus. They developed mice 
mutants with a non-functioning MLC2a gene, all of which died before birth due to 
severe atrial malformations. Also, Rottbauer et al. (2006) demonstrated that the removal 
of MLC2 function leads to a severe disruption of cardiac function in zebrafish. They 
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found that atrial and ventricular cardiomyocytes in zebrafish in which MLC2 function 
had been abolished, were unable to contract. 
 
The insertion at position 211179765, chromosome 2 (c.2_3insA), was identified in a 
single individual displaying a pulmonary atresia with intact ventricular septum (PAIVS), 
while the deletion at position 211179766, chromosome 2 (c.1delA), was identified in 
two individuals displaying non compaction and PAIVS respectively. Both variants occur 
in a highly conserved region early on in exon 1 (Figure 5.4) of the gene, were predicted 
as potentially disease causing, and are not present in the EVS5400, 1000 genomes or in 
the dbSNP databases (Table 5.6). The variants are also not present in the control list, but 
the indel was present in 8 random controls sequenced by Dr. Elise Glen. 
 
PAIVS is a rare congenital disorder, making up about 1% of all congenital cardiac 
disorders, and is characterised by a complete obstruction of blood flow from the right 
ventricle to the pulmonary trunk and left ventricle (Gutgesell, 1975; Trusler et al., 1976; 
Ashburn et al., 2004). It is a morphologically diverse malformation showing large 
variations in the anatomy of the right ventricle and coronary arteries (Bull et al., 1982; 
Mi et al., 2005). 
 
Non compaction cardiomyopthies are heart muscle disorders which can arise in either 
children or adults and manifest as heart failure (Engberding et al., 2010). As well as 
occurring as singular isolated cases, they can also occur within multiple members of 
families (Oechslin et al., 2000; Ichida et al., 2001; Engberding et al., 2010). The genetic 
causes of non compaction cardiomyopathies are diverse and have been shown to be 
caused by various genes such as MYH7, ACTC and TNNT2 (Klaassen et al., 2008). 
Chapter 4 of my thesis also highlights other genes which have been shown to be 
responsible for some forms of cardiomyopathy. 
 
The influence of myosin light chains on proper cardiac development, and subsequent 
function, make the MYL1 a good candidate for the disease gene in these three 
individuals. However, the variability of this region will make it difficult to assess the 
true impact of these indels on disease. 
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Figure 5.4. The position of the variable T region and the position of both indels which were identified in the MYL1 gene 
(http://genome.ucsc.edu). 
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5.5.2 Deletion, NOTCH1 
A single base deletion was identified in the NOTCH1 gene. The NOTCH1 gene is 
located at chromosomal position 9q34.3, is 9309 base pairs long and comprises 34 
exons (NCBI). The deletion results in a frameshift in exon 16 of the gene (c.2527delG), 
and brings the reading frame forward by one position. It is in a highly conserved region 
(Figure 5.5), was predicted to be potentially disease causing, and not present in the 
EVS5400, 1000 genomes, or dbSNP databases (Table 5.6). It was also not present in the 
control list. However, I can not confirm whether it is a de novo variant as at the time of 
writing my thesis the fathers DNA was not available. 
The NOTCH1 gene forms part of the highly conserved Notch signalling pathway which 
is involved in cell-cell communications, in particular, it is an integral pathway involved 
in cell-fate determinations (Gordon et al., 2008; de la Pompa and Epstein, 2012) and its 
signalling regulates organogenesis and cellular processes, including proliferation and 
apoptosis in mammals (MacGrogan et al., 2011). NOTCH signalling is especially 
important for the formation of the heart, which requires the coordinated development of 
multiple parts (de la Pompa and Epstein, 2012). There are currently four recognised 
NOTCH genes which all play a very important role in proper cardiac development 
(High and Epstein, 2008; MacGrogan et al., 2011; de la Pompa and Epstein, 2012).     
 
Disruptions to the Notch signalling genes have been shown to cause various 
cardiovascular developmental disorders (Krantz et al., 1999; Eldadah et al., 2001; Garg 
et al., 2005). MacGrogan et al. (2011) provide a good review of the role that NOTCH 
signalling plays in cardiac development. In particular during valve development, where 
the epithelial-mesenchyme transition, which is activated by endocardial Notch 
signalling, give rise to the valve primordial. For example, Garg et al. (2005) have 
demonstrated that mutations within the NOTCH1 gene can lead to aortic valve disease. 
They analysed a multi-generational pedigree with 11 cases of congenital heart disease, 9 
of which displayed aortic valve disease. Direct sequencing of the NOTCH1 gene 
revealed a R1108X nonsense mutation present in all cases. This variant was not found in 
unaffected family members or in 1 136 control samples. There are also many mouse 
models supporting the influence of the Notch pathway genes on cardiovascular defects 
(Krebs et al., 2000; Duarte et al., 2004). For example, Krebs et al. (2000) developed 
both NOTCH1-deficient and NOTCH4-deficient mice. The resultant embryos had severe 
abnormalities in angiogenic vascular remodelling. 
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The insertion I identified (Chromosome 9, position 139405664) was found in a patient 
with mitral valve atresia. Mitral valve abnormalities are often complex, with severe 
forms occurring rarely (Remenyi and Gentles, 2012). The true incidence is difficult to 
assess as it is often classified with other congenital cardiac malformations (Summerell 
et al., 1968). For example, in Marfan Syndrome where mitral valve disease is the 
leading cause of death in children suffering from this disorder (Ng et al., 2004). 
However, the genetic causes of some forms of non-syndromic cardiac valve diseases 
have also been identified, such as in isolated, non-syndromic valvular dystrophy (Kyndt 
et al., 2007). By sequencing the FLNA gene Kyndt et al. (2007) identified mutations in 
all of their 43 cases that were not present in unaffected family members or in 500 
controls.  
 
The influence of NOTCH1 in various cardiac disorders involving abnormal valve 
development (Garg et al., 2005; McKellar et al., 2007; McBride et al., 2008; Acharya et 
al., 2011) make this gene a good candidate for disease in this patient. 
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Figure 5.5. Indel which I identified in the NOTCH1 gene (http://genome.ucsc.edu). 
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5.5.3 Deletion, TNNT2 
The TNNT2 gene is located at chromosomal position 1q32, is 1153 base pairs long, and 
comprises 17 exons (NCBI). I was able to identify and validate a single base deletion in 
the TNNT2 gene (c.330delA). The deletion is in a conserved region and results in a 
frameshift in exon 9 of this gene (Figure 5.6). It was also predicted to be potentially 
disease causing by MutationTaster. TNNT2 is part of the troponin protein complex that 
regulates the interaction of myosin and actin, thereby influencing the contraction of 
vertebrate striated muscle (Zot and Potter, 1987; Morimoto et al., 2002; Huang et al., 
2009). The complex comprises three interacting proteins that stimulate contraction of 
the heart in response to the presence of Ca
2+
 (Morimoto et al., 2002; Parmacek and 
Solaro, 2004; Huang et al., 2009). 
Deletions within cardiac troponin T genes, such as TNNT2, have been shown to cause 
various cardiomyopathies, such as dilated cardiomyopathy (Kamisago et al., 2000; 
Morimoto et al., 2002; Villard et al., 2005) and hypertrophic cardiomyopathy (Forissier 
et al., 1996; Marian and Roberts, 2001). For example, by sequencing the TNNT2 gene, 
Forissier et al. (1996) were able to identify a Arg102Leu missense mutation found only 
in the four affected individuals. Mutation screening was performed using a single strand 
conformation polymorphism analysis and sequencing using the Biosystem 373A DNA 
sequencer. The variant was not present in the healthy family members, or in 92 healthy 
controls. Also, by sequencing various sarcomere protein encoding genes in a set of 
patients displaying dilated cardiomyopathy, Kamisago et al. (2000) were able to identify 
a three nucleotide deletion in troponin T in all the affected family members, but not in 
the healthy members of the family, or in 200 unrelated controls. 
 
The deletion was only identified in a single patient displaying Ebsteins Anomaly (EA). 
EA is a complex congenital malformation characterised by a structural deformity of the 
tricuspid valve that results in a wide range of morphological and physiological changes 
(Correa-Villasenor et al., 1994; Attenhofer Jost et al., 2007). The malformation results 
in the abnormal flow of blood through the right side of the heart resulting in right 
ventricular dilation in about 60% of patients with EA (Attenhofer Jost et al., 2007). 
Various genes have been found to cause EA, such as GATA4 and NKX2.4 (Digilio et al., 
2011). However, the enlargement of the heart chambers and decreased cardiac function 
through chamber enlargement seen in EA and the strong influence of TNNT2 mutations 
132 
 
on cardiomyopathies implicates this gene as possibly disease causing in this individual. 
Other possible genetic causes of EA have been discussed in more detail in chapter 4. 
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Figure 5.6. Position of the identified indel in the TNNT2 gene (http://genome.ucsc.edu). 
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5.5.4 Insertion, DSC2 
The DSC2 gene is found at chromosomal position 18q12.1, is 5257 base pairs long, and 
comprises 17 exons (NCBI). I identified a E896fsX900insertion in a conserved region 
of the DSC2 gene (Figure 5.7), that was predicted to be potentially disease causing. It 
was found in 7 of the samples, but was not present in my final table because it had a 
frequency >1% in  the control list. The presence of this insertion within the control list 
is expected as it is known to have a low level population frequency estimated to be ~3% 
(Syrris et al., 2007; De Bortoli et al., 2010). The insertion was identified in the final 
exon (Exon 17) of the gene, and affects the final 4 amino acids of the exon, truncating 
the protein. It was found in ~5% of the samples, and not present in the dbSNP database. 
However, it is present in the 1000 genomes project at a frequency of 1%. The difference 
in allele frequencies between the samples and the 1000 genomes is significant 
(p=0.00026). This specific variant has been previously reported in a number of studies 
assessing its potential as a cause of right ventricular cardiomyopathy (Syrris et al., 2006; 
De Bortoli et al., 2010; Gehmlich et al., 2011).   
A study by De Bortoli et al. (2010) found the variant in 5 of their 112 cardiomyopathy 
cases (allele frequency = 2.2%) but also in 6 out of 200 (allele frequency = 1.5%) of 
their healthy controls. This difference is not statistically significant and while not able to 
show an association of the insertion with disease, a functional analysis showed that the 
insertion altered the proper desmosomal localisation along cell boundaries. Also, 
alternative splicing produces two DSC2 isoforms, DSC2a and DSC2b (Syrris et al., 
2006). The insertion only alters the DSC2a isoform and not the DSC2b isoform, and it is 
possible that DSC2b is compensating for the alteration in DSC2a in the control samples 
in which the insertion was identified (De Bortoli et al., 2010). Syrris et al. (2006) state 
that due to the importance of desmocollins for cell adhesion, mutations in these genes 
would result in the decreased desmosome function and the possible detachment and 
death of cardiac myocytes, therefore negatively influencing cardiac development. 
 
The patients in whom this variant was identified suffered from a range of cardiac 
abnormalities including EA, non compaction, PAIVS, right ventricular hypoplasia, 
double inlet left ventricle and hypoplastic left heart syndrome. Although, this variant 
has been reported to largely cause right ventricular cardiomyopathies (Syrris et al., 2006; 
De Bortoli et al., 2010; Gehmlich et al., 2011), its potential effect on cardiac myocytes 
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and therefore proper cardiac development could implicate it in a range of other cardiac 
developmental disorders. 
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Figure 5.7. Position and degree of conservation of the indel which I identified in the DSC2 gene (http://genome.ucsc.edu). 
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5.5.5 Deletion, PTGER3 
The PTGER3 gene is a little known gene located at chromosomal position 1p31.2 
(http://www.ncbi.nlm.nih). This gene is expressed in the heart and is part of the G-
Protein coupled receptor family, and is one of the four receptors of Prostaglandin E2 
which may be involved in several biological functions. The gene is involved in various 
pathways, some of which influence smooth muscle contraction and relaxation, figure 
5.8. For example, PTGER3 interacts with KNG1 and PTGER1 which both influence 
smooth muscle contraction (http://www.genecards.org). 
 
I identified a c.1185delC deletion in the PTGER3 gene in a single individual suffering 
from EA. The deletion is located in chromosome 1 at position 71418662 and results in a 
frameshift in the last exon of this gene (exon 4). It was predicted to be potentially 
disease causing and is in a region which is conserved in three other organisms (Figure 
5.9), however, it is described as being intronic in all but one of the known transcripts 
(NM_198718). It is not found in the EVS or dbSNP databases, but the variant has been 
seen in the 1000 genomes at a frequency of below 1% (Table 5.6). Also, at the time of 
writing this thesis, the presence of this variant had not been validated in the parents, so I 
am unsure whether it is de novo. 
Due to the limited information on this gene and the fact that the deletion occurs in the 
final exon of PTGER3, as well as it being described largely as an intronic region, it 
would be very difficult to identify the influence of this variant on disease in this patient. 
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Figure 5.8. Genetic pathway interactions of the PTGER3 gene. From 
http://www.genecards.org. 
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Figure 5.9. The deleted base from the PTGER3 gene (http://genome.ucsc.edu). 
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5.5.6 Deletion, ANKRD2 
The ANKRD2 gene encodes the ANKRD2 protein which is one of the three members of 
the conserved muscle ankyrin repeat proteins that may be involved in muscle stress 
response pathways (Miller et al., 2003). Human Ankrd2 is similar to proteins found in 
mice, rats and rabbits, but in all these organisms they are expressed predominantly in 
cardiac muscle, however in humans they are expressed predominantly in skeletal muscle 
(Pallavicini et al., 2001; Belgrano et al., 2011). It has been hypothesised, that although 
the human and mice proteins may be functionally related, they may well show 
specialisation for the tissues they are expressed in (Pallavicini et al., 2001), therefore 
may not be active in the heart. 
 
I identified a frameshift deletion in chromosome 10 (c.327delG) in the ANKRD2 gene in 
a patient which suffers from double inlet left ventricle. At the time of writing my thesis, 
this variant had not been validated in the parents yet. The deletion was identified in a 
conserved region of the gene (Figure 5.10), and was predicted to be potentially disease 
causing. However, because of the features of Ankrd2 described above, I am unable to 
state whether this gene is a plausible candidate for disease in this patient.  
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Figure 5.10. The position and extent of conservation of the deleted base identified in the ANRD2 gene (http://genome.ucsc.edu). 
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5.5.7 Insertion, NCOR2 
The NCOR2 gene encodes a nuclear receptor co-repressor responsible for the mediation 
of transcription silencing in certain genes.  The gene encodes for a protein member of 
thyroid hormone and retinoic acid receptor associated co-repressors 
(http://www.genecards.org). This gene is part of the NOTCH signalling pathway (Figure 
5.11), which as described earlier, is a very important pathway in heart development. 
 
I identified a frameshift variant (c.5470_5471insCGGC) in exon 37 (Of 47) in this gene. 
The variant was identified in 16 patients suffering from a range of cardiac 
malformations including EA, noncompaction, tricuspid atresia, univentricular heart, 
pulmonary atresia with intact intraventriculal septum, and double inlet ventricle. The 
variant is located in a region conserved across a range of organisms (Figure 5.12), and 
was predicted to be potentially disease causing. However, the variant was validated as a 
9bp insertion (/GCCGCTGCT) that is located in dbSNP (rs77661573), meaning that it is 
in fact not frameshifting. Also, rs77661573 is identified in the majority of people in the 
EVS database, and was validated using Sanger Sequencing (Dr. Elise Glen) in 7 random 
controls. The variant is also present in both parents. Therefore, this variant is likely not 
responsible for disease in these patients. 
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Figure 5.11. The NOTCH1 signalling pathway and the NCOR gene in this pathway 
(http://pathwaymaps.com).  
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Figure 5.12. The inserted bases from the NCOR2 gene (http://genome.ucsc.edu). 
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5.6 Conclusions 
Using two different indel calling pipelines I was able to identify potentially disease 
causing variants in a group of 133 patients suffering from various congenital 
cardiovascular malformations, 46% of which were validated.  All genes studied in this 
experiment had been selected for their influence on cardiac development and function, 
so it is possibly questionable to assert that certain genes out of the selected 403 are of 
greater interest than others a posteriori.  However, it is noticeable that four of the genes 
harbouring indels are known causative genes for human cardiovascular disease, namely 
MYL1, NOTCH1, TNNT2, and DSC2. However it is important to note that these results 
do not infer causality, and despite their potential to influence disease in these patients, 
functional studies still need to be performed on these indels to assess their functional 
importance in cardiovascular development.   
 
An important future direction for this work is to validate whether these indels are de 
novo. At the writing of this thesis, DNA was only available for some of the parents. 
Therefore, I could not assess whether all of the variants I identified were in fact de novo. 
Since these cases are assumed not to come from Mendelian families,  Iassumed that in 
most cases, rare, de novo variants are responsible for disease in these patients. This 
would need to be assessed further. 
 
The selection of the BWA-Dindel and BWA-GATK pipelines was done at the onset of 
the study based on current knowledge available in the literature; many studies had 
demonstrated that these were the most appropriate indel callers available at the time. 
Also, as this study progressed, so did the work in chapter 3 in which I designed a novel 
method for assessing the performance of NGS variant calls. Indeed, in my analysis 
BWA-Dindel and BWA-GATK did achieve the highest sensitivity values, in comparison 
to the other pipelines.  
 
As the data chapters (Chapters 3, 4, and 5) of my thesis each contain in depth 
discussions, the summary discussion (Chapter 6) which follows, will recap the main 
findings of my thesis and highlight the areas which I think are important. It will also 
focus on the limitations and future directions of this work. 
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Chapter 6. Summary Discussion 
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6.1. Summary of findings 
The aim of my PhD was to use NGS methods to identify rare, potentially disease 
causing variants involved in various diseases, particularly in CVM. My thesis took the 
form of three linked sub-projects, which developed concurrently with one another. In 
the first, I developed a novel approach to calculate the sensitivity and specificity of 
variant calls in NGS data using population SNP frequency information. This method 
allowed me to test the performance of various alignment and variant calling 
programmes. The NovoAlign-Samtools pipeline achieved the highest sensitivity and 
specificity values for identifying single nucleotide substitutions, and the BWA-Dindel 
and BWA-GATK pipelines achieved the highest sensitivity and specificity values for 
identifying indel variants.  
The three pipelines mentioned above were used in the remaining two sub-projects of my 
PhD. In the first of these, I attempted to identify potentially disease causing variants in 
three families with disorders appearing to segregate in a Mendelian dominant fashion.  
These were atrioventricular septal defect (AVSD), dilated cardiomyopathy (DCM) and 
hereditary sclerosing poikiloderma (HSP). In the pedigrees where cases presented with 
DCM and HSP I was able to identify potentially disease causing variants in plausible 
candidate genes for disease. In the second sub-project, I used NGS to identify 
potentially disease causing and novel variants in a group of unrelated individuals 
suffering from various CVMs selected (by my colleagues in clinical cardiology) to 
involve either right or left ventricular hypoplasia.  In these analyses I focused on indel 
variants, given the recognised challenges in correctly identifying these variants.  In the 
133 cases, evaluated for 403 candidate genes, I discovered 4 previously undescribed, 
frameshifting indels that, given the strong evolutionary constraints on such indels and 
the known consequences of variants in these genes, have a high a priori likelihood of 
being related to disease.   
Since historically CVM has been a condition with a high early mortality, selective 
pressure on causative variants is likely to have been strong.  Therefore, with regard to 
the adoption of NGS methodology in “sporadic” cases, it was a reasonable hypothesis 
when I commenced my project that common variants causing an increase in CVM risk 
might not exist, or be very few in number and of very small effect.  I reasoned that risk 
alleles were more likely to be rare in the population, justifying a sequencing approach.   
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6.2 Limitations of this work 
Limitations of the method proposed in chapter 3 
My method for calculating sensitivity and specificity provided comparable results to 
methods requiring microarray data. Using this method, I was able to compare different 
variant calling pipelines and identify the best performing pipelines as those generating 
the highest sensitivity and specificity values. However, in the case of specificity, values 
are always close to 1. In fact, specificity values substantially lower than 1 would make 
NGS non-viable, as the number of false positives would be too large. Therefore, it is 
necessary to assess very small differences between pipelines in assigning a rank order. 
In instances where the number of variants is not high, such as was the case for indels, 
this assessment is difficult. This is not strictly a limitation of my method, but more a 
limitation of available data. 
I made use of the HapMap and 1000 genomes databases to obtain population allele 
frequency information. I could increase the number of markers by including information 
from other databases. However, there is a large amount of overlap between the different 
databases, therefore this will not lead to a substantial increase in the number of markers.   
An alternative means to increase the number of available markers for the calculation of 
specificity would be to include sites for which there are no reported variants and assume 
a low minor allele frequency for all of these sites. This would increase the number of 
sites used and improve the ability to estimate specificity. Additionally, since I was 
interested in using NGS to identify rare variants responsible for disease, it may be 
appropriate to use all the polymorphisms present in the coding regions, and possibly in 
regions outside of these. Although the results are not presented I did indeed try this by 
making use of all of the HapMap SNPs which were present in the Agilent whole exome 
targets, not just the on-target SNPs represented in the microarray. This resulted in a 
lower sensitivity being achieved for all pipelines, with the NovoAlign-Samtools 
pipeline achieving the highest sensitivity of ~85%. One possible reason for this drop in 
sensitivity is that the polymorphisms present on microarrays represent a selection based 
on criteria that include the probability of being efficiently typed. It is possible that NGS 
is accurate, or inaccurate, in exactly the same regions. 
Results presented in chapter 3 based on my approach had indicated little difference in 
specificity between the GATK and Dindel pipelines. However, empirical evidence 
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presented in chapter 5 indicated that there was in fact a difference in specificity values 
between the two pipelines with respect to indel calling. After filtering, the BWA-GATK 
pipeline only identified 35 indels, while the BWA-Dindel pipeline identified 317 indels. 
Variant calls from the BWA-Dindel pipeline achieved a laboratory validation rate below 
30%, whereas when using the BWA-GATK pipeline a validation rate approaching 50% 
was achieved, indicating a significantly higher specificity with BWA-GATK that had 
not been detected using my method. The explanation for this apparent discrepancy is 
related to variation between the read coverage parameter selected in the two chapters.  
Due to the large number of windows produced when using the Bowtie2 aligner in 
combination with Dindel in chapter 3, a minimum threshold of 7 reads covering each 
indel variant had to be applied in all instances where Dindel was used. For all other 
indel callers tested in chapter 3, the default parameters were used, which only impose a 
minimum threshold of 1 read covering each indel. However, the BWA-Dindel pipeline 
in chapter 4 and 5 generated far fewer windows and as such I was able to make use of 
the default parameter sets (a minimum threshold of 1 read covering each indel). Due to 
the variability in the performance of different indel calling pipelines, to increase the 
confidence of the indel calls in chapter 5, I used the intersection of both the BWA-
Dindel and BWA-GATK pipeline. This approach seemed to increase the validation rate 
and remove many of the false positive calls.   
As well as the method I proposed, there are other performance measures which could be 
used. For example, a popular performance metric is the proportion of identified variants 
at sites known to be polymorphic. The known polymorphic sites are obtained from 
databases such as dbSNP and the 1000 genomes. Although this is a commonly used 
method to assess the performance of a variant calling pipeline, it will not allow for the 
identification of the best performing pipeline, because  this estimate will be very high 
(>95%) in most cases. Also, the proportion of identified variants matching SNPs in 
public databases is likely to increase in the future as methods improve and as the 
number of SNPs in these databases increases. The increasing number of variants in 
these databases will mean that an even greater proportion of identified variants will 
match the polymorphic sites. However, this will also increase the power of my method 
for calculating sensitivity and specificity by providing a greater number of allele 
frequencies. Using the proportion of identified variants matching polymorphic sites in 
public databases as a performance measure may also bias results towards a particular 
pipeline. For example, using an analysis pipeline to identify variants, and then assessing 
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its performance by matching the identified variants to a database which used the same 
(or a very similar) pipeline, will obviously lead to high degree of concordance. 
An alternative performance metric to use could be by assessing base call quality, 
alignment quality or coverage. These measures are often used as performance metrics in 
the literature; however they only assess the performance of the base caller and aligner, 
not the entire pipeline. Conversely, my method provides a means of assessing the 
performance of an entire NGS analysis pipeline. However, all these methods could 
certainly be used in conjunction with one another to provide a complete overview of all 
aspects of the pipeline used in an NGS experiment.  Further work could be undertaken 
to provide an appropriate framework to unify these methods and provide a suitable user 
interface for routine use; however, this was beyond the scope of the present work. 
 
Limitations of causative variant identification in chapter 4 
I was able to identify potentially disease causing variants in plausible candidate genes in 
both the DCM and the HSP pedigrees, but not in the AVSD pedigree. These genes were 
identified as potential candidates based on the current understanding of their function, 
as identified from databases such as OMIM. However, there are possibly many genes 
for which no functional information or influence on disorders displaying similar 
characteristics may be available, but which may still influence disease in these 
pedigrees. For example, in the case of the FAM111B gene I identified in the HSP 
pedigree. There is very little information available for this gene, and had it not been for 
the second pedigree which was identified by my collaborators in Nantes, France, I 
would not have identified this gene as a plausible candidate for disease in this family. 
There are also several other potential reasons for failure to identify a likely causative 
variant in the AVSD pedigree.  First, the causative variants may not have been captured 
by the exon capture kit, due to the various technical limitations of the method, or they 
may have been removed by one of the filtering steps (See chapter 3 and 4). In particular, 
the causative variant may well occur outside of the exonic regions. 
Also, I relied on the MutationTaster programme to assess the potential pathogenicity of 
the variants. Many studies have highlighted the potential shortfalls of using such 
prediction programmes (See chapter 4 and 5). Indeed, had it not been for the 
identification of a second HSP pedigree, I would likely have removed the FAM111B 
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gene as a plausible candidate as the variant was not predicted to be disease causing by 
MutationTaster. 
Another possibility is that the variants causing disease in the AVSD pedigree are not 
necessarily distinct in all four affected individuals. One of the filtering steps I used 
involved selecting only variants common to all the affected individuals. This of course 
assumes that the presence of affected individuals with AVSD is as a result of them 
having inherited the same disease causing variant (Bamshad et al., 2011). However, this 
may not necessarily be true and there is a chance that for at least one of the affected 
individuals in the pedigree, disease is as a result of a variant which was not inherited 
(Gilissen et al., 2011).  
 
Limitations of causative variant identification in chapter 5 
Recent data from the 1000 Genomes and EVS projects indicate that frameshifting indels 
are not only much rarer than non-synonymous single nucleotide substitutions, but that 
they are evolutionarily younger, and therefore a priori have a higher likelihood of being 
disease-causing. However, due to the difficulties involved in identifying indels, if 
disease was indeed caused by such variants there is a chance that the causative variant 
was not identified in my analysis. Additionally, methods for identifying copy number 
variants using NGS approaches remain at an early stage of development; I did not 
attempt to study CNVs in my present work. Previous observations indicate that CNVs 
do indeed contribute to CVM risk (Greenway et al., 2009; Soemedi et al., 2012); 
however, in the analysis of sporadic patients, any that had been shown to have a 
potentially causative CNV (>1Mb) based on analyses done by others within the host lab 
on SNP chip data were removed from analysis. 
One of the main limitations of this work is that of sample size. For instance, using 
simulated data, Kiezun et al. (2012) expect that over 10 000 exomes would be required 
to achieve sufficient statistical power to detect associations of rare variations with 
complex traits. This was highlighted in a study investigating the role of rare genetic 
variants in breast cancer, which targeted 507 genes implicated in DNA repair and 
sequenced these on an Illumina HiSeq2000 in  1 150 cases (Ruark et al., 2013). The 
study identified 1 044 protein truncating variants, and stratified the genes based on the 
number of different, rare truncating variants present in the samples. The PPM1D gene 
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was the most overrepresented in this regard. To further explore the role of PPM1D in 
breast and ovarian cancer they performed a large scale case-control replication 
experiment using 7 781 unrelated individuals with breast and/ovarian cancer and 5 861 
controls. They identified protein truncating variants in 25 of the 7 781 cases, and only 1 
of the 5 861 controls (p=1.12 x 10
-5
). This study highlights the large sample sizes which 
are likely to be required in such a case-control study.  The relatively small sample size 
in this work represented all the patient resource from a multi-centre international 
collaboration, since the CVM phenotypes I studied are rare.  The seriousness of the 
conditions and their rarity led to thehypothesis at the outset of this work that rare 
deleterious variants might be significantly over-represented in cases, even in a relatively 
small discovery cohort.  The work was commenced before the bulk of the 1000 
Genomes data (eg the paper of MacArthur et al. 2012) was released showing a large 
excess of rare variants in the population, due to bottlenecks and weak selection, 
compared to what would be predicted from previous simulation-based studies. The 
discovery from that data that each of us harbours about 100 strictly defined loss of 
function alleles and 20 fully inactivate genes, with more than 50 heterozygous OMIM 
alleles, clearly mandates much larger studies if rare variants are to be successfully 
identified. 
  
Issues of causality 
It is important to note that even though variants were identified in plausible candidate 
genes, this does not imply causality. For infrequently occurring or unique variants, 
laboratory validation for each variant may be the only route to establishing a causal 
relationship.  For more frequently occurring variants, or aggregated variants within 
particular genes, causality may seem more likely where there is an overrepresentation of 
variants in cases when compared to controls (thus establishing association). However, 
causality still remains an experimental issue that was beyond the scope of this work.  Of 
note, even among common variants identified by GWAS in various diseases, molecular 
mechanisms accounting for the associations have in general yet to be discovered.  
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6.3. Future directions 
Bioinformatic challenges 
As the method proposed in chapter 3 is simple to implement, it would be possible to 
integrate it into a variant caller. It could then be used in much the same way as the 
recalibration steps used by the GATK variant caller to improve variant calls. The benefit 
of such a procedure was demonstrated in chapter 3 where a base quality >20 resulted in 
a large drop in sensitivity, while a base quality of >30 only resulted in a small increase 
in specificity. The ideal analysis pipeline should maximise sensitivity and specificity by 
optimising analysis parameters such as the base quality threshold. 
A further aspect which would have to be considered in any future work would be 
whether or not to carry out whole genome sequencing. In both the analysis of the family 
data and in the analysis of the unrelated HeartRepair samples a targeted sequencing 
approach was used. For the family data a whole exome targeting approach was used, 
and for the analysis of the unrelated samples, the exons of 403 genes were targeted. 
Possibly a better option would be to sequence the whole genome in all samples as this 
would capture more of the genetic information. However, a major problem with whole 
genome sequencing is that it will identify a great many variants for which very 
little/nothing is known.  Also, the costs of whole genome sequencing are very high, for 
which a low coverage yield is obtained. Most whole genome sequencing experiments 
only achieve a coverage of ~10 fold. In chapter 3, I demonstrated that at a coverage of 
10 fold, the sensitivity is only ~20%. However, whole genome sequencing does benefit 
from not having an enrichment step and the associated biases of enrichment. 
Also, as mentioned earlier, it is quite possible that the diseases in these cases are not 
caused by single base substitutions or by indels. Of particular interest would be the 
identification of CNVs. At the time of writing my thesis, methods for identifying CNVs 
robustly using short-read NGS data had not been well established or tested, and I did 
not attempt to identify these types of genetic variants. However, large CNVs should be 
identified and assessed in any future analysis. 
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Future work for the variants identified in chapter 4 
I was able to identify three genes of particular interest in the HSP family, namely 
FAM111B, AGAP6, and CNTNAPSB. These three genes are of great interest because 
they were mutated in both HSP pedigrees. Due to the rarity of HSP, identifying genes 
mutated in both the unrelated pedigrees should be prioritised in any future work. For 
FAM111B, my collaborators are currently performing skin biopsies on both pedigrees.  
FAM111B expression in skin fibroblasts will be compared, and the expression levels of 
“classic” fibrotic genes (eg Collagen 1, TIMP-1, TGFB1, PDGF) evaluated in 
fibroblasts from case and control patients. Although I will not be directly involved in 
these analyses, a similar approach can also be taken for the AGAP6 and CNTNAPSB 
genes, where expression levels in cases and controls could be compared.  
It is also possible to use exome data from a small number of samples to perform 
association tests between cases and controls. Samtools, for example, provides some 
functionality in this regard. However, these methods are not widely used, largely 
because they have not been thoroughly tested. However, methods such as these could 
provide extra supporting evidence for my results. Recently, methods have also been 
developed to identify CNV’s using only a small number of exomes. The potential 
importance of CNV’s in disease has been discussed throughout my PhD, and even 
though methods for CNV detection using only a small number of exomes are presently 
limited, it would be an important step in any future analysis on these samples.  
 
Future work for the variants identified in chapter 5 
With regards to the HeartRepair study of sporadic CVM cases, the sequencing will be 
repeated in cases and controls in a replication cohort on the genes of interest. Of 
particular interest are the MYL1, NOTCH1, TNNT2, and DSC2 genes, because they are 
known causative genes for human cardiovascular disease. A similar approach has been 
performed for the single nucleotide polymorphisms which have been identified by 
collaborators in Belgium. Dr. Elise Glen (University of Newcastle) used the EVS 
database as a control database to obtain allele frequencies for the 403 genes used in the 
HeartRepair study. She then compared the allele frequencies from the 133 cases against 
this set of controls using a chi-square test. In this first round of analysis, the NKX2.3 
gene was found to be overrepresented for variants in the cases (chi2 = 1.17E-06). A 
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similar approach could be used for the indel data to identify any genes showing an 
overrepresentation of variants; however, far larger numbers of samples would need to 
undergo targeted capture and sequencing in order to provide a sufficient number of 
indels to enable any such statistical comparison to be conducted.  This could be used as 
a test case, and if any genes are shown to be overrepresented, additional cases and 
controls could be sequenced. 
 
6.4 Concluding remarks 
During my PhD, I developed a method to calculate the sensitivity and specificity of 
NGS variant calls, which unlike current methods, does not require microarray data as a 
reference. It is a fast and simple to use method which can be used to test the 
performance of an entire NGS analysis pipeline. Using a whole exome sequencing 
approach I was also able to identify potentially disease causing variants in three families 
displaying Mendelian disorders. Additionally, using targeted sequence data I was able 
to identify potentially disease causing indels in group of unrelated individuals suffering 
from various sporadic CVMs.  
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Appendices: 
 
use warnings; 
use Getopt::Long; 
my $Index=""; 
my ($command1, $command2, $command3=""; 
GetOptions ("CWD:s"=>\$command1,"InputFile:s"=>\$command2,"SampleId:s"=>\$command3); 
my $CWD=$command1; 
my $Input=$command2; 
my $Id=$command3; 
my $CurrentDir=$CWD; 
chomp $CurrentDir; 
my @DirContent=`ls $CurrentDir`; 
my $file="$CurrentDir/$Input"; 
my $ConvertedFile=ConvertFileForMutaionTaster($file,$Id); 
my $snp2snippetOut=$CurrentDir."/snp2snippetResults_hg19_".$Id.".txt"; 
my $ErrorsRemoved=$CurrentDir."/snp2snippetResults_hg19_".$Id.".txt_ErrorsRemoved"; 
`perl snp2snippet.pl $Input -g ref.fa -t EnsemblTranscripts_37.R59.tsv > $snp2snippetOut`;  
`perl snp2snippet_removeSBVerrors.pl --file $snp2snippetOut`; 
`perl mutation_taster_batch_query.pl -i $ErrorsRemoved`; 
`perl mutation_taster_results.pl`; 
 
sub ConvertFileForMutaionTaster{ 
 my $file=$_[0]; 
 my $Id=$_[1]; 
open FILE, $file; 
my $out=”Output.txt”; 
open OUT, “>>$out”; 
while(<FILE>){ 
  chomp $_; 
  my @SplitLine=split('\t', $_); 
  my $Position=$SplitLine[2]; 
  my $Id=$SplitLine[0]."_".$Position."_".$Position."_".$SplitLine[3]."_".$SplitLine[4]; 
  print OUT “$SplitLine[0]\t$Position\t$SplitLine[4]\t$Id\n"; 
} 
close FILE; 
close OUT; 
return($Out); 
exit; 
 
Script 2.1 Script used to run MutationTaster. 
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#!/usr/bin/perl -w 
my $currentdir=`pwd`; 
chomp $currentdir; 
my @dircontent=`ls $currentdir`; 
my %insertion=(); 
my %deletion=(); 
my $in="Input.txt"; 
open IN, "$in"; 
while(<IN>){ 
        chomp $_; 
        my @splitline=split('\t', $_); 
        if(length $splitline[3]==1){ 
                my $inslength=length $splitline[4]; 
                my $adjinslength=$inslength-1; 
                if(!exists $insertion{$adjinslength}){ 
                        $insertion{$adjinslength}=1; 
                }else{ 
                        $insertion{$adjinslength}=$insertion{$adjinslength}+1; 
                } 
        }elsif(length $splitline[4]==1){ 
                my $dellength=length $splitline[3]; 
                my $adjdellength=$dellength-1; 
                if(!exists $deletion{$adjdellength}){ 
                        $deletion{$adjdellength}=1; 
                }else{ 
                        $deletion{$adjdellength}=$deletion{$adjdellength}+1; 
                } 
        } 
} 
close IN; 
exit; 
 
Script 2.2 Script used calculate the size distribution of insertions and deletions. 
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my $out="Output.txt"; 
open OUT, ">>$out"; 
my %gatk=(); 
my $gatk="gatkinput.txt"; 
open GATK, "$gatk"; 
while(<GATK>){ 
chomp $_; 
if($_=~/chr\S+/){ 
my @splitline=split('\t', $_); 
$match=”$splitline[0].$splitline[1].$splitline[2].$splitline[3].$splitline[4].$splitline[5].$splitline[6]”; 
$gatk{$match}=1; 
}} 
close GATK; 
my $counter=0; 
my $dindel="bwainput.txt"; 
open DINDEL, "$dindel"; 
while(<DINDEL>){ 
chomp $_; 
if($_=~/chr\S+/){ 
my @splitline=split('\t', $_); 
$match=”$splitline[0]$splitline[1].$splitline[2].$splitline[3].$splitline[4].$splitline[5].$splitline[6]”; 
if(exists $gatk{$match}){ 
my @splitvalues=split('_',$gatk{$match}); 
print OUT 
"$splitline[0]\t$splitline[1]\t$splitline[2]\t$splitline[3]\t$splitline[4]\t$splitline[5]\t$splitline[6]\n"; 
}else{ 
$counter++; 
}}} 
close GATK; 
close OUT; 
print $counter; 
exit; 
 
Script 2.3 Script used to identify variant overlaps between the BWA-Dindel and 
BWA-GATK pipelines. 
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Gene name         
ACTC1 NTF3 HOPX hsa-mir-133a-1 ARSE 
ACTN2 NTRK3 HSPB7 hsa-mir-133a-2 CLIC2 
ACVRL1 (ALK1) PDGFA IGF1 hsa-mir-208a SRY 
ADAM17 PDLIM3 IGFBP3 hsa-mir-208b TNNI1 
ADAM19 PDPK1 ISL1 hsa-mir-15b TNNI2 
ADRB1 PHC1 ITGA11 hsa-mir-15a NPTX1 
BMP2 PITX2 ITGA4 hsa-mir-21 SPOCK3 
BMP4 PKP2 ITGA7 mmu-mir-715 
 
BMP10 PLN ITGB1BP2 mmu-mir-190 
 
BMPR1A PPP3R1 (CNB1) ITGB1BP3 mmu-mir-22 
 
BMPR1B PRKAG2 (AMPK) JAK2 mmu-mir-199a-1 
 
BRAF PTPN11 JPH1 mmu-mir-15a 
 
CAV3 RXRA LAMA2 mmu-mir-378 
 
CFC1 RYR2 LAMA5 mmu-mir-466j 
 
CHD7 SALL1 LBR mmu-mir-17 
 
CITED2 SCN5A LBX1 mmu-mir-23a 
 
CREBBP SEMA3C LIMK1 mmu-mir-143 
 
CRELD1 SGCB MAP2K3 mmu-mir-23b 
 
CRYAB SGCD MAP2K6 mmu-mir-1186 
 
CSRP3 SGCG MAP3K7IP1 hsa-mir-23b 
 
DES SLC2A4 MAPK12 hsa-mir-27b 
 
DSC2 SLC6A6 MBNL1 hsa-mir-130a 
 
DSG2 SLC8A1 MBNL3 hsa-mir-106a 
 
DSP SMYD1 MEF2A hsa-mir-199a-1 
 
EGFR SOX9 MEF2B hsa-mir-199a-2 
 
ELN SRF MEF2D hsa-mir-22 
 
ERBB2 TAZ MET hsa-mir-199b 
 
ERBB3 TBX1 MIB1 hsa-mir-202 
 
ERBB4 TBX2 MKL2 DGCR14 
 
EVC TBX20  MRAS CLTC 
 
FBN1 TBX3 MTPN IL15 
 
FGF2 TBX5 MUSK DVL2 
 
FGF8 TCAP MYL1 SC5DL 
 
FGF9 TEAD1 MYL4 TFAP2B 
 
FGFR1 TGFB2 MYL5 CECR1 
 
FGFR2 TGFBR3 MYL6 CUGBP2 
 
FOXC1 TMEM43 MYL6B PAX3 
 
FOXC2 TMPO MYL9 DRAP1 
 
FOXM1 TNNC1 MYOCD IGF2 
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Table 2.1 Continued 
FOXP1 TNNI3 MYOD1 NODAL 
GAB1 TNNT2 MYOG CECR2 
GATA4 TPM1 MYOM1 EXT1 
GATA5 TXNRD2 MYOM2 SATB1 
GATA6 UFD1L PBRM1 NR2F2 
GJA1 VCL PGAM2 DRG2 
GJA5 VEGFA POU6F1 RAI1 
GLA WNT7b PPP1R12A IRX5 
HAND1 ZFPM1 PPP1R12B DGCR2 
HAND2 ZFPM2 (FOG2) PPP3CA DVL1 
HBEGF ZIC3 PPP3CB ENG 
HDAC2 SMAD6 PRDM6 KCNJ2 
HDAC5 ROCK1 PRKAR1A NR2C2 
HDAC7A WNT5a PRKCA Irx3 
HDAC9 ISL1 PRKDC PLXNA2 
HEY1 FOXA2 PRKG1 Hoxb2 
HEY2 BOP1 PSEN1 HTR2B 
HHEX ANK2 PTGER3 SHH 
HIRA ANKRD2 PTGER2 KCNQ1 
HOPX (HOP) ANKRD1 PTPRJ KCNE1 
HOXA3 BARX2 RAB3GAP2 NFATC4 
HRAS BARX1 SHOX2 CITED1 
IDUA CASQ2 SMYD1 NFATC1 
IGF1R CAV2 SOX15 NSD1 
INSR CNBP SOX2 FKBP6 
IRX4 CTF1 SOX6 TBL2 
JAG1 CXADR TBX18 NDN 
JAG2 DNER TEAD1 UBE3A 
JUN DVL3 WNT3A PRKCZ 
JUP EDN2 SIRT2 EXO1 
KCNA5 DYRK1B SMPX SH3YL1 
KRAS EFEMP2 SMTN SEPT2 
LAMP2 EGLN1 SSPN CHL1 
LDB3 EGR3 TMOD4 NCBP2 
LEFTY1 ELN WNT4 IRF2 
LEFTY2 EMD ZEB2 LMBR1 
LMNA EVC2 DPF3 MAML1 
MAP2K1 (MEK1) FBLN5 TLL1 MAFK 
MAP2K2 (MEK2) FGF12 SOX4 SMARCA1 
MAPK14 FGF19 MEIS1 CACNA1B 
MEF2C FGF2 ACVR2B GTPBP4 
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Table 2.1 Continued 
MESP1 FGF6 ZYX BCCIP 
MYBPC3 FGF9 NCAM1 YY1AP1 
MYH6 FHL1 SKI NINJ2 
MYL2 FHL3 FOXO3 CHFR 
MYL3 FKRP SIRT1 RAN 
MYL7 FKTN HES1 CDC16 
MYLK2 FLNC LBH PCSK6 
MYOZ2 FOXH1 LRRC20 OCA2 
NCOA6 FOXK1 TWIST1 PIGQ 
NCOR2 FOXL2 PIAS1 GALNS 
NF1 FOXO4 MSX1 RPA1 
NFATC3 FOXP1 MYLK3 ADCYAP1 
NKX2-3 GLI2 MYH7 ADNP2 
NKX2-5 GTF2I MAP3K7IP2 FSTL3 
NOS3 GTF2IRD1 ADAM17  PEG3AS 
NOTCH1 HDAC4 PROX1 BIRC7 
NOTCH2 HDAC5 hsa-mir-1-2 PRMT2 
NPPA HDAC7 hsa-mir-1-1 NCAM2 
NRG1 HDAC9 hsa-mir-133b TYMP 
 
Table 2.1. Lists the genes used in the HeartRepair study. 
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Figure 4.1. Influence of the different filtering steps on variant numbers in the 
DCM cases. 4.1A = Filtering set A, 4.1B = Filtering set B. 
 
 
Figure 4.2. Influence of the different filtering steps on variant numbers in the 
AVSD cases. 4.2A = Filtering set A, 4.2B = Filtering set B. 
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Figure 4.3. Influence of the different filtering steps on variant numbers in the HSP 
cases. 4.3A = Filtering set A, 4.3B = Filtering set B. 
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Sample 
%target covered 
 >20fold 
%target covered  
>10fold 
%target covered  
>5fold 
%target covered 
 >1fold 
Sample1 82.64 89.88 93.42 97.25 
Sample2 94.19 96.10 97.22 98.61 
Sample3 95.78 97.02 97.81 98.78 
Sample4 92.47 95.04 96.60 98.25 
Sample5 94.92 96.29 97.30 98.53 
Sample6 87.24 91.98 94.77 97.75 
Sample7 92.01 94.98 96.66 98.46 
Sample8 89.57 93.43 95.59 97.91 
Sample9 92.54 95.07 96.57 98.35 
Sample10 89.53 93.23 95.46 97.97 
Sample11 91.69 94.81 96.48 98.36 
Sample12 89.21 93.01 95.18 97.71 
Sample13 89.96 93.69 95.91 98.18 
Sample14 89.46 93.33 95.56 97.98 
Sample15 88.27 92.41 95.01 97.90 
Sample16 91.63 94.40 96.12 98.11 
Sample17 92.45 95.03 96.61 98.38 
Sample18 90.99 94.23 96.08 98.16 
Sample19 45.19 77.67 88.47 95.88 
Sample20 92.39 95.14 96.71 98.46 
Sample21 93.96 95.95 97.21 98.54 
Sample22 88.90 93.06 95.31 97.90 
Sample23 93.74 95.86 97.15 98.57 
Sample24 89.96 93.59 95.72 97.99 
Sample25 88.60 92.91 95.26 97.86 
Sample26 89.36 93.52 95.77 98.08 
Sample27 85.96 91.68 94.74 97.83 
Sample28 85.42 91.18 94.22 97.55 
Sample29 85.39 91.24 94.35 97.63 
Sample30 89.46 93.50 95.72 98.06 
Sample31 94.33 96.20 97.35 98.59 
Sample32 88.46 93.09 95.56 98.08 
Sample33 84.48 91.64 94.84 97.47 
Sample34 95.18 96.35 97.17 98.27 
Sample35 89.84 93.85 96.08 98.38 
Sample36 85.22 92.61 95.61 98.14 
Sample37 93.93 95.73 96.96 98.41 
Sample38 69.93 86.57 92.86 97.53 
Sample39 91.05 94.32 96.23 98.35 
Sample40 91.42 94.43 96.32 98.32 
Sample41 95.03 96.61 97.65 98.69 
Sample42 83.39 90.54 94.03 97.50 
Sample43 86.76 93.37 96.41 98.50 
Sample44 83.60 90.97 94.29 97.64 
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Table 5.1 Continued 
Sample45 93.25 95.44 96.88 98.43 
Sample46 93.80 95.69 97.01 98.42 
Sample47 88.18 92.78 95.25 97.97 
Sample48 93.65 95.68 96.99 98.50 
Sample49 94.24 96.09 97.31 98.60 
Sample50 83.06 89.67 93.38 97.05 
Sample51 86.74 92.16 94.96 97.78 
Sample52 83.81 91.85 95.42 98.13 
Sample53 94.67 96.42 97.42 98.65 
Sample54 87.34 92.19 94.90 97.74 
Sample55 84.01 89.81 93.30 97.15 
Sample56 83.14 90.70 94.18 97.62 
Sample57 89.85 93.58 95.71 98.24 
Sample58 88.08 94.14 96.83 98.62 
Sample59 94.00 95.96 97.13 98.50 
Sample60 91.91 94.68 96.31 98.14 
Sample61 94.25 96.00 97.24 98.66 
Sample62 92.04 94.80 96.33 98.26 
Sample63 96.41 97.39 98.00 98.73 
Sample64 93.10 95.45 96.85 98.30 
Sample65 85.07 90.52 93.82 97.16 
Sample66 95.30 96.72 97.64 98.62 
Sample67 91.50 94.25 95.84 97.79 
Sample68 90.36 93.61 95.67 97.99 
Sample69 88.47 92.60 94.89 97.53 
Sample70 90.82 93.82 95.61 97.92 
Sample71 93.47 95.44 96.70 98.28 
Sample72 94.10 95.91 97.09 98.49 
Sample73 91.63 94.38 96.14 98.06 
Sample74 90.51 94.17 95.95 98.08 
Sample75 92.89 95.11 96.45 98.21 
Sample76 93.07 95.40 96.82 98.38 
Sample77 86.47 93.32 96.46 98.55 
Sample78 91.64 94.61 96.32 98.23 
Sample79 86.26 91.01 93.96 97.33 
Sample80 89.51 93.48 95.69 98.15 
Sample81 90.57 93.82 95.85 98.08 
Sample82 94.21 96.03 97.24 98.60 
Sample83 85.36 90.59 93.76 97.43 
Sample84 88.93 92.52 94.92 97.74 
Sample85 92.45 95.10 96.66 98.43 
Sample86 83.20 89.43 92.73 96.44 
Sample87 89.38 93.88 96.03 98.03 
Sample88 77.12 87.62 92.87 97.13 
Sample89 90.65 94.52 96.44 98.27 
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Sample90 92.34 95.13 96.65 98.27 
Sample91 87.35 92.24 94.97 97.71 
Sample92 91.98 94.68 96.31 98.11 
Sample93 81.06 89.59 93.37 97.10 
Sample94 92.01 94.85 96.54 98.27 
Sample95 90.92 94.06 95.76 97.72 
Sample96 92.92 95.40 96.88 98.49 
Sample97 91.38 94.11 95.67 97.51 
Sample98 87.26 92.04 94.69 97.57 
Sample99 91.54 94.40 96.12 97.94 
Sample100 88.44 92.43 94.91 97.74 
Sample101 80.52 88.19 92.15 96.22 
Sample102 91.13 94.17 96.01 98.06 
Sample103 82.59 89.45 93.08 96.87 
Sample104 86.31 91.73 94.57 97.63 
Sample105 93.65 95.35 96.55 97.92 
Sample106 74.59 86.19 91.45 96.23 
Sample107 80.94 88.74 92.68 96.72 
Sample108 91.91 94.60 96.25 97.99 
Sample109 88.88 92.77 95.17 97.92 
Sample110 90.41 93.72 95.73 97.78 
Sample111 94.75 96.33 97.44 98.60 
Sample112 90.57 93.76 95.63 97.67 
Sample113 89.93 93.20 95.16 97.36 
Sample114 90.59 94.14 96.17 98.25 
Sample115 87.03 91.60 94.49 97.61 
Sample116 85.65 92.09 95.01 97.89 
Sample117 88.24 92.76 95.28 97.95 
Sample118 83.21 90.73 94.15 97.38 
Sample119 91.61 94.48 96.23 98.21 
Sample120 94.45 96.22 97.41 98.68 
Sample121 89.34 93.53 95.73 98.17 
Sample122 87.14 92.13 94.76 97.69 
Sample123 90.53 93.99 95.94 98.07 
Sample124 87.58 92.63 95.24 98.00 
Sample125 91.21 94.46 96.25 98.36 
Sample126 92.69 95.26 96.74 98.50 
Sample127 91.14 94.48 96.33 98.35 
Sample128 85.51 90.90 93.93 97.31 
Sample129 90.47 93.85 95.89 98.18 
Sample130 89.81 93.62 95.75 98.09 
Sample131 80.88 89.75 93.65 97.33 
Sample132 88.38 92.73 95.10 97.80 
Sample133 88.49 92.93 95.41 97.89 
Table 5.1. Target base coverage of HeartRepair samples. 
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Chrom. Position Ref. Variant Gene EVS5400 
1000 
Genomes dbsnp135 control list 
chr11 65688382 G - DRAP1 0 0   0 
chr9 140807675 A - CACNA1B 0 0   0 
chr19 19258537 A - 
MEF2B,MEF2BNB-
MEF2B 0 0   0 
chr17 17697123 GC - RAI1 0 0   0 
chr16 86601682 G - FOXC2 0 0   0 
chr9 140917757 C - CACNA1B 0 0   0 
chr5 156021946 A - SGCD 0 0   0 
chr15 68606119 G - ITGA11 0 0   0 
chr20 60905911 G - LAMA5 0 0   0 
chr1 120612003 GG - NOTCH2 0 0   0 
chr16 3778372 C - CREBBP 0 0   0 
chr5 122515971 A - PRDM6 0 0   0 
chr2 240002822 T - HDAC4 0 0   0 
chr6 1611589 C - FOXC1 0 0   0 
chr2 220290413 G - DES 0 0   0 
chr16 88601159 C - ZFPM1 0 0   0 
chr22 19754108 G - TBX1 0 0   0 
chr1 201334355 T - TNNT2 0 0   0 
chr12 9091915 G - PHC1 0 0   0 
chr3 38622801 G - SCN5A 0 0   0 
chr8 38271271 C - FGFR1 0 0   0 
chr12 124820088 T - NCOR2 0 0   0 
chr10 99338053 G - ANKRD2 0 0   0 
chr5 122425851 CA - PRDM6 0 0   0 
chr3 157823620 C - SHOX2 0 0   0 
chr1 202407190 T - PPP1R12B 0 0   0 
chr1 156106799 A - LMNA 0 0   0 
chr10 72061238 T - LRRC20 0 0   0 
chr12 5154544 T - KCNA5 0 0   0 
chr9 140918091 C - CACNA1B 0 0   0 
chr6 43139816 G - SRF 0 0   0 
chr10 99337655 G - ANKRD2 0 0   0 
chr7 74149837 AAGA - GTF2I 0 0   0 
chr2 211179766 T - MYL1 0 0   0 
chr19 4102407 A - MAP2K2 0 0   0 
chr14 23895248 T - MYH7 0 0   0 
chr1 155630185 C - YY1AP1 0 0   0 
chr12 124831127 C - NCOR2 0 0   0 
chr19 47259864 T - FKRP 0 0   0 
chr6 50791258 TA - TFAP2B 0 0   0 
chr1 220379328 T - RAB3GAP2 0 0   0 
chr9 141013169 G - CACNA1B 0 0   0 
chr8 145699791 A - FOXH1 0 0   0 
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Table 5.2 Continued 
chr16 624455 G - PIGQ 0 0   0 
chr20 60895929 C - LAMA5 0 0   0 
chr4 102001782 A - PPP3CA 0 0   0 
chr11 2869100 A - KCNQ1 0 0   0 
chr9 139396296 G - NOTCH1 0 0   0 
chr9 139405664 C - NOTCH1 0 0   0 
chr12 9085217 C - PHC1 0 0   0 
chr7 73521406 G - LIMK1 0 0   0 
chr1 156106096 A - LMNA 0 0   0 
chr5 88056864 C - MEF2C 0 0   0 
chr11 2154242 G - IGF2 0 0   0 
chr12 56491631 A - ERBB3 0 0   0 
chr1 202533599 A - PPP1R12B 0 0   0 
chrX 131518723 G - MBNL3 0 0   0 
chr14 105634397 C - JAG2 0 0   0 
chr12 9086909 T - PHC1 0 0   0 
chr4 5758035 C - EVC 0 0   0 
chr1 202396297 T - PPP1R12B 0 0   0 
chr1 202464500 CA - PPP1R12B 0 0   0 
chr15 90294049 G - MESP1 0 0   0 
chr3 14180757 C - TMEM43 0 0   0 
chr5 153857387 G - HAND1 0 0   0 
chr15 90294203 GC - MESP1 0 0   0 
chrX 136649076 C - ZIC3 0 0   0 
chr20 60898582 G - LAMA5 0 0   0 
chr2 220290416 C - DES 0 0   0 
chr12 51589833 C - POU6F1 0 0   0 
chr12 114804154 T - TBX5 0 0   0 
chr4 174450159 C - HAND2 0 0   0 
chr1 151144790 AT - TMOD4 0 0   0 
chr7 73470659 - T ELN 0 0   0 
chr10 94449776 - G HHEX 0 0   0 
chr17 17697130 - A RAI1 0 0   0 
chr16 46744687 - A MYLK3 0 0   0 
chr18 77171468 - C NFATC1 0 0   0 
chr4 114275546 - C ANK2 0 0   0 
chr4 123748299 - C FGF2 0 0   0 
chr12 124820063 - CAAC NCOR2 0 0   0 
chr17 21215536 - A MAP2K3 0 0   0 
chr19 40317590 - CCCC DYRK1B 0 0   0 
chr12 5603608 - C NTF3 0 0   0 
chr12 33031069 - G PKP2 0 0   0 
chr12 52308249 - G ACVRL1 0 0   0 
chr12 115109685 - A TBX3 0 0   0 
chr12 124829420 - C NCOR2 0 0   0 
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chr11 2869086 - G KCNQ1 0 0   0 
chr10 75758098 - C VCL 0 0   0 
chr17 7130528 - C DVL2 0 0   0 
chr16 3823776 - G CREBBP 0 0   0 
chr16 3828061 - GG CREBBP 0 0   0 
chr15 68612614 - C ITGA11 0 0   0 
chr15 90293392 - C MESP1 0 0   0 
chr19 7119593 - C INSR;INSR 0 0   0 
chr19 40321175 - C DYRK1B 0 0   0 
chr18 19751314 - G GATA6 0 0   0 
chr18 29125917 - AC DSG2 0 0   0 
chr22 31492745 - G SMTN 0 0   0 
chr22 50968118 - G TYMP 0 0   0 
chr20 6750839 - G BMP2 0 0   0 
chr20 10626013 - G JAG1 0 0   0 
chr7 128483879 - GG FLNC 0 0   0 
chr7 128497213 - C FLNC 0 0   0 
chr7 143078671 - GCCCC ZYX 0 0   0 
chr6 50807921 - TC TFAP2B 0 0   0 
chr6 126073017 - G HEY2 0 0   0 
chr5 1880895 - G IRX4 0 0   0 
chr5 155771583 - GG SGCD 0 0   0 
chr4 5800385 - G EVC 0 0   0 
chr4 114274870 - A ANK2 0 0   0 
chr4 114275546 - CC ANK2 0 0   0 
chr3 55508547 - G WNT5A 0 0   0 
chr3 152163311 - C MBNL1 0 0   0 
chr3 193855814 - G HES1 0 0   0 
chr2 121746627 - GC GLI2 0 0   0 
chr1 1273756 - C DVL1 0 0   0 
chr1 16343694 - G HSPB7 0 0   0 
chr1 231557037 - GC EGLN1 0 0   0 
chr1 237777981 - AA RYR2 0 0   0 
chr9 130588044 - G ENG 0 0   0 
chr9 139391543 - G NOTCH1 0 0   0 
chr8 11565886 - GC GATA4 0 0   0 
chr8 80677838 - C HEY1 0 0   0 
chr1 59248148 - G JUN 0 0   0 
chr12 131360223 - GTAA RAN 0 0   0 
chr12 124824739 - GCCG NCOR2 0 0   0 
chr17 29686010 - G NF1 0 0   0 
chr7 128483890 - C FLNC 0 0   0 
chr9 139413208 - G NOTCH1 0 0   0 
chr17 17697121 - A RAI1 0 0   0 
chr6 139694497 - C CITED2 0 0   0 
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chr17 37883553 - G ERBB2 0 0   0 
chr5 172662040 - TTTG NKX2-5 0 0   0 
chr5 172659759 - C NKX2-5 0 0   0 
chr17 21204186 - T MAP2K3 0 0   0 
chr5 153857391 - T HAND1 0 0   0 
chr12 5154214 - GG KCNA5 0 0   0 
chr12 48185398 - GG HDAC7 0 0   0 
chr11 2869088 - GC KCNQ1 0 0   0 
chr17 39925377 - G JUP 0 0   0 
chr16 3778897 - C CREBBP 0 0   0 
chr14 24845989 - G NFATC4 0 0   0 
chr18 77171472 - CG NFATC1 0 0   0 
chr22 17662874 - A CECR1 0 0   0 
chr20 60884404 - C LAMA5 0 0   0 
chr7 73535521 - C LIMK1 0 0   0 
chr7 128483879 - G FLNC 0 0   0 
chr4 995530 - G IDUA 0 0   0 
chr4 4864617 - C MSX1 0 0   0 
chr4 5620311 - C EVC2 0 0   0 
chr4 5800385 - GG EVC 0 0   0 
chr3 152163311 - CC MBNL1 0 0   0 
chr3 181430234 - G SOX2 0 0   0 
chr2 88387383 - G SMYD1 0 0   0 
chr2 121747180 - G GLI2 0 0   0 
chr2 220283241 - G DES 0 0   0 
chr1 156106155 - G LMNA 0 0   0 
chr1 202318126 - G PPP1R12B 0 0   0 
chr1 208202181 - C PLXNA2 0 0   0 
chr1 226074643 - GC LEFTY1 0 0   0 
chr1 226125353 - GG LEFTY2 0 0   0 
chr1 231557037 - C EGLN1 0 0   0 
chr9 139396883 - C NOTCH1 0 0   0 
chr8 2091344 - G MYOM2 0 0   0 
chr17 7189170 - G SLC2A4 0 0   0 
chr14 73664749 - GG PSEN1 0 0   0 
chr7 4722241 - C FOXK1 0 0   0 
chr7 35288308 - G TBX20 0 0   0 
chr6 1610775 - G FOXC1 0 0   0 
chr6 1612158 - G FOXC1 0 0   0 
chr4 123748299 - CC FGF2 0 0   0 
chr3 193855820 - G HES1 0 0   0 
chr12 98909901 - G TMPO 0 0   0 
chr12 124826453 - G NCOR2 0 0   0 
chr15 23932221 - G NDN 0 0   0 
chr15 48712976 - G FBN1 0 0   0 
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chr15 48720570 - G FBN1 0 0   0 
chr15 68480091 - T PIAS1 0 0   0 
chr14 105617337 - G JAG2 0 0   0 
chr22 19463076 - G UFD1L 0 0   0 
chr20 6750841 - GC BMP2 0 0   0 
chr7 128478720 - G FLNC 0 0   0 
chr4 5586474 - C EVC2 0 0   0 
chr2 223086008 - G PAX3 0 0   0 
chr1 231557219 - C EGLN1 0 0   0 
chr12 124885147 - G NCOR2 0 0   0 
chr10 88478558 - C LDB3 0 0   0 
chr22 39826174 - TC TAB1 0 0   0 
chr20 60884469 - C LAMA5 0 0   0 
chr20 60899259 - G LAMA5 0 0   0 
chr5 88024395 - G MEF2C 0 0   0 
chr4 114158192 - G ANK2 0 0   0 
chr1 1275458 - C DVL1 0 0   0 
chr17 29686003 - T NF1 0 0   0 
chr2 145156625 - T ZEB2 0 0   0 
chr12 2975681 - G FOXM1 0 0   0 
chr16 3823776 - GG CREBBP 0 0   0 
chr16 51175706 - G SALL1 0 0   0 
chr18 77171472 - A NFATC1 0 0   0 
chr20 60897798 - G LAMA5 0 0   0 
chr1 120548001 - T NOTCH2 0 0   0 
chr10 115804489 - G ADRB1 0 0   0 
chr1 2161015 - C SKI 0 0   0 
chr12 48185398 - G HDAC7 0 0   0 
chr21 48081813 - C PRMT2 0 0   0 
chr3 14526404 - C SLC6A6 0 0   0 
chr1 92185675 - C TGFBR3 0 0   0 
chr8 118830716 - G EXT1 0 0   0 
chr5 1881946 - G IRX4 0 0   0 
chr17 29686007 - G NF1 0 0   0 
chr4 5800389 - C EVC 0 0   0 
chr9 139413094 - G NOTCH1 0 0   0 
chr19 47259732 - CC FKRP 0 0   0 
chr10 101295306 - G NKX2-3 0 0   0 
chr10 115805199 - G ADRB1 0 0   0 
chr17 59482922 - C TBX2 0 0   0 
chr18 19752017 - G GATA6 0 0   0 
chr18 3215058 - G MYOM1 0 0   0 
chr10 101295394 - G NKX2-3 0 0   0 
chr9 141014796 - C CACNA1B 0 0 rs34080813 0 
chr16 54967277 - G IRX5 0 0   0 
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Table 5.2 Continued 
chr12 133425243 - C CHFR 0 0   0 
chr17 17701501 - C RAI1 0 0   0 
chr16 46744687 - AA MYLK3 0 0   0 
chr2 66739378 - A MEIS1 0 0   0 
chr6 108985582 - TC FOXO3 0 0   0 
chr10 92679010 - T ANKRD1 0 0   0 
chr13 23898659 - C SGCG 0 0   0 
chr12 56092638 - C ITGA7 0 0   0 
chr12 114793568 - A TBX5 0 0   0 
chr10 11356106 - G CELF2 0 0   0 
chr10 75857054 - G VCL 0 0   0 
chr18 3116449 - G MYOM1 0 0   0 
chr4 114275830 - C ANK2 0 0   0 
chr3 152174125 - C MBNL1 0 0   0 
chr2 66739381 - T MEIS1 0 0   0 
chr1 120459193 - CG NOTCH2 0 0   0 
chr17 39925395 - C JUP 0 0   0 
chr17 78449427 - A NPTX1 0 0   0 
chr19 4117556 - C MAP2K2 0 0   0 
chr19 7119592 - C INSR 0 0   0 
chr6 1612231 - T FOXC1 0 0   0 
chr4 995896 - C IDUA 0 0   0 
chr2 40655623 - T SLC8A1 0 0   0 
chr2 145157529 - C ZEB2 0 0   0 
chr9 96715377 - C BARX1 0 0   0 
chr12 52309205 - C ACVRL1 0 0   0 
chr11 2869086 - GG KCNQ1 0 0   0 
chr11 129306804 - T BARX2 0 0   0 
chr18 19751197 - G GATA6 0 0   0 
chr7 44105053 - C PGAM2 0 0   0 
chr7 143085428 - A ZYX 0 0   0 
chr6 108985155 - G FOXO3 0 0   0 
chr1 1991007 - C PRKCZ 0 0   0 
chr9 139413210 - C NOTCH1 0 0   0 
chr12 56092638 - GC ITGA7 0 0   0 
chr10 88659814 - G BMPR1A 0 0   0 
chr17 7189172 - GT SLC2A4 0 0   0 
chr17 29686003 - TT NF1 0 0   0 
chr17 37883560 - GC ERBB2 0 0   0 
chr15 68599984 - C ITGA11 0 0   0 
chr5 122435478 - G PRDM6 0 0   0 
chr5 172659762 - C NKX2-5 0 0   0 
chr4 996233 - AA IDUA 0 0   0 
chr3 193855818 - A HES1 0 0   0 
chr2 239988508 - C HDAC4 0 0   0 
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chr1 226075310 - C LEFTY1 0 0  0 
chr1 2235396 - G SKI 0 0  0 
chr20 10626015 - GGTTT JAG1 0 0   0 
chr2 239975199 - G HDAC4 0 0   0 
chr7 151372701 - T PRKAG2 0 0   0 
chr12 56088713 - G ITGA7 0 0   0 
chr2 234170 - C SH3YL1 0 0   0 
chr14 105616985 - G JAG2 0 0   0 
chr21 48069627 - G PRMT2 0 0   0 
chr1 2106679 - C PRKCZ 0 0   0 
chr20 10626015 - GGGTT JAG1 0 0   0 
chr2 121747069 - A GLI2 0 0   0 
chr5 139722381 - T HBEGF 0 0   0 
chr9 140772466 - G CACNA1B 0 0   0 
chr18 77211049 - G NFATC1 0 0   0 
chr6 1612155 - G FOXC1 0 0   0 
chr3 71090482 - C FOXP1 0 0   0 
chr1 120464352 - G NOTCH2 0 0   0 
chr15 25616578 - A UBE3A 0 0   0 
chr2 121747180 - GG GLI2 0 0   0 
chr9 140946627 - G CACNA1B 0 0   0 
chr8 119122640 - C EXT1 0 0   0 
chr10 75854057 - C VCL 0 0   0 
chr3 138665524 - C FOXL2 0 0   0 
chr1 237777981 - TA RYR2 0 0   0 
chr10 123263420 - A FGFR2 0 0   0 
chr19 7119590 - G INSR 0 0   0 
chr4 114213583 - C ANK2 0 0   0 
chr14 105617343 - G JAG2 0 0   0 
chr20 10626013 - GG JAG1 0 0   0 
chr9 140946548 - C CACNA1B 0 0   0 
chr6 121768197 - ATCT GJA1 0 0   0 
chr6 139694488 - C CITED2 0 0   0 
chr1 228238594 - C WNT3A 0 0   0 
chr1 59248275 - GCCC JUN 0 0   0 
chr16 3860722 - G CREBBP 0 0   0 
chr3 55508479 - T WNT5A 0 0   0 
chr17 57768006 T - CLTC 0 0   0 
chr7 128481026 T - FLNC 0 0   0 
chr1 156108278 G - LMNA 0 0   0 
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chr11 1860757 G - TNNI2 0 0   0 
chr17 66508691 - G PRKAR1A 0 0   0 
chr20 33334734 - AAA NCOA6 0 0   0 
chr1 71418662 G - PTGER3 0 0.0041   0 
chr7 35288303 - G TBX20 0 0   0.002358491 
chr2 211179765 - T MYL1 0 0   0.002358491 
chr18 29125917 - C DSG2 0 0   0.002358491 
chr20 33334734 - A NCOA6 0 0   0.002358491 
chr17 21207781 - T MAP2K3 0 0   0.004716981 
 
Table 5.2. Filtered indels identified using the BWA-Dindel pipeline for the 133 
HeartRepair samples. 
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Chrom. Position Ref. Variant Gene EVS5400 
1000 
Genomes dbsnp135 control list 
chr1 120612003 GG - NOTCH2 0 0   0 
chr1 201334355 T - TNNT2 0 0   0 
chr1 202407190 T - PPP1R12B 0 0   0 
chr10 99338053 G - ANKRD2 0 0   0 
chr2 211179766 T - MYL1 0 0   0 
chr11 112832341 CA - NCAM1 0 0   0 
chr9 139405664 C - NOTCH1 0 0   0 
chr12 124824739 - GCCG NCOR2 0 0   0 
chr3 71090482 - C FOXP1 0 0   0 
chr5 139722381 - TT HBEGF 0 0   0 
chr12 124824739 - G NCOR2 0 0   0 
chr10 88478558 - C LDB3 0 0   0 
chr10 88478560 - C LDB3 0 0   0 
chr12 2983338 - C FOXM1 0 0   0 
chr1 92185675 - C TGFBR3 0 0   0 
chr1 226127214 - G LEFTY2 0 0   0 
chr2 121747069 - A GLI2 0 0   0 
chr6 50807921 - C TFAP2B 0 0   0 
chr11 2869086 - GG KCNQ1 0 0   0 
chr11 2869088 - GC KCNQ1 0 0   0 
chr12 115109685 - A TBX3 0 0   0 
chr14 73664749 - GG PSEN1 0 0   0 
chr16 3778897 - C CREBBP 0 0   0 
chr20 6750839 - G BMP2 0 0   0 
chr4 123748299 - C FGF2 0 0   0 
chr12 124885147 - G NCOR2 0 0   0 
chr10 92679010 - T ANKRD1 0 0   0 
chr2 66739381 - T MEIS1 0 0   0 
chr1 2235396 - G SKI 0 0   0 
chr9 140773612 - A CACNA1B 0 0   0 
chr9 140777194 A - CACNA1B 0 0   0 
chr1 71418662 G - PTGER3 0 0.0041   0 
chr4 168155291 CA - SPOCK3 0 0.01   0 
chr2 211179765 - T MYL1 0 0   0.002358491 
chr20 33334734 - A NCOA6 0 0   0.002358491 
 
Table 5.3. Filtered indels identified using the BWA-GATK pipeline for the 133 
HeartRepair samples. 
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